US20230271922A9 - Polymorphs of phenyl pyrrole aminoguandium salts - Google Patents
Polymorphs of phenyl pyrrole aminoguandium salts Download PDFInfo
- Publication number
- US20230271922A9 US20230271922A9 US17/821,500 US202217821500A US2023271922A9 US 20230271922 A9 US20230271922 A9 US 20230271922A9 US 202217821500 A US202217821500 A US 202217821500A US 2023271922 A9 US2023271922 A9 US 2023271922A9
- Authority
- US
- United States
- Prior art keywords
- crystalline form
- exhibiting
- nitrophenyl
- pyrrol
- allylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 title claims description 68
- IRTLROCMFSDSNF-UHFFFAOYSA-N 2-phenyl-1h-pyrrole Chemical compound C1=CNC(C=2C=CC=CC=2)=C1 IRTLROCMFSDSNF-UHFFFAOYSA-N 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 claims description 513
- 239000000843 powder Substances 0.000 claims description 350
- 230000005855 radiation Effects 0.000 claims description 350
- 239000000203 mixture Substances 0.000 claims description 156
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 155
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 149
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 115
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 113
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 110
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 104
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 103
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 92
- 229940109275 cyclamate Drugs 0.000 claims description 87
- 201000010099 disease Diseases 0.000 claims description 86
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 66
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 64
- 208000035475 disorder Diseases 0.000 claims description 62
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 58
- 230000003612 virological effect Effects 0.000 claims description 58
- 239000002904 solvent Substances 0.000 claims description 57
- 229960000448 lactic acid Drugs 0.000 claims description 54
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 44
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 43
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 43
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 38
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 37
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 35
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 34
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 31
- 229910002651 NO3 Inorganic materials 0.000 claims description 29
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 29
- 229960000250 adipic acid Drugs 0.000 claims description 29
- 235000011037 adipic acid Nutrition 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 27
- 239000001361 adipic acid Substances 0.000 claims description 27
- 208000017169 kidney disease Diseases 0.000 claims description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 24
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 23
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 18
- 230000009885 systemic effect Effects 0.000 claims description 17
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 16
- 208000027866 inflammatory disease Diseases 0.000 claims description 16
- 230000002917 arthritic effect Effects 0.000 claims description 15
- 206010003246 arthritis Diseases 0.000 claims description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 239000012296 anti-solvent Substances 0.000 claims description 13
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 238000001704 evaporation Methods 0.000 claims description 12
- 238000002955 isolation Methods 0.000 claims description 12
- 239000003880 polar aprotic solvent Substances 0.000 claims description 12
- 235000006408 oxalic acid Nutrition 0.000 claims description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 230000008020 evaporation Effects 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 10
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
- 229960000485 methotrexate Drugs 0.000 claims description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 241001678559 COVID-19 virus Species 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 206010050685 Cytokine storm Diseases 0.000 claims description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 201000001474 proteinuria Diseases 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 206010003267 Arthritis reactive Diseases 0.000 claims description 3
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 201000001223 septic arthritis Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 206010035737 Pneumonia viral Diseases 0.000 claims description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000002365 Viral Bronchiolitis Diseases 0.000 claims description 2
- 230000009429 distress Effects 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 208000009421 viral pneumonia Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- ZSDGHWLLLGYAJV-AHEHSYJASA-N 2-[(E)-[(E)-3-[1-(2-nitrophenyl)pyrrol-2-yl]prop-2-enylidene]amino]guanidine Chemical compound NC(N)=N\N=C\C=C\C1=CC=CN1C1=CC=CC=C1[N+]([O-])=O ZSDGHWLLLGYAJV-AHEHSYJASA-N 0.000 description 990
- 238000000634 powder X-ray diffraction Methods 0.000 description 283
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 174
- 238000000113 differential scanning calorimetry Methods 0.000 description 174
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 129
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 82
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 79
- 239000007787 solid Substances 0.000 description 61
- 229960004592 isopropanol Drugs 0.000 description 59
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 53
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 50
- 239000000523 sample Substances 0.000 description 49
- 238000004128 high performance liquid chromatography Methods 0.000 description 47
- 150000001875 compounds Chemical class 0.000 description 44
- -1 AP1189 acetate salt Chemical class 0.000 description 43
- 239000008194 pharmaceutical composition Substances 0.000 description 43
- 238000001757 thermogravimetry curve Methods 0.000 description 41
- 230000004580 weight loss Effects 0.000 description 38
- 238000009472 formulation Methods 0.000 description 36
- 238000010438 heat treatment Methods 0.000 description 35
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 34
- 238000002441 X-ray diffraction Methods 0.000 description 31
- 239000008186 active pharmaceutical agent Substances 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 29
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000002552 dosage form Substances 0.000 description 24
- 239000002002 slurry Substances 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 159000000021 acetate salts Chemical class 0.000 description 12
- 239000001384 succinic acid Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 150000003890 succinate salts Chemical class 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 7
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000003586 protic polar solvent Substances 0.000 description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 5
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 108090000950 Melanocortin Receptors Proteins 0.000 description 4
- 102000004378 Melanocortin Receptors Human genes 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000003891 oxalate salts Chemical class 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- ZSDGHWLLLGYAJV-LDRJOUGUSA-N 2-[(Z)-[(E)-3-[1-(2-nitrophenyl)pyrrol-2-yl]prop-2-enylidene]amino]guanidine Chemical compound C1=CC=C(C(=C1)N2C=CC=C2/C=C/C=N\N=C(N)N)[N+](=O)[O-] ZSDGHWLLLGYAJV-LDRJOUGUSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102100024484 Codanin-1 Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 2
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 2
- 108010008364 Melanocortins Proteins 0.000 description 2
- 101800000520 Melanotropin gamma Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 150000001279 adipic acids Chemical class 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000001336 alkenes Chemical group 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000002865 melanocortin Substances 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 231100000855 membranous nephropathy Toxicity 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical group OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000005490 tosylate group Chemical class 0.000 description 2
- OTXHZHQQWQTQMW-UHFFFAOYSA-N (diaminomethylideneamino)azanium;hydrogen carbonate Chemical compound OC([O-])=O.N[NH2+]C(N)=N OTXHZHQQWQTQMW-UHFFFAOYSA-N 0.000 description 1
- GRDPPSMNRDZCGL-TYYBGVCCSA-N (e)-but-2-enedioic acid;propan-2-ol Chemical compound CC(C)O.OC(=O)\C=C\C(O)=O GRDPPSMNRDZCGL-TYYBGVCCSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- NDTDVKKGYBULHF-UHFFFAOYSA-N 2-(1-hydroxy-3-phenylnaphthalen-2-yl)-3-phenylnaphthalen-1-ol Chemical compound C=1C2=CC=CC=C2C(O)=C(C=2C(=CC3=CC=CC=C3C=2O)C=2C=CC=CC=2)C=1C1=CC=CC=C1 NDTDVKKGYBULHF-UHFFFAOYSA-N 0.000 description 1
- ZIKCHNCVFRYIRB-UHFFFAOYSA-N 2-aminoguanidine 2-phenyl-1H-pyrrole Chemical class NNC(N)=N.C1=CNC(C=2C=CC=CC=2)=C1 ZIKCHNCVFRYIRB-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid Chemical group OC(=O)C(O)C1=CC=CC=C1.OC(=O)C(O)C1=CC=CC=C1 QBYIENPQHBMVBV-UHFFFAOYSA-N 0.000 description 1
- KGEFSAADRVPAIX-UHFFFAOYSA-N 2-hydroxypropanoic acid pentanedioic acid Chemical group C(C(O)C)(=O)O.C(CCCC(=O)O)(=O)O KGEFSAADRVPAIX-UHFFFAOYSA-N 0.000 description 1
- CIFNWWSBOFZXJI-UHFFFAOYSA-N 2-hydroxypropanoic acid;propan-2-one Chemical compound CC(C)=O.CC(O)C(O)=O CIFNWWSBOFZXJI-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical group CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- OKRCRKPDQBZCPB-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;propan-2-ol Chemical compound CC(C)O.CC1=CC=C(S(O)(=O)=O)C=C1 OKRCRKPDQBZCPB-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical group N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- YBJPSUYLHZJWJC-UHFFFAOYSA-N CC(C)=O.OC(C(O)=O)c1ccccc1 Chemical compound CC(C)=O.OC(C(O)=O)c1ccccc1 YBJPSUYLHZJWJC-UHFFFAOYSA-N 0.000 description 1
- YWMMBLXNWFCIMF-UHFFFAOYSA-N CC(C)O.C(CCC(=O)O)(=O)O Chemical compound CC(C)O.C(CCC(=O)O)(=O)O YWMMBLXNWFCIMF-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
- 102400000744 Melanotropin gamma Human genes 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- ZSDGHWLLLGYAJV-HELWLUGBSA-N NC(N)=N/N=C/C=CC1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O Chemical group NC(N)=N/N=C/C=CC1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O ZSDGHWLLLGYAJV-HELWLUGBSA-N 0.000 description 1
- ZSDGHWLLLGYAJV-KFIJFHHBSA-N NC(N)=N/N=C/C=C\C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O Chemical compound NC(N)=N/N=C/C=C\C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O ZSDGHWLLLGYAJV-KFIJFHHBSA-N 0.000 description 1
- ZSDGHWLLLGYAJV-WALZVQGWSA-N NC(N)=N/N=C\C=C/C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O Chemical compound NC(N)=N/N=C\C=C/C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O ZSDGHWLLLGYAJV-WALZVQGWSA-N 0.000 description 1
- ZSDGHWLLLGYAJV-UPLRZAPISA-N NC(N)=N/N=C\C=CC1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O Chemical compound NC(N)=N/N=C\C=CC1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O ZSDGHWLLLGYAJV-UPLRZAPISA-N 0.000 description 1
- ZSDGHWLLLGYAJV-CFVHLLPYSA-N NC(N)=NN=C/C=C/C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O Chemical group NC(N)=NN=C/C=C/C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O ZSDGHWLLLGYAJV-CFVHLLPYSA-N 0.000 description 1
- ZSDGHWLLLGYAJV-FDTFQMGPSA-N NC(N)=NN=C/C=C\C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O Chemical compound NC(N)=NN=C/C=C\C1=CC=CN1C(C=CC=C1)=C1[N+]([O-])=O ZSDGHWLLLGYAJV-FDTFQMGPSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101100002888 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) asa-1 gene Proteins 0.000 description 1
- OWFMXTBDASJVKN-UHFFFAOYSA-N OC=O.CCC(C)=O Chemical compound OC=O.CCC(C)=O OWFMXTBDASJVKN-UHFFFAOYSA-N 0.000 description 1
- HILXIZVUTMSJCK-DKWTVANSSA-N O[C@H](C(=O)O)C.C(=O)O Chemical group O[C@H](C(=O)O)C.C(=O)O HILXIZVUTMSJCK-DKWTVANSSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000004318 Schistosomiasis haematobia Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- HJTDVSBDUXIOMN-UHFFFAOYSA-N [N+](=O)(O)[O-].C(C)C(=O)C Chemical compound [N+](=O)(O)[O-].C(C)C(=O)C HJTDVSBDUXIOMN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- UTKBLLDLHPDWDU-TYYBGVCCSA-N acetic acid;(e)-but-2-enedioic acid Chemical group CC(O)=O.OC(=O)\C=C\C(O)=O UTKBLLDLHPDWDU-TYYBGVCCSA-N 0.000 description 1
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical group CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- JXYRIQRQKAUQIY-UHFFFAOYSA-N acetic acid;oxolane Chemical compound CC(O)=O.C1CCOC1 JXYRIQRQKAUQIY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical group CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- XPDIFRSEWAKQRX-UHFFFAOYSA-N benzenesulfonic acid oxalic acid Chemical group C(C(=O)O)(=O)O.C1(=CC=CC=C1)S(=O)(=O)O XPDIFRSEWAKQRX-UHFFFAOYSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- HRFMGQVNTQOSES-UHFFFAOYSA-N butanedioic acid 4-methylbenzenesulfonic acid Chemical group C1(=CC=C(C=C1)S(=O)(=O)O)C.C(CCC(=O)O)(=O)O HRFMGQVNTQOSES-UHFFFAOYSA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229940125542 dual agonist Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HMEIRFWCTWTHPU-UHFFFAOYSA-N hexanedioic acid propan-2-one Chemical compound CC(C)=O.OC(=O)CCCCC(O)=O HMEIRFWCTWTHPU-UHFFFAOYSA-N 0.000 description 1
- KBVZCXJTMMETLB-UHFFFAOYSA-N hexanedioic acid;pentanedioic acid Chemical group OC(=O)CCCC(O)=O.OC(=O)CCCCC(O)=O KBVZCXJTMMETLB-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229940071257 lithium acetate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000005478 oxoglutarate group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000004410 urinary schistosomiasis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- GZWUQPQBOGLSIM-VOOUCTBASA-N γ msh Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C(C)C)C1=CC=C(O)C=C1 GZWUQPQBOGLSIM-VOOUCTBASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to salts of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine having a high solubility at low pH.
- the melanocortin system is a set of neuropeptidergic and immuneendocrine signalling pathways that play an integral role in the homeostatic control of a diverse array of physiological functions, including melanogenesis, stress response, inflammation, immunomodulation and adrenocortical steroidogenesis. It consists of multiple components, including the five G protein-couple melanocortin receptors: melanocortin receptor 1 (MC1R) to MC5R; peptide ligands; ⁇ , ⁇ , ⁇ -melanocyte stimulating hormone ( ⁇ , ⁇ , ⁇ -MSH); adrenocorticotropic hormone (ACTH) secreted by the anterior pituitary; and endogenous antagonists.
- MCRs melanocortin receptors
- Phenyl pyrrole aminoguanidine derivatives with activity on the melanocortin receptors have previously been disclosed.
- One example of such compound is the anti-inflammatory AP1189 (N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine) which was first shown to bind the MC1R and later was identified as a biased dual agonist at receptors MC1R and MC3R that does not provoke canonical cAMP generation (and hence no MC1R-induced melanogenesis) but instead appear to induce alternative pathways including ERK1/2-phosphorylation and Ca 2+ mobilisation.
- AP1189 N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine
- the present inventors have discovered salts of AP1189 with particularly favourable solubility profiles for gastric delivery.
- the inventors found that certain polymorphs of AP1189 salts have very high solubilities, especially at low pH.
- one aspect of the present disclosure provides for a crystalline Form A of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 11.5 ⁇ 0.2, 23.5 ⁇ 0.2, and 27.0 ⁇ 0.2.
- Another aspect of the present disclosure provides for a crystalline Form B of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 9.7 ⁇ 0.2, 22.8 ⁇ 0.2, and 26.7 ⁇ 0.2.
- the present disclosure also provides methods of producing such crystalline forms.
- One aspect of the present disclosure provides a method for producing the N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate of crystalline Form A as disclosed herein, said method comprising:
- One aspect of the present disclosure provides a method for producing the N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate of crystalline Form A as disclosed herein, said method comprising:
- One aspect of the present disclosure provides a method for producing the N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate of crystalline Form A as disclosed herein, said method comprising:
- One aspect of the present disclosure provides a method for producing N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate of crystalline Form B as disclosed herein, said method comprising:
- One aspect of the present disclosure provides a method for producing N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate of crystalline Form B as disclosed herein, said method comprising:
- One aspect of the present disclosure provides a crystalline Form A of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate produced by a method as disclosed herein.
- One aspect of the present disclosure provides a crystalline Form B of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate produced by a method as disclosed herein.
- One aspect of the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising the crystalline Form A of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate as disclosed herein and a pharmaceutically acceptable excipient.
- One aspect of the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising the crystalline Form B of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate as disclosed herein and a pharmaceutically acceptable excipient.
- One aspect of the present disclosure provides a method of preparing a pharmaceutical composition comprising mixing the crystalline Form A of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate as disclosed herein and a pharmaceutically acceptable excipient.
- One aspect of the present disclosure provides a method of preparing a pharmaceutical composition, said method comprising mixing the crystalline Form B of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate as disclosed herein with a pharmaceutically acceptable excipient.
- One aspect of the present disclosure provides a method of treating a disease or disorder in a subject in need thereof, said method comprising administering crystalline Form A of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate as disclosed herein, the crystalline Form B of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate as disclosed herein, or the pharmaceutical composition as disclosed herein to a subject in need thereof.
- One aspect of the disclosure provides for a use of the crystalline Form A of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate as disclosed herein or the crystalline Form B of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate as disclosed herein, or the pharmaceutical composition as disclosed herein, for the manufacture of a medicament for treatment of a disease or disorder.
- One aspect of the present disclosure is to provide for crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts having high solubility at low pH, e.g. at pH 1.2.
- one aspect provides for a crystalline Form of an N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salt selected from the group consisting of:
- One aspect of the present disclosure is to provide crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts that can be converted into useful crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts.
- one aspect of the present disclosure provides for a crystalline Form of an N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salt selected from the group consisting of:
- One aspect of the present disclosure is to provide for N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts that can be converted into useful crystalline Forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts.
- compositions, a pharmaceutical composition, a liquid composition, a unit dosage form, or an oral formulation comprising the crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salt disclosed herein.
- One aspect of the disclosure provides for use of such crystalline form of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salt, composition, pharmaceutical composition, liquid composition, unit dosage form, or oral formulation in medicine.
- One aspect of the disclosure provides for use of such crystalline form of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salt, composition, pharmaceutical composition, liquid composition, unit dosage form, or oral formulation in the treatment of a kidney disease, an arthritic disease, a cardiovascular disease, atherosclerosis, a viral disease or disorder, or a systemic inflammatory disorder.
- FIG. 1 XRPD diffractogram for AP1189 acetate salt Pattern 1 crystallised from acetonitrile.
- FIG. 2 XRPD diffractogram for AP1189 acetate salt Pattern 1 and 2 crystallised from ethyl acetate.
- FIG. 3 XRPD diffractogram for AP1189 acetate salt Pattern 3 crystallised from THF.
- FIG. 4 XRPD diffractogram for AP1189 tosylate salt Pattern 1 crystallised from methanol.
- FIG. 5 XRPD diffractogram for AP1189 fumarate salt Pattern 1 crystallised from isopropylalcohol:water 90:10 v/v.
- FIG. 6 XRPD diffractogram for AP1189 succinate salt Pattern 1 crystallised from isopropylalcohol:water 90:10 v/v.
- FIG. 7 TGA/DSC thermogram of AP1189 acetate Pattern 1 from 1,4-dioxane. Peak temperature: 183.75° C.; onset: 164.62° C.; enthalpy (normalised): 629.95 J/g. Weight loss: 0.001 mg; weight percent loss: 0.057%.
- FIG. 8 DSC thermogram of AP1189 acetate Pattern 1 from acetonitrile. Peak temperature 197.86° C.; onset: 192.19° C.; enthalpy (normalised): 147.26 J/g.
- FIG. 9 TGA/DSC thermogram of AP1189 acetate Pattern 1 & 2 from 2-methyl THF. Peak temperature: 194.18° C.; onset: 171.54° C.; enthalpy (normalised): 475.77 J/g. Weight loss: 0.021 mg; weight percent loss: 0.478%.
- FIG. 10 TGA/DSC thermogram of AP1189 acetate Pattern 3 from THF. Peak temperature: 118.76° C.; onset: 100.62° C.; enthalpy (normalised): 138.49 J/g.
- First weight loss segment weight loss: 0.002 mg; weight percent loss: 0.067%.
- Second weight loss segment weight loss: 0.672 mg; weight percent loss: 18.610%.
- FIG. 11 TGA/DSC thermogram of AP1189 tosylate Pattern 1 from IPA:water 90:10 v/v after storage at 40° C. Peak temperature: 239.24° C.; onset: 233.75° C.; enthalpy (normalised): 99.785 J/g. Weight loss: 0.006 mg; weight percent loss: 0.330%.
- FIG. 12 TGA/DSC thermogram of AP1189 fumarate Pattern 1 from 2-propanol:water 90:10. Peak temperature: 218.27° C.; onset: 214.61° C.; enthalpy (normalised): 68.467 J/g. WE0.012 mg; weight percent loss: 0.319%.
- FIG. 13 DSC thermogram of AP1189 succinate Pattern 1 from IPA:water 90:10 v/v. Peak temperature: 196.27° C.; onset: 195.18° C.; enthalpy (normalised): 196.27 J/g.
- FIG. 14 XRPD Diffractogram of AP1189 Napadisylate Pattern 1.
- FIG. 15 XRPD Diffractogram of AP1189 Napadisylate Pattern 2.
- FIG. 16 XRPD Diffractogram of AP1189 Esylate Pattern 1.
- FIG. 17 XRPD Diffractogram of AP1189 Edisylate Pattern 1.
- FIG. 18 XRPD Diffractogram of AP1189 Edisylate Pattern 2.
- FIG. 19 XRPD Diffractogram of AP1189 Edisylate Pattern 4.
- FIG. 20 XRPD Diffractogram of AP1189 Edisylate Pattern 5.
- FIG. 21 XRPD Diffractogram of AP1189 Nitrate Pattern 1.
- FIG. 22 XRPD Diffractogram of AP1189 Cyclamate Pattern 2.
- FIG. 23 XRPD Diffractogram of AP1189 Cyclamate Pattern 4.
- FIG. 24 XRPD Diffractogram of AP1189 Cyclamate Pattern 5.
- FIG. 25 XRPD Diffractogram of AP1189 Besylate Pattern 1.
- FIG. 26 XRPD Diffractogram of AP1189 Oxalate Pattern 1.
- FIG. 27 XRPD Diffractogram of AP1189 Oxalate Pattern 2.
- FIG. 28 XRPD Diffractogram of AP1189 Oxalate Pattern 4.
- FIG. 29 XRPD Diffractogram of AP1189 (+)-Camphor-10-sulfonic acid Pattern 1.
- FIG. 30 XRPD Diffractogram of AP1189 Oxoglutarate Pattern 1.
- FIG. 31 XRPD Diffractogram of AP1189 DL-mandelic acid Pattern 2.
- FIG. 32 XRPD Diffractogram of AP1189 DL-mandelic acid Pattern 3.
- FIG. 33 XRPD Diffractogram of AP1189 Hippuric acid Pattern 1.
- FIG. 34 XRPD Diffractogram of AP1189 Formic acid Pattern 1.
- FIG. 35 XRPD Diffractogram of AP1189 DL-Lactic acid Pattern 1.
- FIG. 36 XRPD Diffractogram of AP1189 DL-Lactic acid Pattern 1.
- FIG. 37 XRPD Diffractogram of AP1189 Glutaric acid Pattern 1.
- FIG. 38 XRPD Diffractogram of AP1189 Glutaric acid Pattern 1.
- FIG. 39 XRPD Diffractogram of AP1189 Adipic acid Pattern 1.
- FIG. 40 TG/DSC thermogram of AP1189 Napadisylate Pattern 1. Weight loss: 0.1356 mg. Weight Percent Loss: 3.974%. Enthalpy (normalised): 29.422 J/g; Onset x: 87.38° C.; peak temperature: 104.76° C. Enthalpy (normalised): 1.8937 J/g; Peak temperature: 187.47° C.
- FIG. 41 TG/DSC thermogram of AP1189 Esylate Pattern 1. Weight Loss: 0.032 mg. Weight Percent Loss: 0.911%. Enthalpy (normalised): 42.119 J/g; Onset x: 201.95° C.; Peak temperature: 207.06° C.
- FIG. 42 TG/DSC thermogram of AP1189 Edisylate Pattern 2. Weight Loss: 0.061 mg. Weight Percent Loss: 1.175%. Weight Loss: 0.158 mg. Weight Percent Loss: 3.040%. Enthalpy (normalised): 3.1886 J/g; Onset x: 220.71° C.; Peak temperature: 224.57° C.
- FIG. 43 TG/DSC thermogram of AP1189 Edisylate Pattern 4. Weight Loss: 1.463 mg. Weight Percent Loss: 6.372%. Enthalpy (normalised): 100.17 J/g. Onset x: 208.40° C.; Peak temperature: 217.37° C.
- FIG. 44 TG/DSC thermogram of AP1189 Edisylate Pattern 5. Weight Loss: 0.120 mg. Weight Percent Loss: 4.701%. Enthalpy (normalised): 54.800 J/g; Onset x: 58.52° C.; Peak temperature: 78.51° C. Enthalpy (normalised): 0.93567 J/g; Onset x: Not found; Peak temperature: 151.11° C.
- FIG. 45 TG/DSC thermogram of AP1189 Nitrate Pattern 1. Weight Loss: 0.095 mg. Weight Percent Loss: 2.139%. Enthalpy (normalised): 0.4851 J/g; Onset x: 178.54° C.; Peak temperature: 182.88° C.
- FIG. 46 TG/DSC thermogram of AP1189 Cyclamate Pattern 2. Weight Loss: 0.033 mg. Weight Percent Loss: 0.459%. Enthalpy (normalised): 6.4491 J/g; Onset x: 129.90° C.; Peak temperature: 137.27° C.
- FIG. 47 TG/DSC thermogram of AP1189 Cyclamate Pattern 4. Weight Loss: 0.041 mg. Weight Percent Loss: 1.080%. Weight Loss: 0.088 mg. Weight Percent Loss: 2.337%. Enthalpy (normalised): 0.0143 J/g; Onset x: 133.07° C.; Peak temperature: 138.20° C.
- FIG. 48 TG/DSC thermogram of AP1189 Besylate Pattern 1. Weight Loss: 0.014 mg. Weight Percent Loss: 2.369%. Enthalpy (normalised): 48.524 J/g; Onset x: 216.45° C.; Peak temperature: 220.49° C.
- FIG. 49 TG/DSC thermogram of AP1189 Oxalate Pattern 1. Weight Loss: 0.023 mg. Weight Percent Loss: 1.665%. Enthalpy (normalised): 0.32686 J/g; Peak temperature: 210.52° C.
- FIG. 50 TG/DSC thermogram of AP1189 Oxalate Pattern 2. Weight Loss. 0.035 mg. Weight Percent Loss: 2.156%. Enthalpy (normalised): 40.935 J/g; Onset x: 207.42° C.; Peak temperature: 211.50° C.
- FIG. 51 TG/DSC thermogram of AP1189 Oxalate Pattern 4. Weight Loss: 0.016 mg. Weight Percent Loss: 2.164%.
- FIG. 52 TG/DSC thermogram of AP1189 (+)-Camphor-10-sulfonic acid Pattern 1. Weight Loss: 0.017 mg. Weight Percent Loss: 1.843%. Enthalpy (normalised): 107.65 J/g; Onset x: 205.38° C.; Peak temperature: 209.93° C.
- FIG. 53 TG/DSC thermogram of AP1189 Oxoglutarate Pattern 1. Weight Loss: 0.167 mg. Weight Percent Loss: 2.379%. Weight Loss: 0.462 mg. Weight Percent Loss: 6.588%. Enthalpy (normalised): 68.335 J/g. Onset x: 81.31° C. Peak temperature: 87.92° C.
- FIG. 54 TG/DSC thermogram of AP1189 DL-mandelic acid Pattern 2. Weight Loss: 0.424 mg. Weight Percent Loss: 8.372%. Enthalpy (normalised): 43.266 J/g; Onset x: 104.13° C.; Peak temperature: 110.06° C.
- FIG. 55 TG/DSC thermogram of AP1189 DL-mandelic acid Pattern 3. Weight Los: 0.066 mg. Weight Percent Loss: 3.021%. Weight Loss: 0.081 mg. Weight Percent Loss: 3.698%.
- FIG. 56 TG/DSC thermogram of AP1189 Hippuric acid Pattern 1. Weight Loss: 0.022 mg. Weight Percent Loss: 1.294%. Weight Loss: 0.026 mg. Weight Percent Loss: 1.495%. Enthalpy (normalised): 4.7263 J/g; Onset x: 138.92° C.; Peak temperature: 149.72° C.
- FIG. 57 FT-IR Spectrum of AP1189 Napadisylate Pattern 1.
- FIG. 58 FT-IR Spectrum of AP1189 Napadisylate Pattern 2.
- FIG. 59 FT-IR Spectrum of AP1189 Esylate Pattern 1.
- FIG. 60 FT-IR Spectrum of AP1189 Edisylate Pattern 2.
- FIG. 61 FT-IR Spectrum of AP1189 Edisylate Pattern 4.
- FIG. 62 FT-IR Spectrum of AP1189 Edisylate Pattern 5.
- FIG. 63 FT-IR Spectrum of AP1189 Nitrate Pattern 1.
- FIG. 64 FT-IR Spectrum of AP1189 Cyclamate Pattern 2.
- FIG. 65 FT-IR Spectrum of AP1189 Cyclamate Pattern 4.
- FIG. 66 FT-IR Spectrum of AP1189 Cyclamate Pattern 5.
- FIG. 67 FT-IR Spectrum of AP1189 Besylate Pattern 1.
- FIG. 68 FT-IR Spectrum of AP1189 Oxalate Pattern 1.
- FIG. 69 FT-IR Spectrum of AP1189 Oxalate Pattern 2.
- FIG. 70 FT-IR Spectrum of AP1189 Oxalate Pattern 4.
- FIG. 71 FT-IR Spectrum of AP1189 (+)-Camphor-10-sulfonic acid Pattern 1.
- FIG. 72 FT-IR Spectrum of AP1189 Oxoglutarate Pattern 1.
- FIG. 73 FT-IR Spectrum of AP1189 DL-mandelic acid Pattern 2.
- FIG. 74 FT-IR Spectrum of AP1189 DL-mandelic acid Pattern 3.
- FIG. 75 FT-IR Spectrum of AP1189 Hippuric acid Pattern 1.
- FIG. 76 FT-IR Spectrum of AP1189 Formic acid Pattern 1.
- FIG. 77 FT-IR Spectrum of AP1189 DL-Lactic acid Pattern 1.
- FIG. 78 FT-IR Spectrum of AP1189 DL-Lactic acid Pattern 1.
- FIG. 79 FT-IR Spectrum of AP1189 Glutaric acid Pattern 1.
- FIG. 80 FT-IR Spectrum of AP1189 Glutaric acid Pattern 2.
- FIG. 81 TG/DSC thermogram of AP1189 Napadisylate Pattern 2. Weight Loss: 0.157 mg. Weight Percent Loss: 7.940%.
- FIG. 82 TG/DSC thermogram of AP1189 Edisylate Pattern 1. Weight Loss: 0.082 mg. Weight Percent Loss: 4.634%. Enthalpy (normalised): 3.2707 J/g; Onset x: 69.98° C.; Peak temperature: 78.37° C. Enthalpy (normalised): 0.83635 J/g; Peak temperature: 151.31° C.
- FIG. 83 TG/DSC thermogram of AP1189 Cyclamate Pattern 5. Weight Loss: 0.070 mg. Weight Percent Loss: 1.696%. Enthalpy (normalised): 0.68855 J/g; Onset x: 140.91° C.; Peak temperature: 146.39° C.
- FIG. 84 TG/DSC thermogram of AP1189 Formic acid Pattern 1. Weight Loss: 0.008 mg. Weight Percent Loss: 3.049%. Enthalpy (normalised): 7.5282 J/g; Onset x: 169.12° C.; Peak temperature: 171.97° C.
- FIG. 85 TG/DSC thermogram of AP1189 DL-Lactic acid Pattern 1. Weight Loss: 0.026 mg. Weight Percent Loss: 0.859%. Enthalpy (normalised): 31.499 J/g. Onset x: 189.47° C. Peak temperature: 192.80° C.
- FIG. 86 TG/DSC thermogram of AP1189 DL-Lactic acid Pattern 1. Weight Loss: 0.034 mg. Weight Percent Loss: 1.476%. Enthalpy (normalised): 2.2523 J/g; Onset x: 198.48° C.; Peak temperature: 200.63° C.
- FIG. 87 TG/DSC thermogram of AP1189 Glutaric acid Pattern 1. Weight Loss: 0.27 mg. Weight Percent Loss: 1.256%. Enthalpy (normalised): 0.0964 J/g; Onset x: 109.24° C.; Peak temperature: 115.31° C. Enthalpy (normalised): 16.647 J/g; Onset x: 159.93° C.; Peak temperature: 164.02° C.
- FIG. 88 TG/DSC thermogram of AP1189 Glutaric acid Pattern 2. Weight Loss: 0.019 mg. Weight Percent Loss: 1.001%. Enthalpy (normalised): 48.550 J/g; Onset x: 162.77° C.; Peak temperature: 165.94° C.
- FIG. 89 TG/DSC thermogram of AP1189 Glutaric acid Pattern 4. Weight Loss: 0.010 mg. Weight Percent Loss: 1.764%. Enthalpy (normalised): 18.475 J/g; Onset x: 114.55° C.; Peak temperature: 148.15° C. Enthalpy (normalised): 10.102 J/g; Onset x: 160.45° C.; Peak temperature: 163.28° C.
- FIG. 90 TG/DSC thermogram of AP1189 Adipic acid Pattern 1. Weight Loss: 0.015 mg. Weight Percent Loss: 6.117%. Enthalpy (normalised): 12.428 J/g. Onset x: 183.34° C.; Peak temperature: 187.98° C.
- FIG. 91 XRPD Diffractogram of AP1189 Glutaric acid Pattern 4.
- FIG. 92 IR spectrum of AP1189 acetate Pattern 1.
- the term “AP1189” may refer to either the free base structure of Formula I or it may refer to the acetate salt of AP1189.
- the term “AP1189 free base” refers to the structure of Formula I.
- the term “AP1189 acetate” refers to the acetate salt of the structure of Formula I.
- SP1189 refers to the succinate salt of the structure of Formula I.
- SP1189 and AP1189 succinate are synonymous as used herein.
- N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetic acid then the non-protonated form is meant of that compound, e.g. “N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine acetic acid” is meant.
- the compound of the disclosure N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, including tautomers and stereoisomers thereof.
- the compound of the disclosure is N- ⁇ (1E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, including tautomers and stereoisomers thereof.
- the compound of the disclosure is N′′-[(E)-[3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, including tautomers and stereoisomers thereof.
- the compound of the disclosure is N- ⁇ (2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, including tautomers and stereoisomers thereof.
- the compound of the disclosure is N′′-[[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, including tautomers and stereoisomers thereof.
- the compound of the disclosure is N- ⁇ (1E,2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine (also termed (E)-N-trans- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine herein)), including tautomers thereof.
- the compound of the disclosure is N′′-[(E)-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, including tautomers thereof.
- the compound of the disclosure is selected from the group consisting of N- ⁇ (1Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, N- ⁇ (2Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, N- ⁇ (1Z,2Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, N- ⁇ (1Z,2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, and N- ⁇ (1E,2Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine, and N- ⁇ (1E,2Z)-3-[1-
- the compound of the disclosure is selected from the group consisting of N′′-[(Z)-[3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, N′′-[[(2Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, N′′-[(Z)-[(2Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, N′′-[(Z)-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine, and N′′-[(E)-[(2Z)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-
- the alkene moiety of the compound is in the E configuration, and the imine moiety is in the Z or the E configuration.
- the compound is a mixture of N′′-[(E)-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine and N′′-[(Z)-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]prop-2-en-1-ylidene]amino]guanidine.
- the compound of the disclosure may additionally be any tautomer of the above structures.
- tautomer means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom.
- the method of measuring the value inherently comprises some degree of uncertainty. For example, measurements of 2-theta values may have an uncertainty of 0.2°.
- a crystalline “Form A” of AP1189 acetate is meant the crystalline form of AP1189 acetate that exhibits the X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation corresponding to AP1189 acetate Pattern 1 as disclosed herein.
- a crystalline “Form B” of AP1189 succinate is meant the crystalline form of AP1189 succinate that exhibits the X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation corresponding to AP1189 succinate Pattern 1 as disclosed herein.
- the unit of 2-theta values is degrees (°).
- onset temperature is meant the designed intersection point of the extrapolated baseline and the inflectional tangent at the beginning of the melting.
- seeding refers to the technique of adding a “seed” crystal to the crystallization solution to promote the formation of crystals.
- the composition of the seed crystal is the same as the composition of the crystals being formed.
- the present disclosure provides the compound AP1189, specifically a salt thereof.
- One embodiment provides for the compound AP1189, including tautomeric forms thereof and/or isomeric forms thereof, such as enantiomeric forms and/or diastereomeric forms thereof.
- the diastereomeric forms comprise cis and trans forms of the compound, specifically with respect to the alkene moiety.
- the compound may also exist as either the E or Z form with respect to the C ⁇ N double bond of the structure of Formula I.
- E configuration is synonymous to trans configuration
- Z configuration is synonymous to cis configuration.
- both of the atoms forming part of a double bond are each bound to exactly 1 further moiety that is not a hydrogen moiety or a lone pair.
- One embodiment of the present disclosure provides for the acetate salt of AP1189.
- Another embodiment of the present disclosure provides for the succinate salt of AP1189.
- the term “compound of the disclosure” means the crystalline Form A of AP1189 acetate.
- the term “compound of the disclosure” means the crystalline Form B of AP1189 succinate.
- the pharmaceutically acceptable salt of AP1189 is selected from the group consisting of:
- a pharmaceutically acceptable salt of AP1189 is selected from the group consisting of the acetate salt of AP1189, the succinate salt of AP1189, the DL-mandelic acid salt of AP1189, the hippuric acid salt of AP1189, the L-lactic acid salt of AP1189, the besylate salt of AP1189, the oxoglutarate salt of AP1189, the formic acid salt of AP1189, the DL-lactic acid salt of AP1189, the glutaric acid salt of AP1189, the adipic acid salt of AP1189 and the nitrate salt of AP1189.
- One embodiment provides for a salt of AP1189 selected from the group consisting of:
- treatment refers to the management and care of a subject for the purpose of combating a condition, disease or disorder.
- the term is intended to include the full spectrum of treatments for a given condition from which the subject is suffering.
- the subject to be treated is preferably a mammal, in particular a human being.
- Treatment of animals, such as mice, rats, dogs, cats, horses, cows, sheep and pigs, is, however, also within the scope of the present context.
- the subjects to be treated can be of various ages.
- an oral formulation as disclosed herein comprising a crystalline form of an AP1189 salt disclosed herein, for use in the treatment of a disease or disorder in a subject, wherein the subject to be treated is a mammal.
- the mammal is a human being.
- the mammal is a domestic animal.
- the mammal is selected from the group consisting of mice, rats, dogs, cats, horses, cows, sheep and pigs.
- the present disclosure relates to crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts. It is an object of the disclosure to provide crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salts having high solubility in aqueous medium, particularly at low pH.
- Crystalline forms of AP1189 and salts thereof may be characterised by X-Ray Powder Diffraction (XRPD) analysis.
- XRPD X-Ray Powder Diffraction
- Such analysis may be carried out using a suitable X-ray powder diffractometer such as a PANalytical X'pert pro with PIXcel detector (128 channels). Scanning of samples may be performed between 3 and 35° 2 ⁇ . Samples may be gently ground prior to measurement to release any agglomerates. Samples may be loaded onto a multi-well plate with Kapton or Mylar polymer film to support the sample.
- Table 1 shows an overview of the polymorphs disclosed herein
- the present disclosure provides for a crystalline Form A of AP1189 acetate.
- Crystalline Form A of AP1189 acetate exhibits an XRPD diffractogram as shown in FIG. 1 .
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 11.5 ⁇ 0.2, 23.5 ⁇ 0.2, and 27.0 ⁇ 0.2.
- One embodiment provides for a crystalline Form A of AP1189 acetate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.7 ⁇ 0.2, 13.0 ⁇ 0.2, 15.5 ⁇ 0.2, 15.6 ⁇ 0.2, 16.2 ⁇ 0.2, 19.6 ⁇ 0.2, 20.0 ⁇ 0.2, 21.1 ⁇ 0.2, and 24.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 1 .
- One embodiment of the disclosure provides for a crystalline Form A of AP1189 acetate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.1, 11.5, 11.7, 12.2, 13.0, 15.5, 15.6, 15.9, 16.2, 18.3, 18.6, 19.6, 20.0, 20.6, 21.1, 21.5, 21.8, 22.3, 23.5, 24.8, 25.7, 27.0, 27.5, 28.2, 28.5, 30.2, 30.7, 31.2, 32.3, 32.9, 33.4, and 34.3.
- One embodiment of the disclosure provides for a crystalline Form A of AP1189 acetate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.1 ⁇ 0.2, 11.5 ⁇ 0.2, 11.7 ⁇ 0.2, 12.2 ⁇ 0.2, 13.0 ⁇ 0.2, 15.5 ⁇ 0.2, 15.6 ⁇ 0.2, 15.9 ⁇ 0.2, 16.2 ⁇ 0.2, 18.3 ⁇ 0.2, 18.6 ⁇ 0.2, 19.6 ⁇ 0.2, 20.0 ⁇ 0.2, 20.6 ⁇ 0.2, 21.1 ⁇ 0.2, 21.5 ⁇ 0.2, 21.8 ⁇ 0.2, 22.3 ⁇ 0.2, 23.5 ⁇ 0.2, 24.8 ⁇ 0.2, 25.7 ⁇ 0.2, 27.0 ⁇ 0.2, 27.5 ⁇ 0.2, 28.2 ⁇ 0.2, 28.5 ⁇ 0.2, 30.2 ⁇ 0.2, 30.7 ⁇ 0.2, 31.2 ⁇ 0.2, 32.3 ⁇ 0.2, 32.9 ⁇ 0.2, 33.4 ⁇ 0.2, and 34.3 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.5, 11.7, 13.0, 15.5, 15.6, 16.2, 19.6, 20.0, 21.1, 23.5, 24.8, and 27.0.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.5 ⁇ 0.2, 11.7 ⁇ 0.2, 13.0 ⁇ 0.2, 15.5 ⁇ 0.2, 15.6 ⁇ 0.2, 16.2 ⁇ 0.2, 19.6 ⁇ 0.2, 20.0 ⁇ 0.2, 21.1 ⁇ 0.2, 23.5 ⁇ 0.2, 24.8 ⁇ 0.2, and 27.0 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 2.
- AP1189 acetate Another crystalline form of AP1189 acetate has been identified herein which exhibits a mixture of a XRPD Pattern 1 and XRPD Pattern 2.
- the crystalline Form A of AP1189 acetate is substantially free of the polymorph of AP1189 acetate, which gives rise to XRPD Pattern 2.
- “substantially free” means that the crystalline Form A of AP1189 acetate comprises less than 90% of the polymorph of AP1189 acetate which gives rise to XRPD Pattern 2, such as less than 80%, such as less than 70%, such as less than 60%, such as less than 50%, such as less than 40%, such as less than 30%, such as less than 20%, such as less than 15%, such as less than 10%, such as less than 5% of the polymorph of AP1189 acetate, which gives rise to XRPD Pattern 2.
- the content of the polymorph of AP1189 acetate, which gives rise to XRPD Pattern 2 may be assessed by the intensity of X-ray lines of Pattern 2 relative to the intensity of the X-ray lines of Pattern 1 of AP1189 acetate.
- Pattern 2 exhibits X-ray lines at (2-theta values) 14.9, 18.0, and 24.2 which do not overlap with X-ray lines originating from Pattern 1 of AP1189.
- one embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate substantially free of a second crystalline form of AP1189 acetate, the second crystalline form of AP1189 acetate exhibits X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.9 ⁇ 0.2, 18.0 ⁇ 0.2, and/or 24.2 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate substantially free of a second crystalline form of AP1189 acetate, the second crystalline form of AP1189 acetate exhibits X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.9, 18.0, and/or 24.2.
- the crystalline Form A of AP1189 acetate exhibits no X-ray lines at 14.9 ⁇ 0.2, 18.0 0.2, and/or 24.2 ⁇ 0.2 in an powder diffraction pattern, or the crystalline Form A of AP1189 acetate exhibits lines at 14.9 ⁇ 0.2, 18.0 ⁇ 0.2, and/or 24.2 ⁇ 0.2 that have a relative intensity less than 30%, such as less than 25%, such as less than 20%, such as less than 15%, such as less than 10%, such as less than 5%.
- the present disclosure provides for a crystalline Form B of AP1189 succinate.
- Crystalline Form B of AP1189 succinate exhibits an XRPD diffractogram as shown in FIG. 6 .
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 9.7 ⁇ 0.2, 22.8 ⁇ 0.2, and 26.7 ⁇ 0.2.
- One embodiment provides for a crystalline Form B of AP1189 succinate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 13.4 ⁇ 0.2, 16.3 ⁇ 0.2, and 19.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.2 ⁇ 0.2, 15.8 ⁇ 0.2, 21.8 ⁇ 0.2, and 28.5 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form B of AP1189 succinate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 6 .
- One embodiment of the disclosure provides for a crystalline Form B of AP1189 succinate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4, 9.7, 12.2, 12.7, 13.4, 13.6, 15.8, 16.3, 18.1, 18.6, 18.9, 19.5, 19.9, 21.1, 21.8, 21.8, 22.0, 22.2, 22.4, 22.8, 23.4, 23.7, 24.6, 25.0, 25.3, 26.1, 26.3, 26.7, 27.5, 28.5, 29.1, 29.4, 30.0, 31.5, 32.3, 32.7, 33.6, and 34.1.
- One embodiment of the disclosure provides for a crystalline Form B of AP1189 succinate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 9.7 ⁇ 0.2, 12.2 ⁇ 0.2, 12.7 ⁇ 0.2, 13.4 ⁇ 0.2, 13.6 ⁇ 0.2, 15.8 ⁇ 0.2, 16.3 ⁇ 0.2, 18.1 ⁇ 0.2, 18.6 ⁇ 0.2, 18.9 ⁇ 0.2, 19.5 ⁇ 0.2, 19.9 ⁇ 0.2, 21.1 ⁇ 0.2, 21.8 ⁇ 0.2, 21.8 ⁇ 0.2, 22.0 ⁇ 0.2, 22.2 ⁇ 0.2, 22.4 ⁇ 0.2, 22.8 ⁇ 0.2, 23.4 ⁇ 0.2, 23.7 ⁇ 0.2, 24.6 ⁇ 0.2, 25.0 ⁇ 0.2, 25.3 ⁇ 0.2, 26.1 ⁇ 0.2, 26.3 ⁇ 0.2, 26.7 ⁇ 0.2, 27.5 ⁇ 0.2, 28.5 ⁇ 0.2, 29.1 ⁇ 0.2, 29.4 ⁇ 0.2, 30.0 ⁇ 0.2, 31.5 ⁇ 0.2, 32.3 ⁇ 0.2, 32.7 ⁇ 0.2, 33.6 ⁇ 0.2, and 34.1 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4, 9.7, 12.2, 13.4, 15.8, 16.3, 19.5, 21.8, 22.8, 26.7, and 28.5.
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 9.7 ⁇ 0.2, 12.2 ⁇ 0.2, 13.4 ⁇ 0.2, 15.8 ⁇ 0.2, 16.3 ⁇ 0.2, 19.5 ⁇ 0.2, 21.8 ⁇ 0.2, 22.8 ⁇ 0.2, 26.7 ⁇ 0.2, and 28.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 7.
- One embodiment provides for crystalline forms of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate, which may be converted to AP1189 acetate of crystalline Form A.
- One embodiment provides for a crystalline Form I of AP1189 acetate corresponding to XRPD Pattern 1 and 2.
- a specific embodiment provides for a crystalline Form I of AP1189 acetate exhibiting X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at one or more of 11.5 ⁇ 0.2, 11.7 ⁇ 0.2, 12.9 ⁇ 0.2, 14.9 ⁇ 0.2, 15.4 ⁇ 0.2, 15.6 ⁇ 0.2, 18.0 ⁇ 0.2, 19.9 ⁇ 0.2, 20.0 ⁇ 0.2, 21.1 ⁇ 0.2, 21.5 ⁇ 0.2, 21.8 ⁇ 0.2, 22.4 ⁇ 0.2, 23.5 ⁇ 0.2, 24.2 ⁇ 0.2, 24.7 ⁇ 0.2, and 26.9 ⁇ 0.2.
- One embodiment provides for a crystalline Form I of AP1189 acetate exhibiting X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation as shown in FIG. 2 .
- One embodiment of the present disclosure provides for a crystalline Form II of AP1189 acetate corresponding to XRPD Pattern 3.
- a specific embodiment provides for a crystalline Form II of AP1189 acetate exhibiting X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at one or more of 7.5 ⁇ 0.2, 9.4 ⁇ 0.2, 12.8 ⁇ 0.2, 13.3 ⁇ 0.2, 14.2 ⁇ 0.2, 15.3 ⁇ 0.2, 16.0 ⁇ 0.2, 17.0 ⁇ 0.2, 18.8 ⁇ 0.2, 19.7 ⁇ 0.2, 20.3 ⁇ 0.2, 21.1 ⁇ 0.2, 21.4 ⁇ 0.2, 21.9 ⁇ 0.2, 22.0 ⁇ 0.2, 22.7 ⁇ 0.2, and 23.1 ⁇ 0.2.
- One embodiment provides for a crystalline Form II of AP1189 acetate exhibiting X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation as shown in FIG. 3 .
- One embodiment of the present disclosure provides for a solid form of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate.
- One embodiment of the present disclosure provides for a solid, amorphous form of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate.
- the disclosure also provides for a crystalline Form C of AP1189 tosylate.
- Crystalline Form C of AP1189 tosylate exhibits an XRPD diffractogram as shown in FIG. 4 .
- One embodiment of the present disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.5 ⁇ 0.2, 21.0 ⁇ 0.2, and 25.2 ⁇ 0.2.
- the crystalline Form C of AP1189 tosylate further exhibits one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 13.4 ⁇ 0.2 and 16.0 ⁇ 0.2. In one embodiment of the present disclosure, the crystalline Form C of AP1189 tosylate further exhibits one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.0 ⁇ 0.2, 9.4 ⁇ 0.2, 10.0 ⁇ 0.2, 15.3 ⁇ 0.2, 16.7 ⁇ 0.2, 17.6 ⁇ 0.2, 19.2 ⁇ 0.2, 19.8 ⁇ 0.2, 21.3 ⁇ 0.2, and 25.4 ⁇ 0.2. In one embodiment, the crystalline Form C of AP1189 tosylate exhibits an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 4 .
- One embodiment of the disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.0, 9.4, 10.0, 10.8, 12.1, 12.3, 13.4, 14.1, 14.5, 15.3, 15.7, 16.0, 16.7, 17.6, 19.2, 19.8, 20.0, 20.7, 21.0, 21.3, 22.0, 22.4, 22.7, 22.8, 23.1, 23.6, 24.1, 24.3, 25.2, 25.4, 25.7, 26.1, 26.7, 27.1, 27.7, 28.1, 29.0, 29.2, 29.9, 30.3, 30.7, 31.4, 32.7, 33.2, 33.5, and 34.1.
- One embodiment of the disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.0 ⁇ 0.2, 9.4 ⁇ 0.2, 10.0 ⁇ 0.2, 10.8 ⁇ 0.2, 12.1 ⁇ 0.2, 12.3 ⁇ 0.2, 13.4 ⁇ 0.2, 14.1 ⁇ 0.2, 14.5 ⁇ 0.2, 15.3 ⁇ 0.2, 15.7 ⁇ 0.2, 16.0 ⁇ 0.2, 16.7 ⁇ 0.2, 17.6 ⁇ 0.2, 19.2 ⁇ 0.2, 19.8 ⁇ 0.2, 20.0 ⁇ 0.2, 20.7 ⁇ 0.2, 21.0 ⁇ 0.2, 21.3 ⁇ 0.2, 22.0 ⁇ 0.2, 22.4 ⁇ 0.2, 22.7 ⁇ 0.2, 22.8 ⁇ 0.2, 23.1 ⁇ 0.2, 23.6 ⁇ 0.2, 24.1 ⁇ 0.2, 24.3 ⁇ 0.2, 25.2 ⁇ 0.2, 25.4 ⁇ 0.2, 25.7 ⁇ 0.2, 26.1 ⁇ 0.2, 26.7 ⁇ 0.2, 27.1 ⁇ 0.2, 27.7 ⁇ 0.2, 28.1 ⁇ 0.2, 29.0 ⁇ 0.2, 29.
- one embodiment of the present disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.0, 9.4, 10.0, 13.4, 14.5, 15.3, 16.0, 16.7, 17.6, 19.2, 19.8, 21.0, 21.3, 25.2, and 25.4.
- One embodiment of the present disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.0 ⁇ 0.2, 9.4 ⁇ 0.2, 10.0 0.2, 13.4 ⁇ 0.2, 14.5 ⁇ 0.2, 15.3 ⁇ 0.2, 16.0 ⁇ 0.2, 16.7 ⁇ 0.2, 17.6 ⁇ 0.2, 19.2 ⁇ 0.2, 19.8 ⁇ 0.2, 21.0 ⁇ 0.2, 21.3 ⁇ 0.2, 25.2 ⁇ 0.2, and 25.4 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 5.
- the disclosure also provides for a crystalline Form D of AP1189 fumarate.
- Crystalline Form D of AP1189 fumarate exhibits an XRPD diffractogram as shown in FIG. 5 .
- One embodiment of the present disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 17.6 ⁇ 0.2, 21.2 ⁇ 0.2, and 26.3 ⁇ 0.2.
- the crystalline Form D of AP1189 fumarate further exhibits one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.5 ⁇ 0.2, 21.9 ⁇ 0.2, and 23.9 ⁇ 0.2. In one embodiment of the present disclosure, the crystalline Form D of AP1189 fumarate further exhibits one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.2 ⁇ 0.2, 10.5 ⁇ 0.2, 10.9 ⁇ 0.2, 11.9 ⁇ 0.2, 15.8 ⁇ 0.2, 18.7 ⁇ 0.2, 19.4 ⁇ 0.2, 23.4 ⁇ 0.2, and 24.5 ⁇ 0.2. In one embodiment, the crystalline Form D of AP1189 fumarate exhibits an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 5 .
- One embodiment of the disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.6, 9.2, 10.2, 10.5, 10.9, 11.5, 11.9, 13.4, 15.8, 16.0, 16.4, 16.6, 17.3, 17.6, 18.2, 18.5, 18.7, 19.4, 19.6, 19.8, 20.6, 21.2, 21.4, 21.9, 22.7, 23.1, 23.4, 23.9, 24.5, 24.8, 25.0, 26.1, 26.3, 27.0, 27.6, 28.0, 28.5, 28.8, 29.1, 29.5, 29.9, 30.3, 31.0, 31.0, 31.5, 32.0, 32.4, 33.1, 33.5, 34.2, and 34.7.
- One embodiment of the disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.6 ⁇ 0.2, 9.2 ⁇ 0.2, 10.2 ⁇ 0.2, 10.5 ⁇ 0.2, 10.9 ⁇ 0.2, 11.5 ⁇ 0.2, 11.9 ⁇ 0.2, 13.4 ⁇ 0.2, 15.8 ⁇ 0.2, 16.0 ⁇ 0.2, 16.4 ⁇ 0.2, 16.6 ⁇ 0.2, 17.3 ⁇ 0.2, 17.6 ⁇ 0.2, 18.2 ⁇ 0.2, 18.5 ⁇ 0.2, 18.7 ⁇ 0.2, 19.4 ⁇ 0.2, 19.6 ⁇ 0.2, 19.8 ⁇ 0.2, 20.6 ⁇ 0.2, 21.2 ⁇ 0.2, 21.4 ⁇ 0.2, 21.9 ⁇ 0.2, 22.7 ⁇ 0.2, 23.1 ⁇ 0.2, 23.4 ⁇ 0.2, 23.9 ⁇ 0.2, 24.5 ⁇ 0.2, 24.8 ⁇ 0.2, 25.0 ⁇ 0.2, 26.1 ⁇ 0.2, 26.3 ⁇ 0.2, 27.0 ⁇ 0.2, 27.6 ⁇ 0.2, 28.0 ⁇ 0.2, 28.5 ⁇ 0.2, 28.8 ⁇ 0.2,
- one embodiment of the present disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.2, 10.5, 10.9, 11.5, 11.9, 15.8, 17.6, 18.7, 19.4, 21.2, 21.9, 23.4, 23.9, 24.5, 26.3.
- One embodiment of the present disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.2 ⁇ 0.2, 10.5 ⁇ 0.2, 10.9 ⁇ 0.2, 11.5 ⁇ 0.2, 11.9 ⁇ 0.2, 15.8 ⁇ 0.2, 17.6 ⁇ 0.2, 18.7 ⁇ 0.2, 19.4 ⁇ 0.2, 21.2 ⁇ 0.2, 21.9 ⁇ 0.2, 23.4 ⁇ 0.2, 23.9 ⁇ 0.2, 24.5 ⁇ 0.2, 26.3 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 6.
- the present disclosure provides for a crystalline Form III of AP1189 napadisylate.
- Crystalline Form III of AP1189 napadisylate exhibits an XRPD diffractogram as shown in FIG. 14 .
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 13.4 ⁇ 0.2, 22.2 ⁇ 0.2, and 26.8 ⁇ 0.2.
- One embodiment provides for a crystalline Form III of AP1189 napadisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 15.1 ⁇ 0.2, 15.5 ⁇ 0.2, 23.5 ⁇ 0.2, and 28.0 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.6 ⁇ 0.2, 10.7 ⁇ 0.2, 12.4 ⁇ 0.2, and 22.8 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 14 .
- One embodiment of the disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.5, 10.7, 12.4, 13.4, 14.0, 15.1, 15.5, 17.2, 18.3, 18.8, 19.3, 20.3, 21.4, 21.8, 22.2, 22.8, 23.5, 24.3, 24.9, 25.3, 26.8, 27.1, 27.6, 28.0, 28.5, 28.9, 29.5, 29.9, 30.5, 31.4, 31.9, 32.6, and 33.5.
- embodiment of the disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.5 ⁇ 0.2, 10.7 ⁇ 0.2, 12.4 ⁇ 0.2, 13.4 ⁇ 0.2, 14.0 ⁇ 0.2, 15.1 ⁇ 0.2, 15.5 ⁇ 0.2, 17.2 ⁇ 0.2, 18.3 ⁇ 0.2, 18.8 ⁇ 0.2, 19.3 ⁇ 0.2, 20.3 ⁇ 0.2, 21.4 ⁇ 0.2, 21.8 ⁇ 0.2, 22.2 ⁇ 0.2, 22.8 ⁇ 0.2, 23.5 ⁇ 0.2, 24.3 ⁇ 0.2, 24.9 ⁇ 0.2, 25.3 ⁇ 0.2, 26.8 ⁇ 0.2, 27.1 ⁇ 0.2, 27.6 ⁇ 0.2, 28.0 ⁇ 0.2, 28.5 ⁇ 0.2, 28.9 ⁇ 0.2, 29.5 ⁇ 0.2, 29.9 ⁇ 0.2, 30.5 ⁇ 0.2, 31.4 ⁇ 0.2, 31.9 ⁇ 0.2, 32.6 ⁇ 0.2, and 33.5 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.6, 10.7, 12.4, 13.4, 15.1, 15.5, 22.2, 22.8, 23.5, 26.8, and 28.0.
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.6 ⁇ 0.2, 10.7 ⁇ 0.2, 12.4 ⁇ 0.2, 13.4 ⁇ 0.2, 15.1 ⁇ 0.2, 15.5 ⁇ 0.2, 22.2 ⁇ 0.2, 22.8 ⁇ 0.2, 23.5 ⁇ 0.2, 26.8 ⁇ 0.2, and 28.0 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 9.
- the present disclosure provides for a crystalline Form IV of AP1189 napadisylate.
- Crystalline Form IV of AP1189 napadisylate exhibits an XRPD diffractogram as shown in FIG. 15 .
- One embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 5.4 ⁇ 0.2, 15.6 ⁇ 0.2, and 23.4 ⁇ 0.2.
- One embodiment provides for a crystalline Form IV of AP1189 napadisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 18.4 ⁇ 0.2, 22.0 0.2, 24.2 ⁇ 0.2, and 25.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.5 ⁇ 0.2, 10.8 ⁇ 0.2, 12.6 ⁇ 0.2, 13.1 ⁇ 0.2, 19.5 ⁇ 0.2, 19.9 ⁇ 0.2, 21.1 ⁇ 0.2, 22.7 ⁇ 0.2, and 25.2 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 15 .
- One embodiment of the disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4, 6.5, 7.4, 8.5, 10.1, 10.8, 11.3, 12.1, 12.6, 13.1, 15.6, 16.3, 16.6, 18.4, 19.0, 19.5, 19.9, 20.3, 21.1, 22.0, 22.7, 23.4, 24.2, 25.2, 25.8, 26.9, and 30.5.
- One embodiment of the disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 6.5 ⁇ 0.2, 7.4 ⁇ 0.2, 8.5 ⁇ 0.2, 10.1 ⁇ 0.2, 10.8 ⁇ 0.2, 11.3 ⁇ 0.2, 12.1 ⁇ 0.2, 12.6 ⁇ 0.2, 13.1 ⁇ 0.2, 15.6 ⁇ 0.2, 16.3 ⁇ 0.2, 16.6 ⁇ 0.2, 18.4 ⁇ 0.2, 19.0 ⁇ 0.2, 19.5 ⁇ 0.2, 19.9 ⁇ 0.2, 20.3 ⁇ 0.2, 21.1 ⁇ 0.2, 22.0 ⁇ 0.2, 22.7 ⁇ 0.2, 23.4 ⁇ 0.2, 24.2 ⁇ 0.2, 25.2 ⁇ 0.2, 25.8 ⁇ 0.2, 26.9 ⁇ 0.2, and 30.5 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4, 8.5, 10.8, 12.6, 13.1, 15.6, 18.4, 19.5, 19.9, 21.1, 22.0, 22.7, 23.4, 24.2, 25.2, and 25.8.
- One embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 8.5 ⁇ 0.2, 10.8 ⁇ 0.2, 12.6 ⁇ 0.2, 13.1 ⁇ 0.2, 15.6 ⁇ 0.2, 18.4 ⁇ 0.2, 19.5 ⁇ 0.2, 19.9 ⁇ 0.2, 21.1 ⁇ 0.2, 22.0 ⁇ 0.2, 22.7 ⁇ 0.2, 23.4 ⁇ 0.2, 24.2 ⁇ 0.2, 25.2 ⁇ 0.2, and 25.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 10.
- the present disclosure provides for a crystalline Form V of AP1189 esylate.
- Crystalline Form V of AP1189 esylate exhibits an XRPD diffractogram as shown in FIG. 16 .
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.5 ⁇ 0.2, 16.5 ⁇ 0.2, and 18.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form V of AP1189 esylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.8 ⁇ 0.2, 19.7 ⁇ 0.2, 20.1 ⁇ 0.2, and 26.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.5 ⁇ 0.2, 10.4 ⁇ 0.2, 15.3 ⁇ 0.2, 21.9 ⁇ 0.2, 22.5 ⁇ 0.2, and 26.1 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form V of AP1189 esylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 16 .
- One embodiment of the disclosure provides for a crystalline Form V of AP1189 esylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.5, 9.8, 10.4, 11.3, 11.5, 13.0, 14.3, 14.5, 15.3, 16.5, 18.6, 19.7, 20.1, 21.0, 21.1, 21.9, 22.4, 23.9, 25.5, 26.1, 26.4, 26.8, 27.5, 29.7, 31.4, 32.2, and 33.5.
- One embodiment of the disclosure provides for a crystalline Form V of AP1189 esylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.5 ⁇ 0.2, 9.8 ⁇ 0.2, 10.4 ⁇ 0.2, 11.3 ⁇ 0.2, 11.5 ⁇ 0.2, 13.0 ⁇ 0.2, 14.3 ⁇ 0.2, 14.5 ⁇ 0.2, 15.3 ⁇ 0.2, 16.5 ⁇ 0.2, 18.6 ⁇ 0.2, 19.7 ⁇ 0.2, 20.1 ⁇ 0.2, 21.0 ⁇ 0.2, 21.1 ⁇ 0.2, 21.9 ⁇ 0.2, 22.4 ⁇ 0.2, 23.9 ⁇ 0.2, 25.5 ⁇ 0.2, 26.1 ⁇ 0.2, 26.4 ⁇ 0.2, 26.8 ⁇ 0.2, 27.5 ⁇ 0.2, 29.7 ⁇ 0.2, 31.4 ⁇ 0.2, 32.2 ⁇ 0.2, and 33.5 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.5, 9.8, 10.4, 14.5, 15.3, 16.5, 18.6, 19.7, 20.1, 21.9, 22.5, 26.1, and 26.8.
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.5 ⁇ 0.2, 9.8 ⁇ 0.2, 10.4 ⁇ 0.2, 14.5 ⁇ 0.2, 15.3 ⁇ 0.2, 16.5 ⁇ 0.2, 18.6 ⁇ 0.2, 19.7 ⁇ 0.2, 20.1 ⁇ 0.2, 21.9 ⁇ 0.2, 22.5 ⁇ 0.2, 26.1 ⁇ 0.2, and 26.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 11.
- the present disclosure provides for a crystalline Form VI of AP1189 edisylate.
- Crystalline Form VI of AP1189 edisylate exhibits an XRPD diffractogram as shown in FIG. 17 .
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 4.8 ⁇ 0.2, 12.8 ⁇ 0.2, and 16.5 ⁇ 0.2.
- One embodiment provides for a crystalline Form VI of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 17.9 ⁇ 0.2, 21.4 ⁇ 0.2, 23.4 ⁇ 0.2, and 27.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.5 ⁇ 0.2, 10.9 ⁇ 0.2, 14.3 ⁇ 0.2, 15.2 ⁇ 0.2, 18.6 ⁇ 0.2, and 24.5 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 17 .
- One embodiment of the disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.8, 9.5, 10.9, 11.6, 12.8, 14.3, 15.2, 16.5, 17.0, 17.9, 18.6, 19.2, 20.3, 21.4, 22.5, 23.4, 24.5, 25.3, 25.5, 26.5, 27.2, 28.0, 29.5, 29.7, 30.2, 31.0, 32.6, 33.3, and 34.3.
- One embodiment of the disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.8 ⁇ 0.2, 9.5 ⁇ 0.2, 10.9 ⁇ 0.2, 11.6 ⁇ 0.2, 12.8 ⁇ 0.2, 14.3 ⁇ 0.2, 15.2 ⁇ 0.2, 16.5 ⁇ 0.2, 17.0 ⁇ 0.2, 17.9 ⁇ 0.2, 18.6 ⁇ 0.2, 19.2 ⁇ 0.2, 20.3 ⁇ 0.2, 21.4 ⁇ 0.2, 22.5 ⁇ 0.2, 23.4 ⁇ 0.2, 24.5 ⁇ 0.2, 25.3 ⁇ 0.2, 25.5 ⁇ 0.2, 26.5 ⁇ 0.2, 27.2 ⁇ 0.2, 28.0 ⁇ 0.2, 29.5 ⁇ 0.2, 29.7 ⁇ 0.2, 30.2 ⁇ 0.2, 31.0 ⁇ 0.2, 32.6 ⁇ 0.2, 33.3 ⁇ 0.2, and 34.3 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.8, 9.5, 10.9, 12.8, 14.3, 15.2, 16.5, 17.9, 18.6, 21.4, 23.4, 24.5, and 27.1.
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.8 ⁇ 0.2, 9.5 ⁇ 0.2, 10.9 ⁇ 0.2, 12.8 ⁇ 0.2, 14.3 ⁇ 0.2, 15.2 ⁇ 0.2, 16.5 ⁇ 0.2, 17.9 ⁇ 0.2, 18.6 ⁇ 0.2, 21.4 ⁇ 0.2, 23.4 ⁇ 0.2, 24.5 ⁇ 0.2, and 27.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 12.
- the present disclosure provides for a crystalline Form VII of AP1189 edisylate.
- Crystalline Form VII of AP1189 edisylate exhibits an XRPD diffractogram as shown in FIG. 18 .
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 6.1 ⁇ 0.2, 15.7 ⁇ 0.2, and 23.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form VII of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.1, 20.1 ⁇ 0.2, and 21.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.7 ⁇ 0.2, 12.7 ⁇ 0.2, and 19.3 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 18 .
- One embodiment of the disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.1, 10.0, 11.7, 12.1, 12.7, 14.1, 15.7, 16.3, 17.6, 17.9, 18.3, 19.3, 20.1, 20.9, 21.8, 22.4, 22.7, 23.6, 24.3, 24.8, 25.1, 25.8, 26.5, 27.0, 27.5, 28.2, 28.6, 29.7, 30.6, 31.2, 31.9, 32.4, 32.9, 33.5, and 34.1.
- One embodiment of the disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.1 ⁇ 0.2, 10.0 ⁇ 0.2, 11.7 ⁇ 0.2, 12.1 ⁇ 0.2, 12.7 ⁇ 0.2, 14.1 ⁇ 0.2, 15.7 ⁇ 0.2, 16.3 ⁇ 0.2, 17.6 ⁇ 0.2, 17.9 ⁇ 0.2, 18.3 ⁇ 0.2, 19.3 ⁇ 0.2, 20.1 ⁇ 0.2, 20.9 ⁇ 0.2, 21.8 ⁇ 0.2, 22.4 ⁇ 0.2, 22.7 ⁇ 0.2, 23.6 ⁇ 0.2, 24.3 ⁇ 0.2, 24.8 ⁇ 0.2, 25.1 ⁇ 0.2, 25.8 ⁇ 0.2, 26.5 ⁇ 0.2, 27.0 ⁇ 0.2, 27.5 ⁇ 0.2, 28.2 ⁇ 0.2, 28.6 ⁇ 0.2, 29.7 ⁇ 0.2, 30.6 ⁇ 0.2, 31.2 ⁇ 0.2, 31.9 ⁇ 0.2, 32.4 ⁇ 0.2, 32.9 ⁇ 0.2, 33.5 ⁇ 0.2, and 34.1 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.1, 11.7, 12.1, 12.7, 15.7, 19.3, 20.1, 21.8, and 23.6.
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.1 ⁇ 0.2, 11.7 ⁇ 0.2, 12.1 ⁇ 0.2, 12.7 ⁇ 0.2, 15.7 ⁇ 0.2, 19.3 ⁇ 0.2, 20.1 ⁇ 0.2, 21.8 ⁇ 0.2, and 23.6 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 13.
- the present disclosure provides for a crystalline Form VIII of AP1189 edisylate.
- Crystalline Form VIII of AP1189 edisylate exhibits an XRPD diffractogram as shown in FIG. 19 .
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 15.5 ⁇ 0.2, 20.7 ⁇ 0.2, and 21.7 ⁇ 0.2.
- One embodiment provides for a crystalline Form VIII of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.1 ⁇ 0.2, 13.0 ⁇ 0.2, and 24.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.4 ⁇ 0.2 and 25.2 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 19 .
- One embodiment of the disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.4, 9.9, 12.1, 12.5, 13.0, 14.0, 15.5, 17.8, 18.3, 18.7, 19.5, 20.0, 20.7, 21.7, 22.2, 23.1, 24.1, 25.2, 25.7, 27.1, 27.9, 30.7, 31.1, 31.6, and 34.5.
- One embodiment of the disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.4 ⁇ 0.2, 9.9 ⁇ 0.2, 12.1 ⁇ 0.2, 12.5 ⁇ 0.2, 13.0 ⁇ 0.2, 14.0 ⁇ 0.2, 15.5 ⁇ 0.2, 17.8 ⁇ 0.2, 18.3 ⁇ 0.2, 18.7 ⁇ 0.2, 19.5 ⁇ 0.2, 20.0 ⁇ 0.2, 20.7 ⁇ 0.2, 21.7 ⁇ 0.2, 22.2 ⁇ 0.2, 23.1 ⁇ 0.2, 24.1 ⁇ 0.2, 25.2 ⁇ 0.2, 25.7 ⁇ 0.2, 27.1 ⁇ 0.2, 27.9 ⁇ 0.2, 30.7 ⁇ 0.2, 31.1 ⁇ 0.2, 31.6 ⁇ 0.2, and 34.5 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.4, 12.1, 13.0, 15.5, 20.7, 21.7, 24.1, and 25.2.
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.4 ⁇ 0.2, 12.1 ⁇ 0.2, 13.0 ⁇ 0.2, 15.5 ⁇ 0.2, 20.7 ⁇ 0.2, 21.7 ⁇ 0.2, 24.1 ⁇ 0.2, and 25.2 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 14.
- the present disclosure provides for a crystalline Form IX of AP1189 edisylate.
- Crystalline Form IX of AP1189 edisylate exhibits an XRPD diffractogram as shown in FIG. 20 .
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 4.5 ⁇ 0.2, 16.7 ⁇ 0.2, and 24.7 ⁇ 0.2.
- One embodiment provides for a crystalline Form IX of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.2 ⁇ 0.2 and 15.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.0 ⁇ 0.2 and 18.0.
- One embodiment of the disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 20 .
- One embodiment of the disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.5, 9.0, 11.7, 12.2, 12.4, 13.1, 15.5, 16.7, 17.3, 18.0, 19.9, 20.4, 21.1, 22.0, 22.9, 24.7, 26.8, and 28.3.
- One embodiment of the disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.5 ⁇ 0.2, 9.0 ⁇ 0.2, 11.7 ⁇ 0.2, 12.2 ⁇ 0.2, 12.4 ⁇ 0.2, 13.1 ⁇ 0.2, 15.5 ⁇ 0.2, 16.7 ⁇ 0.2, 17.3 ⁇ 0.2, 18.0 ⁇ 0.2, 19.9 ⁇ 0.2, 20.4 ⁇ 0.2, 21.1 ⁇ 0.2, 22.0 ⁇ 0.2, 22.9 ⁇ 0.2, 24.7 ⁇ 0.2, 26.8 ⁇ 0.2, and 28.3 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.5, 9.0, 12.2, 15.5, 16.7, 18.0, and 24.7.
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 4.5 ⁇ 0.2, 9.0 ⁇ 0.2, 12.2 ⁇ 0.2, 15.5 ⁇ 0.2, 16.7 ⁇ 0.2, 18.0 ⁇ 0.2, and 24.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 15.
- the present disclosure provides for a crystalline Form X of AP1189 nitrate.
- Crystalline Form X of AP1189 nitrate exhibits an XRPD diffractogram as shown in FIG. 21 .
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 15.3 ⁇ 0.2, 21.4 ⁇ 0.2, and 25.1 ⁇ 0.2.
- One embodiment provides for a crystalline Form X of AP1189 nitrate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.9 ⁇ 0.2, 12.5 ⁇ 0.2, and 27.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.7 ⁇ 0.2, 7.5 ⁇ 0.2, 14.7 ⁇ 0.2, 17.7 ⁇ 0.2, and 18.1 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 21 .
- One embodiment of the disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.7, 7.5, 11.9, 12.5, 13.1, 14.7, 15.3, 16.9, 17.7, 18.1, 18.7, 19.6, 21.4, 23.0, 24.1, 25.1, 26.6, 27.7, 29.5, and 31.7.
- One embodiment of the disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.7 ⁇ 0.2, 7.5 ⁇ 0.2, 11.9 ⁇ 0.2, 12.5 ⁇ 0.2, 13.1 ⁇ 0.2, 14.7 ⁇ 0.2, 15.3 ⁇ 0.2, 16.9 ⁇ 0.2, 17.7 ⁇ 0.2, 18.1 ⁇ 0.2, 18.7 ⁇ 0.2, 19.6 ⁇ 0.2, 21.4 ⁇ 0.2, 23.0 ⁇ 0.2, 24.1 ⁇ 0.2, 25.1 ⁇ 0.2, 26.6 ⁇ 0.2, 27.7 ⁇ 0.2, 29.5 ⁇ 0.2, and 31.7 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.7, 7.5, 11.9, 12.5, 14.7, 15.3, 17.7, 18.1, 21.4, 25.1, and 27.7.
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.7 ⁇ 0.2, 7.5 ⁇ 0.2, 11.9 ⁇ 0.2, 12.5 ⁇ 0.2, 14.7 ⁇ 0.2, 15.3 ⁇ 0.2, 17.7 ⁇ 0.2, 18.1 ⁇ 0.2, 21.4 ⁇ 0.2, 25.1 ⁇ 0.2, and 27.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 16.
- the present disclosure provides for a crystalline Form XI of AP1189 cyclamate.
- Crystalline Form XI of AP1189 cyclamate exhibits an XRPD diffractogram as shown in FIG. 22 .
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 7.0 ⁇ 0.2, 13.8 ⁇ 0.2, and 15.7 ⁇ 0.2.
- One embodiment provides for a crystalline Form XI of AP1189 cyclamate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 15.3 ⁇ 0.2, 20.7 ⁇ 0.2, and 21.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 11.3 ⁇ 0.2, and 21.8 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 22 .
- One embodiment of the disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2, 5.2, 7.0, 10.4, 11.3, 11.9, 13.8, 14.2, 15.3, 15.7, 16.3, 17.6, 18.5, 19.2, 20.1, 20.7, 21.5, 21.8, 22.1, 22.7, 23.4, 25.2, 26.0, and 27.8.
- One embodiment of the disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 5.2 ⁇ 0.2, 7.0 ⁇ 0.2, 10.4 ⁇ 0.2, 11.3 ⁇ 0.2, 11.9 ⁇ 0.2, 13.8 ⁇ 0.2, 14.2 ⁇ 0.2, 15.3 ⁇ 0.2, 15.7 ⁇ 0.2, 16.3 ⁇ 0.2, 17.6 ⁇ 0.2, 18.5 ⁇ 0.2, 19.2 ⁇ 0.2, 20.1 ⁇ 0.2, 20.7 ⁇ 0.2, 21.5 ⁇ 0.2, 21.8 ⁇ 0.2, 22.1 ⁇ 0.2, 22.7 ⁇ 0.2, 23.4 ⁇ 0.2, 25.2 ⁇ 0.2, 26.0 ⁇ 0.2, and 27.8 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2, 7.0, 11.3, 13.8, 15.3, 15.7, 20.7, 21.5, and 21.8.
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 7.0 ⁇ 0.2, 11.3 ⁇ 0.2, 13.8 ⁇ 0.2, 15.3 ⁇ 0.2, 15.7 ⁇ 0.2, 20.7 ⁇ 0.2, 21.5 ⁇ 0.2, and 21.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 17.
- the present disclosure provides for a crystalline Form XII of AP1189 cyclamate. Crystalline Form XII of AP1189 cyclamate exhibits an XRPD diffractogram as shown in FIG. 23 .
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 7.3 ⁇ 0.2, 15.3 ⁇ 0.2, and 17.9 ⁇ 0.2.
- One embodiment provides for a crystalline Form XII of AP1189 cyclamate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 16.3 ⁇ 0.2, 19.1 ⁇ 0.2, 22.0 0.2, and 22.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.3 ⁇ 0.2, 13.1 ⁇ 0.2, and 16.9 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 23 .
- One embodiment of the disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 7.3, 9.3, 11.3, 12.7, 13.1, 14.8, 15.3, 16.3, 16.9, 17.9, 19.1, 19.3, 20.1, 22.0, 22.7, 24.1, 24.8, 25.8, 27.1, 28.0, and 29.0.
- One embodiment of the disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 7.3 ⁇ 0.2, 9.3 ⁇ 0.2, 11.3 ⁇ 0.2, 12.7 ⁇ 0.2, 13.1 ⁇ 0.2, 14.8 ⁇ 0.2, 15.3 ⁇ 0.2, 16.3 ⁇ 0.2, 16.9 ⁇ 0.2, 17.9 ⁇ 0.2, 19.1 ⁇ 0.2, 19.3 ⁇ 0.2, 20.1 ⁇ 0.2, 22.0 ⁇ 0.2, 22.7 ⁇ 0.2, 24.1 ⁇ 0.2, 24.8 ⁇ 0.2, 25.8 ⁇ 0.2, 27.1 ⁇ 0.2, 28.0 ⁇ 0.2, and 29.0 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.3, 11.3, 13.1, 14.3, 16.3, 16.9, 17.9, 19.1, 22.0, and 22.7.
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.3 ⁇ 0.2, 11.3 ⁇ 0.2, 13.1 ⁇ 0.2, 14.3 ⁇ 0.2, 16.3 ⁇ 0.2, 16.9 ⁇ 0.2, 17.9 ⁇ 0.2, 19.1 ⁇ 0.2, 22.0 ⁇ 0.2, and 22.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 18.
- the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate.
- Crystalline Form XIII of AP1189 cyclamate exhibits an XRPD diffractogram as shown in FIG. 24 .
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 15.3 ⁇ 0.2, 18.5 ⁇ 0.2, and 18.7 ⁇ 0.2.
- One embodiment provides for a crystalline Form XIII of AP1189 cyclamate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.4 ⁇ 0.2, 14.6 ⁇ 0.2, 16.7 ⁇ 0.2, and 19.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.6 ⁇ 0.2, 7.1 ⁇ 0.2, 8.5 ⁇ 0.2, 10.5 ⁇ 0.2, 13.1 ⁇ 0.2, and 16.2 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 24 .
- One embodiment of the disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.3, 5.6, 6.4, 7.1, 7.6, 8.5, 9.4, 9.9, 10.2, 10.5, 10.9, 11.6, 11.9, 12.3, 13.1, 13.3, 13.7, 14.1, 14.6, 15.3, 16.2, 16.7, 17.5, 18.5, 18.7, 19.8, 20.2, 20.6, 21.1, 21.1, 21.3, 21.7, 22.1, 22.6, 22.8, 23.7, 24.1, 24.9, 25.1, 25.7, 26.2, 27.0, 27.7, 28.7, 29.4, 30.0, 30.8, 31.6, 32.4, and 33.6.
- One embodiment of the disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.3 ⁇ 0.2, 5.6 ⁇ 0.2, 6.4 ⁇ 0.2, 7.1 ⁇ 0.2, 7.6 ⁇ 0.2, 8.5 ⁇ 0.2, 9.4 ⁇ 0.2, 9.9 ⁇ 0.2, 10.2 ⁇ 0.2, 10.5 ⁇ 0.2, 10.9 ⁇ 0.2, 11.6 ⁇ 0.2, 11.9 ⁇ 0.2, 12.3 ⁇ 0.2, 13.1 ⁇ 0.2, 13.3 ⁇ 0.2, 13.7 ⁇ 0.2, 14.1 ⁇ 0.2, 14.6 ⁇ 0.2, 15.3 ⁇ 0.2, 16.2 ⁇ 0.2, 16.7 ⁇ 0.2, 17.5 ⁇ 0.2, 18.5 ⁇ 0.2, 18.7 ⁇ 0.2, 19.8 ⁇ 0.2, 20.2 ⁇ 0.2, 20.6 ⁇ 0.2, 21.1 ⁇ 0.2, 21.1 ⁇ 0.2, 21.3 ⁇ 0.2, 21.7 ⁇ 0.2, 22.1 ⁇ 0.2, 22.6 ⁇ 0.2, 22.8 ⁇ 0.2, 23.7 ⁇ 0.2, 24.1 ⁇ 0.2, 24.9 ⁇ 0.2
- one embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.6, 6.4, 7.1, 8.5, 10.5, 13.1, 14.6, 15.3, 16.2, 16.7, 18.5, 18.7, 19.8, 26.2, and 27.0.
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.6 ⁇ 0.2, 6.4 ⁇ 0.2, 7.1 ⁇ 0.2, 8.5 ⁇ 0.2, 10.5 ⁇ 0.2, 13.1 ⁇ 0.2, 14.6 ⁇ 0.2, 15.3 ⁇ 0.2, 16.2 ⁇ 0.2, 16.7 ⁇ 0.2, 18.5 ⁇ 0.2, 18.7 ⁇ 0.2, 19.8 ⁇ 0.2, 26.2 ⁇ 0.2, and 27.0 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 19.
- the present disclosure provides for a crystalline Form XIV of AP1189 besylate.
- Crystalline Form XIV of AP1189 besylate exhibits an XRPD diffractogram as shown in FIG. 25 .
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 13.0 ⁇ 0.2, 15.1 ⁇ 0.2, and 19.9 ⁇ 0.2.
- One embodiment provides for a crystalline Form XIV of AP1189 besylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.2 ⁇ 0.2 and 18.3 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.3 ⁇ 0.2, 9.0 0.2, 16.4 ⁇ 0.2, and 18.7 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 25 .
- One embodiment of the disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2, 8.3, 9.0, 9.9, 10.8, 11.2, 13.0, 13.1, 15.1, 16.0, 16.4, 16.7, 17.3, 18.1, 18.3, 18.7, 19.0, 19.4, 19.9, 20.3, 20.9, 21.3, 21.7, 22.0, 22.8, 23.1, 23.6, 24.8, 25.1, 25.4, 26.3, 26.5, 27.1, 28.1, 28.5, 29.8, 30.4, 31.1, 32.0, 33.2, and 34.1.
- One embodiment of the disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 8.3 ⁇ 0.2, 9.0 ⁇ 0.2, 9.9 ⁇ 0.2, 10.8 ⁇ 0.2, 11.2 ⁇ 0.2, 13.0 ⁇ 0.2, 13.1 ⁇ 0.2, 15.1 ⁇ 0.2, 16.0 ⁇ 0.2, 16.4 ⁇ 0.2, 16.7 ⁇ 0.2, 17.3 ⁇ 0.2, 18.1 ⁇ 0.2, 18.3 ⁇ 0.2, 18.7 ⁇ 0.2, 19.0 ⁇ 0.2, 19.4 ⁇ 0.2, 19.9 ⁇ 0.2, 20.3 ⁇ 0.2, 20.9 ⁇ 0.2, 21.3 ⁇ 0.2, 21.7 ⁇ 0.2, 22.0 ⁇ 0.2, 22.8 ⁇ 0.2, 23.1 ⁇ 0.2, 23.6 ⁇ 0.2, 24.8 ⁇ 0.2, 25.1 ⁇ 0.2, 25.4 ⁇ 0.2, 26.3 ⁇ 0.2, 26.5 ⁇ 0.2, 27.1 ⁇ 0.2, 28.1 ⁇ 0.2, 28.5 ⁇ 0.2, 29.8 ⁇ 0.2, 30.4 ⁇ 0.2, 31.1 ⁇
- crystalline Form XIV of AP1189 besylate by X-ray lines (2-theta values) having a high relative intensity, and/or by characteristic X-ray lines.
- a crystalline Form XIV of AP1189 besylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.3, 9.0, 11.2, 13.0, 15.1, 16.4, 18.3, 18.7, and 19.9.
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.3 ⁇ 0.2, 9.0 ⁇ 0.2, 11.2 ⁇ 0.2, 13.0 ⁇ 0.2, 15.1 ⁇ 0.2, 16.4 ⁇ 0.2, 18.3 ⁇ 0.2, 18.7 ⁇ 0.2, and 19.9 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 20.
- the present disclosure provides for a crystalline Form XV of AP1189 oxalate.
- Crystalline Form XV of AP1189 oxalate exhibits an XRPD diffractogram as shown in FIG. 26 .
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 19.5 ⁇ 0.2, 23.3 ⁇ 0.2, and 25.8 ⁇ 0.2.
- One embodiment provides for a crystalline Form XV of AP1189 oxalate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 13.9 ⁇ 0.2, 15.6 ⁇ 0.2, and 23.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.2 ⁇ 0.2, 10.8 ⁇ 0.2, and 21.7 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 26 .
- One embodiment of the disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.2, 10.8, 12.1, 13.9, 14.5, 15.0, 15.6, 16.5, 16.8, 17.3, 18.2, 18.5, 19.5, 20.1, 21.7, 22.9, 23.3, 23.8, 24.3, 24.8, 25.8, 27.0, 27.9, 28.6, 29.3, 29.7, 30.2, 32.2, and 32.9.
- One embodiment of the disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.2 ⁇ 0.2, 10.8 ⁇ 0.2, 12.1 ⁇ 0.2, 13.9 ⁇ 0.2, 14.5 ⁇ 0.2, 15.0 ⁇ 0.2, 15.6 ⁇ 0.2, 16.5 ⁇ 0.2, 16.8 ⁇ 0.2, 17.3 ⁇ 0.2, 18.2 ⁇ 0.2, 18.5 ⁇ 0.2, 19.5 ⁇ 0.2, 20.1 ⁇ 0.2, 21.7 ⁇ 0.2, 22.9 ⁇ 0.2, 23.3 ⁇ 0.2, 23.8 ⁇ 0.2, 24.3 ⁇ 0.2, 24.8 ⁇ 0.2, 25.8 ⁇ 0.2, 27.0 ⁇ 0.2, 27.9 ⁇ 0.2, 28.6 ⁇ 0.2, 29.3 ⁇ 0.2, 29.7 ⁇ 0.2, 30.2 ⁇ 0.2, 32.2 ⁇ 0.2, and 32.9 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.2, 10.8, 13.9, 15.6, 19.5, 21.7, 23.3, 23.8, and 25.8.
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.2 ⁇ 0.2, 10.8 ⁇ 0.2, 13.9 ⁇ 0.2, 15.6 ⁇ 0.2, 19.5 ⁇ 0.2, 21.7 ⁇ 0.2, 23.3 ⁇ 0.2, 23.8 ⁇ 0.2, and 25.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 21.
- the present disclosure provides for a crystalline Form XVI of AP1189 oxalate.
- Crystalline Form XVI of AP1189 oxalate exhibits an XRPD diffractogram as shown in FIG. 27 .
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 17.1 ⁇ 0.2, 17.9 ⁇ 0.2, and 19.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form XVI of AP1189 oxalate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 15.9 ⁇ 0.2, 24.2 ⁇ 0.2, 24.4 ⁇ 0.2, and 27.3 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.5 ⁇ 0.2, 11.3 ⁇ 0.2, 21.2 ⁇ 0.2, and 25.4 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 27 .
- One embodiment of the disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.5, 11.3, 12.1, 13.1, 14.0, 15.3, 15.9, 16.4, 17.1, 17.9, 18.9, 19.6, 20.0, 21.2, 22.0, 22.7, 23.0, 23.4, 24.2, 24.4, 24.8, 25.4, 25.7, 26.3, 27.3, 28.4, 29.9, 30.4, 31.3, 32.2, 33.3, 33.9, 34.3, and 34.9.
- One embodiment of the disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.5 ⁇ 0.2, 11.3 ⁇ 0.2, 12.1 ⁇ 0.2, 13.1 ⁇ 0.2, 14.0 ⁇ 0.2, 15.3 ⁇ 0.2, 15.9 ⁇ 0.2, 16.4 ⁇ 0.2, 17.1 ⁇ 0.2, 17.9 ⁇ 0.2, 18.9 ⁇ 0.2, 19.6 ⁇ 0.2, 20.0 ⁇ 0.2, 21.2 ⁇ 0.2, 22.0 ⁇ 0.2, 22.7 ⁇ 0.2, 23.0 ⁇ 0.2, 23.4 ⁇ 0.2, 24.2 ⁇ 0.2, 24.4 ⁇ 0.2, 24.8 ⁇ 0.2, 25.4 ⁇ 0.2, 25.7 ⁇ 0.2, 26.3 ⁇ 0.2, 27.3 ⁇ 0.2, 28.4 ⁇ 0.2, 29.9 ⁇ 0.2, 30.4 ⁇ 0.2, 31.3 ⁇ 0.2, 32.2 ⁇ 0.2, 33.3 ⁇ 0.2, 33.9 ⁇ 0.2, 34.3 ⁇ 0.2, and 34.9 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.5, 11.3, 15.9, 17.1, 17.9, 19.6, 21.2, 24.2, 24.4, 25.4, and 27.3.
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.5 ⁇ 0.2, 11.3 ⁇ 0.2, 15.9 ⁇ 0.2, 17.1 ⁇ 0.2, 17.9 ⁇ 0.2, 19.6 ⁇ 0.2, 21.2 ⁇ 0.2, 24.2 ⁇ 0.2, 24.4 ⁇ 0.2, 25.4 ⁇ 0.2, and 27.3 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 22.
- the present disclosure provides for a crystalline Form XVII of AP1189 oxalate. Crystalline Form XVII of AP1189 oxalate exhibits an XRPD diffractogram as shown in FIG. 28 .
- One embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 6.3 ⁇ 0.2, 10.6 ⁇ 0.2, and 19.8 ⁇ 0.2.
- One embodiment provides for a crystalline Form XVII of AP1189 oxalate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 11.7 ⁇ 0.2, 12.3 ⁇ 0.2, 18.4 ⁇ 0.2, and 23.8 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 14.1 ⁇ 0.2, 23.5 ⁇ 0.2, and 30.0 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 28 .
- One embodiment of the disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 8.2, 10.6, 11.7, 12.3, 12.6, 12.9, 13.2, 14.1, 14.2, 15.8, 16.1, 17.1, 17.8, 18.4, 19.0, 19.2, 19.8, 20.3, 20.7, 21.0, 21.4, 21.8, 22.0, 22.3, 22.6, 23.2, 23.5, 23.8, 24.4, 24.8, 25.4, 25.9, 26.1, 26.6, 27.1, 27.5, 27.8, 28.3, 28.7, 29.0, 30.0, 31.1, 33.0, 33.7, and 34.3.
- One embodiment of the disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 8.2 ⁇ 0.2, 10.6 ⁇ 0.2, 11.7 ⁇ 0.2, 12.3 ⁇ 0.2, 12.6 ⁇ 0.2, 12.9 ⁇ 0.2, 13.2 ⁇ 0.2, 14.1 ⁇ 0.2, 14.2 ⁇ 0.2, 15.8 ⁇ 0.2, 16.1 ⁇ 0.2, 17.1 ⁇ 0.2, 17.8 ⁇ 0.2, 18.4 ⁇ 0.2, 19.0 ⁇ 0.2, 19.2 ⁇ 0.2, 19.8 ⁇ 0.2, 20.3 ⁇ 0.2, 20.7 ⁇ 0.2, 21.0 ⁇ 0.2, 21.4 ⁇ 0.2, 21.8 ⁇ 0.2, 22.0 ⁇ 0.2, 22.3 ⁇ 0.2, 22.6 ⁇ 0.2, 23.2 ⁇ 0.2, 23.5 ⁇ 0.2, 23.8 ⁇ 0.2, 24.4 ⁇ 0.2, 24.8 ⁇ 0.2, 25.4 ⁇ 0.2, 25.9 ⁇ 0.2, 26.1 ⁇ 0.2, 26.6 ⁇ 0.2, 27.1 ⁇ 0.2, 27.5 ⁇ 0.2, 27
- one embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 10.6, 11.7, 12.3, 14.1, 18.4, 19.8, 23.5, 23.8, and 30.0.
- One embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 10.6 ⁇ 0.2, 11.7 ⁇ 0.2, 12.3 ⁇ 0.2, 14.1 ⁇ 0.2, 18.4 ⁇ 0.2, 19.8 ⁇ 0.2, 23.5 ⁇ 0.2, 23.8 ⁇ 0.2, and 30.0 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 23.
- the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid. Crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibits an XRPD diffractogram as shown in FIG. 29 .
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 6.5 ⁇ 0.2, 11.5 ⁇ 0.2, and 14.8 ⁇ 0.2.
- One embodiment provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 13.0 ⁇ 0.2, 13.7 ⁇ 0.2, 16.1 ⁇ 0.2, and 21.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 15.9 ⁇ 0.2, 18.8 ⁇ 0.2, and 19.8 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 29 .
- One embodiment of the disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.1, 6.5, 7.7, 9.4, 9.9, 10.4, 11.0, 11.5, 12.2, 13.0, 13.7, 14.0, 14.3, 14.8, 15.6, 15.9, 16.1, 17.2, 18.1, 18.4, 18.8, 19.8, 21.1, 21.5, 22.2, 22.7, 23.2, 23.8, 25.1, 25.7, 26.1, 27.2, 28.7, 30.1, and 31.5.
- One embodiment of the disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.1 ⁇ 0.2, 6.5 ⁇ 0.2, 7.7 ⁇ 0.2, 9.4 ⁇ 0.2, 9.9 ⁇ 0.2, 10.4 ⁇ 0.2, 11.0 ⁇ 0.2, 11.5 ⁇ 0.2, 12.2 ⁇ 0.2, 13.0 ⁇ 0.2, 13.7 ⁇ 0.2, 14.0 ⁇ 0.2, 14.3 ⁇ 0.2, 14.8 ⁇ 0.2, 15.6 ⁇ 0.2, 15.9 ⁇ 0.2, 16.1 ⁇ 0.2, 17.2 ⁇ 0.2, 18.1 ⁇ 0.2, 18.4 ⁇ 0.2, 18.8 ⁇ 0.2, 19.8 ⁇ 0.2, 21.1 ⁇ 0.2, 21.5 ⁇ 0.2, 22.2 ⁇ 0.2, 22.7 ⁇ 0.2, 23.2 ⁇ 0.2, 23.8 ⁇ 0.2, 25.1 ⁇ 0.2, 25.7 ⁇ 0.2, 26.1 ⁇ 0.2, 27.2 ⁇ 0.2, 28.7 ⁇ 0.2, 30.1 ⁇ 0.2, and 31.5 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.5, 11.5, 13.0, 13.7, 14.8, 15.9, 16.1, 18.8, 19.8, and 21.1.
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.5 ⁇ 0.2, 11.5 ⁇ 0.2, 13.0 ⁇ 0.2, 13.7 ⁇ 0.2, 14.8 ⁇ 0.2, 15.9 ⁇ 0.2, 16.1 ⁇ 0.2, 18.8 ⁇ 0.2, 19.8 ⁇ 0.2, and 21.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 24.
- the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate. Crystalline Form XIX of AP1189 oxoglutarate exhibits an XRPD diffractogram as shown in FIG. 30 .
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 16.8 ⁇ 0.2, 23.4 ⁇ 0.2, and 23.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form XIX of AP1189 oxoglutarate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 13.4 ⁇ 0.2, 16.4 ⁇ 0.2, 21.6 ⁇ 0.2, and 26.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.1 ⁇ 0.2, 10.7 ⁇ 0.2, 12.8 ⁇ 0.2, 13.2 ⁇ 0.2, 20.8 ⁇ 0.2, 24.1 ⁇ 0.2, and 24.2 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 30 .
- One embodiment of the disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.1, 10.7, 11.8, 12.0, 12.8, 13.2, 13.4, 13.8, 14.0, 15.9, 16.4, 16.8, 17.1, 17.9, 18.3, 19.5, 20.1, 20.8, 21.6, 22.0, 22.9, 23.4, 23.6, 24.1, 24.2, 25.8, 26.5, 26.9, 27.4, 27.9, 28.9, 29.9, 30.3, 30.9, 32.3, 32.6, 33.1, 33.8, and 34.7.
- One embodiment of the disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.1 ⁇ 0.2, 10.7 ⁇ 0.2, 11.8 ⁇ 0.2, 12.0 ⁇ 0.2, 12.8 ⁇ 0.2, 13.2 ⁇ 0.2, 13.4 ⁇ 0.2, 13.8 ⁇ 0.2, 14.0 ⁇ 0.2, 15.9 ⁇ 0.2, 16.4 ⁇ 0.2, 16.8 ⁇ 0.2, 17.1 ⁇ 0.2, 17.9 ⁇ 0.2, 18.3 ⁇ 0.2, 19.5 ⁇ 0.2, 20.1 ⁇ 0.2, 20.8 ⁇ 0.2, 21.6 ⁇ 0.2, 22.0 ⁇ 0.2, 22.9 ⁇ 0.2, 23.4 ⁇ 0.2, 23.6 ⁇ 0.2, 24.1 ⁇ 0.2, 24.2 ⁇ 0.2, 25.8 ⁇ 0.2, 26.5 ⁇ 0.2, 26.9 ⁇ 0.2, 27.4 ⁇ 0.2, 27.9 ⁇ 0.2, 28.9 ⁇ 0.2, 29.9 ⁇ 0.2, 30.3 ⁇ 0.2, 30.9 ⁇ 0.2, 32.3 ⁇ 0.2, 32.6 ⁇ 0.2
- one embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.1, 10.7, 12.8, 13.2, 13.4, 16.4, 16.8, 20.8, 21.6, 23.4, 23.6, 24.1, 24.2, 26.5, and 26.9.
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.1 ⁇ 0.2, 10.7 ⁇ 0.2, 12.8 ⁇ 0.2, 13.2 ⁇ 0.2, 13.4 ⁇ 0.2, 16.4 ⁇ 0.2, 16.8 ⁇ 0.2, 20.8 ⁇ 0.2, 21.6 ⁇ 0.2, 23.4 ⁇ 0.2, 23.6 ⁇ 0.2, 24.1 ⁇ 0.2, 24.2 ⁇ 0.2, 26.5 ⁇ 0.2, and 26.9 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 25.
- the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid. Crystalline Form XX of AP1189 DL-mandelic acid exhibits an XRPD diffractogram as shown in FIG. 31 .
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.8 ⁇ 0.2, 24.2 ⁇ 0.2, and 25.5 ⁇ 0.2.
- One embodiment provides for a crystalline Form XX of AP1189 DL-mandelic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.6 ⁇ 0.2, 10.0 ⁇ 0.2, 19.1 ⁇ 0.2, and 21.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.3 ⁇ 0.2, 12.4 ⁇ 0.2, 13.3 ⁇ 0.2, 16.0 ⁇ 0.2, 16.8 ⁇ 0.2, 17.9 ⁇ 0.2, 21.2 ⁇ 0.2, and 24.8 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 31 .
- One embodiment of the disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.3, 9.6, 10.0, 10.7, 10.9, 11.7, 12.0, 12.4, 13.3, 13.9, 14.8, 15.3, 16.0, 16.8, 17.0, 17.3, 17.6, 17.9, 18.5, 19.1, 19.8, 20.2, 20.7, 21.2, 21.5, 21.8, 22.9, 24.2, 24.5, 24.8, 25.5, 26.4, 26.9, 27.1, 27.5, 28.1, 28.4, 29.7, 30.3, 31.2, 32.4, 32.8, 33.1, 33.5, 34.4, and 34.7.
- One embodiment of the disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.3 ⁇ 0.2, 9.6 ⁇ 0.2, 10.0 ⁇ 0.2, 10.7 ⁇ 0.2, 10.9 ⁇ 0.2, 11.7 ⁇ 0.2, 12.0 ⁇ 0.2, 12.4 ⁇ 0.2, 13.3 ⁇ 0.2, 13.9 ⁇ 0.2, 14.8 ⁇ 0.2, 15.3 ⁇ 0.2, 16.0 ⁇ 0.2, 16.8 ⁇ 0.2, 17.0 ⁇ 0.2, 17.3 ⁇ 0.2, 17.6 ⁇ 0.2, 17.9 ⁇ 0.2, 18.5 ⁇ 0.2, 19.1 ⁇ 0.2, 19.8 ⁇ 0.2, 20.2 ⁇ 0.2, 20.7 ⁇ 0.2, 21.2 ⁇ 0.2, 21.5 ⁇ 0.2, 21.8 ⁇ 0.2, 22.9 ⁇ 0.2, 24.2 ⁇ 0.2, 24.5 ⁇ 0.2, 24.8 ⁇ 0.2, 25.5 ⁇ 0.2, 26.4 ⁇ 0.2, 26.9 ⁇ 0.2, 27.1 ⁇ 0.2, 27.5 ⁇ 0.2, 28.1 ⁇ 0.2, 28.4 ⁇ 0.2
- one embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.3, 9.6, 10.0, 12.4, 13.3, 14.8, 16.0, 16.8, 17.9, 19.1, 21.2, 21.5, 24.2, 24.8, and 25.5.
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.3 ⁇ 0.2, 9.6 ⁇ 0.2, 10.0 ⁇ 0.2, 12.4 ⁇ 0.2, 13.3 ⁇ 0.2, 14.8 ⁇ 0.2, 16.0 ⁇ 0.2, 16.8 ⁇ 0.2, 17.9 ⁇ 0.2, 19.1 ⁇ 0.2, 21.2 ⁇ 0.2, 21.5 ⁇ 0.2, 24.2 ⁇ 0.2, 24.8 ⁇ 0.2, and 25.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 26.
- the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid. Crystalline Form XXI of AP1189 DL-mandelic acid exhibits an XRPD diffractogram as shown in FIG. 32 .
- One embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 5.4 ⁇ 0.2, 10.0 ⁇ 0.2, and 24.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXI of AP1189 further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.8 ⁇ 0.2, 16.6 ⁇ 0.2, 18.1 ⁇ 0.2, and 21.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.7 ⁇ 0.2, 13.5 ⁇ 0.2, 21.7 ⁇ 0.2, and 25.4 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 32 .
- One embodiment of the disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4, 9.8, 10.0, 11.2, 11.5, 11.8, 12.7, 13.5, 14.4, 15.0, 15.5, 15.7, 15.8, 16.6, 17.2, 18.1, 19.6, 20.2, 20.7, 21.1, 21.7, 22.6, 23.3, 23.6, 24.6, 25.4, 26.1, 27.0, 27.3, 28.7, 29.0, 29.8, 30.4, 30.7, 31.2, 32.8, 33.5, 34.0, and 34.5.
- One embodiment of the disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 9.8 ⁇ 0.2, 10.0 ⁇ 0.2, 11.2 ⁇ 0.2, 11.5 ⁇ 0.2, 11.8 ⁇ 0.2, 12.7 ⁇ 0.2, 13.5 ⁇ 0.2, 14.4 ⁇ 0.2, 15.0 ⁇ 0.2, 15.5 ⁇ 0.2, 15.7 ⁇ 0.2, 15.8 ⁇ 0.2, 16.6 ⁇ 0.2, 17.2 ⁇ 0.2, 18.1 ⁇ 0.2, 19.6 ⁇ 0.2, 20.2 ⁇ 0.2, 20.7 ⁇ 0.2, 21.1 ⁇ 0.2, 21.7 ⁇ 0.2, 22.6 ⁇ 0.2, 23.3 ⁇ 0.2, 23.6 ⁇ 0.2, 24.6 ⁇ 0.2, 25.4 ⁇ 0.2, 26.1 ⁇ 0.2, 27.0 ⁇ 0.2, 27.3 ⁇ 0.2, 28.7 ⁇ 0.2, 29.0 ⁇ 0.2, 29.8 ⁇ 0.2, 30.4 ⁇ 0.2, 30.7 ⁇ 0.2, 31.2 ⁇ 0.2, 32.8 ⁇ 0.2, 33.5
- one embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4, 9.8, 10.0, 12.7, 13.5, 16.6, 18.1, 21.1, 21.7, 24.6, and 25.4.
- One embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.4 ⁇ 0.2, 9.8 ⁇ 0.2, 10.0 ⁇ 0.2, 12.7 ⁇ 0.2, 13.5 ⁇ 0.2, 16.6 ⁇ 0.2, 18.1 ⁇ 0.2, 21.1 ⁇ 0.2, 21.7 ⁇ 0.2, 24.6 ⁇ 0.2, and 25.4 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 27.
- the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid. Crystalline Form XXII of AP1189 hippuric acid exhibits an XRPD diffractogram as shown in FIG. 33 .
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 20.1 ⁇ 0.2, 24.1 ⁇ 0.2, and 24.5 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXII of AP1189 hippuric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 10.9 ⁇ 0.2, 11.5 ⁇ 0.2, 14.4 ⁇ 0.2, 14.9 ⁇ 0.2, and 18.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.6 ⁇ 0.2, 14.1 ⁇ 0.2, and 15.5 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 33 .
- One embodiment of the disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.6, 9.6, 9.8, 10.9, 11.5, 11.8, 12.7, 13.3, 13.8, 14.1, 14.4, 14.9, 15.5, 16.4, 17.5, 18.1, 19.5, 20.1, 20.7, 21.0, 22.0, 22.4, 22.8, 23.1, 24.1, 24.5, 25.3, 25.8, 27.1, 28.1, and 29.1.
- One embodiment of the disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.6 ⁇ 0.2, 9.6 ⁇ 0.2, 9.8 ⁇ 0.2, 10.9 ⁇ 0.2, 11.5 ⁇ 0.2, 11.8 ⁇ 0.2, 12.7 ⁇ 0.2, 13.3 ⁇ 0.2, 13.8 ⁇ 0.2, 14.1 ⁇ 0.2, 14.4 ⁇ 0.2, 14.9 ⁇ 0.2, 15.5 ⁇ 0.2, 16.4 ⁇ 0.2, 17.5 ⁇ 0.2, 18.1 ⁇ 0.2, 19.5 ⁇ 0.2, 20.1 ⁇ 0.2, 20.7 ⁇ 0.2, 21.0 ⁇ 0.2, 22.0 ⁇ 0.2, 22.4 ⁇ 0.2, 22.8 ⁇ 0.2, 23.1 ⁇ 0.2, 24.1 ⁇ 0.2, 24.5 ⁇ 0.2, 25.3 ⁇ 0.2, 25.8 ⁇ 0.2, 27.1 ⁇ 0.2, 28.1 ⁇ 0.2, and 29.1 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.6, 10.9, 11.5, 14.1, 14.4, 14.9, 15.5, 18.1, 20.1, 24.1, and 24.5.
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 9.6 ⁇ 0.2, 10.9 ⁇ 0.2, 11.5 ⁇ 0.2, 14.1 ⁇ 0.2, 14.4 ⁇ 0.2, 14.9 ⁇ 0.2, 15.5 ⁇ 0.2, 18.1 ⁇ 0.2, 20.1 ⁇ 0.2, 24.1 ⁇ 0.2, and 24.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 28.
- the present disclosure provides for a crystalline Form XXIII of AP1189 formate.
- Crystalline Form XXIII of AP1189 formate exhibits an XRPD diffractogram as shown in FIG. 34 .
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 13.3 ⁇ 0.2, 15.1 ⁇ 0.2, and 25.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXIII of AP1189 formate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 17.3 ⁇ 0.2, 18.9 ⁇ 0.2, 21.8 ⁇ 0.2, and 23.6 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.2 ⁇ 0.2, 20.6 ⁇ 0.2, 22.8 ⁇ 0.2, 28.9 ⁇ 0.2, and 29.2 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 34 .
- One embodiment of the disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.4, 10.4, 10.6, 12.2, 13.3, 14.1, 15.1, 15.2, 16.8, 17.3, 18.0, 18.5, 18.8, 18.9, 19.1, 20.6, 20.9, 21.4, 21.8, 22.3, 22.6, 22.8, 23.1, 23.6, 24.0, 24.5, 24.9, 25.6, 26.8, 27.1, 27.6, 28.1, 28.6, 28.9, 29.2, 30.5, 30.9, 31.7, 32.2, 32.7, 33.1, and 34.0.
- One embodiment of the disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.4 ⁇ 0.2, 10.4 ⁇ 0.2, 10.6 ⁇ 0.2, 12.2 ⁇ 0.2, 13.3 ⁇ 0.2, 14.1 ⁇ 0.2, 15.1 ⁇ 0.2, 15.2 ⁇ 0.2, 16.8 ⁇ 0.2, 17.3 ⁇ 0.2, 18.0 ⁇ 0.2, 18.5 ⁇ 0.2, 18.8 ⁇ 0.2, 18.9 ⁇ 0.2, 19.1 ⁇ 0.2, 20.6 ⁇ 0.2, 20.9 ⁇ 0.2, 21.4 ⁇ 0.2, 21.8 ⁇ 0.2, 22.3 ⁇ 0.2, 22.6 ⁇ 0.2, 22.8 ⁇ 0.2, 23.1 ⁇ 0.2, 23.6 ⁇ 0.2, 24.0 ⁇ 0.2, 24.5 ⁇ 0.2, 24.9 ⁇ 0.2, 25.6 ⁇ 0.2, 26.8 ⁇ 0.2, 27.1 ⁇ 0.2, 27.6 ⁇ 0.2, 28.1 ⁇ 0.2, 28.6 ⁇ 0.2, 28.9 ⁇ 0.2, 29.2 ⁇ 0.2, 30.5 ⁇ 0.2, 30.9 ⁇ 0.2,
- one embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.2, 13.3, 15.1, 17.3, 18.9, 20.6, 21.8, 22.8, 23.6, 25.6, 28.9, and 29.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.2 ⁇ 0.2, 13.3 ⁇ 0.2, 15.1 ⁇ 0.2, 17.3 ⁇ 0.2, 18.9 ⁇ 0.2, 20.6 ⁇ 0.2, 21.8 ⁇ 0.2, 22.8 ⁇ 0.2, 23.6 ⁇ 0.2, 25.6 ⁇ 0.2, 28.9 ⁇ 0.2, and 29.2 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 29.
- the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid.
- Crystalline Form XXIV of AP1189 DL-lactic acid exhibits an XRPD diffractogram as shown in FIG. 35 .
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 3.8 ⁇ 0.2, 9.9 ⁇ 0.2, and 11.9 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXIV of AP1189 DL-lactic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.7 ⁇ 0.2, 23.0 ⁇ 0.2, and 27.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 15.4 ⁇ 0.2, 23.9 ⁇ 0.2, and 25.3 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 35 .
- One embodiment of the disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8, 7.7, 9.9, 11.9, 13.6, 14.0, 14.2, 14.7, 15.4, 15.8, 18.0, 18.3, 18.7, 19.3, 19.8, 20.2, 20.4, 20.7, 20.9, 21.4, 21.6, 22.4, 22.6, 23.0, 23.3, 23.7, 23.9, 25.3, 25.9, 27.5, 27.8, 28.5, 28.7, 29.6, 30.0, 30.4, 31.4, 31.8, 33.1, and 33.6.
- One embodiment of the disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8 ⁇ 0.2, 7.7 ⁇ 0.2, 9.9 ⁇ 0.2, 11.9 ⁇ 0.2, 13.6 ⁇ 0.2, 14.0 ⁇ 0.2, 14.2 ⁇ 0.2, 14.7 ⁇ 0.2, 15.4 ⁇ 0.2, 15.8 ⁇ 0.2, 18.0 ⁇ 0.2, 18.3 ⁇ 0.2, 18.7 ⁇ 0.2, 19.3 ⁇ 0.2, 19.8 ⁇ 0.2, 20.2 ⁇ 0.2, 20.4 ⁇ 0.2, 20.7 ⁇ 0.2, 20.9 ⁇ 0.2, 21.4 ⁇ 0.2, 21.6 ⁇ 0.2, 22.4 ⁇ 0.2, 22.6 ⁇ 0.2, 23.0 ⁇ 0.2, 23.3 ⁇ 0.2, 23.7 ⁇ 0.2, 23.9 ⁇ 0.2, 25.3 ⁇ 0.2, 25.9 ⁇ 0.2, 27.5 ⁇ 0.2, 27.8 ⁇ 0.2, 28.5 ⁇ 0.2, 28.7 ⁇ 0.2, 29.6 ⁇ 0.2, 30.0 ⁇ 0.2, 30.4 ⁇ 0.2, 31.4
- one embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8, 7.7, 9.9, 11.9, 15.4, 23.0, 23.9, 25.3, and 27.5.
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8 ⁇ 0.2, 7.7 ⁇ 0.2, 9.9 ⁇ 0.2, 11.9 ⁇ 0.2, 15.4 ⁇ 0.2, 23.0 ⁇ 0.2, 23.9 ⁇ 0.2, 25.3 ⁇ 0.2, and 27.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 30.
- the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid. Crystalline Form XXV of AP1189 DL-lactic acid exhibits an XRPD diffractogram as shown in FIG. 36 .
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 9.8 ⁇ 0.2, 11.9 ⁇ 0.2, and 27.6 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXV of AP1189 DL-lactic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8 ⁇ 0.2, 23.3 ⁇ 0.2, and 23.9 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 7.6 ⁇ 0.2, 15.3 ⁇ 0.2, and 25.6 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 36 .
- One embodiment of the disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8, 7.6, 9.8, 11.9, 13.7, 14.1, 14.3, 15.3, 15.8, 18.2, 18.6, 19.2, 19.8, 20.5, 21.0, 21.3, 21.5, 22.5, 22.7, 22.9, 23.3, 23.6, 23.9, 25.0, 25.6, 26.1, 27.6, 28.7, 29.4, 29.6, 29.8, 30.2, 30.6, 31.6, 32.0, and 34.1.
- One embodiment of the disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8 ⁇ 0.2, 7.6 ⁇ 0.2, 9.8 ⁇ 0.2, 11.9 ⁇ 0.2, 13.7 ⁇ 0.2, 14.1 ⁇ 0.2, 14.3 ⁇ 0.2, 15.3 ⁇ 0.2, 15.8 ⁇ 0.2, 18.2 ⁇ 0.2, 18.6 ⁇ 0.2, 19.2 ⁇ 0.2, 19.8 ⁇ 0.2, 20.5 ⁇ 0.2, 21.0 ⁇ 0.2, 21.3 ⁇ 0.2, 21.5 ⁇ 0.2, 22.5 ⁇ 0.2, 22.7 ⁇ 0.2, 22.9 ⁇ 0.2, 23.3 ⁇ 0.2, 23.6 ⁇ 0.2, 23.9 ⁇ 0.2, 25.0 ⁇ 0.2, 25.6 ⁇ 0.2, 26.1 ⁇ 0.2, 27.6 ⁇ 0.2, 28.7 ⁇ 0.2, 29.4 ⁇ 0.2, 29.6 ⁇ 0.2, 29.8 ⁇ 0.2, 30.2 ⁇ 0.2, 30.6 ⁇ 0.2, 31.6 ⁇ 0.2, 32.0 ⁇ 0.2, and 34.1 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8, 7.6, 9.8, 11.9, 15.3, 23.3, 23.9, 25.6, and 27.6.
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.8 ⁇ 0.2, 7.6 ⁇ 0.2, 9.8 ⁇ 0.2, 11.9 ⁇ 0.2, 15.3 ⁇ 0.2, 23.3 ⁇ 0.2, 23.9 ⁇ 0.2, 25.6 ⁇ 0.2, and 27.6 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 31.
- the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid. Crystalline Form XXVI of AP1189 glutaric acid exhibits an XRPD diffractogram as shown in FIG. 37 .
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 8.3 ⁇ 0.2, 15.9 ⁇ 0.2, and 21.9 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXVI of AP1189 glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 12.8 ⁇ 0.2, 15.1 ⁇ 0.2, and 27.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 8.7 ⁇ 0.2, 14.4 ⁇ 0.2, 16.2 ⁇ 0.2, 19.0 ⁇ 0.2, 19.8 ⁇ 0.2, 28.8 ⁇ 0.2, and 29.5 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG.
- One embodiment of the disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2, 6.3, 8.3, 8.7, 9.8, 10.1, 10.5, 12.8, 13.6, 14.4, 15.1, 15.9, 16.2, 17.1, 17.5, 18.0, 18.3, 19.0, 19.8, 20.2, 20.5, 21.0, 21.4, 21.7, 21.9, 23.0, 23.6, 24.1, 24.5, 25.0, 26.0, 26.5, 27.1, 27.6, 28.2, 28.8, 29.5, 30.6, 31.4, 32.3, and 33.8.
- One embodiment of the disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 6.3 ⁇ 0.2, 8.3 ⁇ 0.2, 8.7 ⁇ 0.2, 9.8 ⁇ 0.2, 10.1 ⁇ 0.2, 10.5 ⁇ 0.2, 12.8 ⁇ 0.2, 13.6 ⁇ 0.2, 14.4 ⁇ 0.2, 15.1 ⁇ 0.2, 15.9 ⁇ 0.2, 16.2 ⁇ 0.2, 17.1 ⁇ 0.2, 17.5 ⁇ 0.2, 18.0 ⁇ 0.2, 18.3 ⁇ 0.2, 19.0 ⁇ 0.2, 19.8 ⁇ 0.2, 20.2 ⁇ 0.2, 20.5 ⁇ 0.2, 21.0 ⁇ 0.2, 21.4 ⁇ 0.2, 21.7 ⁇ 0.2, 21.9 ⁇ 0.2, 23.0 ⁇ 0.2, 23.6 ⁇ 0.2, 24.1 ⁇ 0.2, 24.5 ⁇ 0.2, 25.0 ⁇ 0.2, 26.0 ⁇ 0.2, 26.5 ⁇ 0.2, 27.1 ⁇ 0.2, 27.6 ⁇ 0.2, 28.2 ⁇ 0.2, 28.8 ⁇ 0.2, 29.5 ⁇ 0.2
- one embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2, 8.3, 8.7, 12.8, 14.4, 15.1, 15.9, 16.2, 19.0, 19.8, 21.9, 27.1, 28.8, and 29.5.
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 3.2 ⁇ 0.2, 8.3 ⁇ 0.2, 8.7 ⁇ 0.2, 12.8 ⁇ 0.2, 14.4 ⁇ 0.2, 15.1 ⁇ 0.2, 15.9 ⁇ 0.2, 16.2 ⁇ 0.2, 19.0 ⁇ 0.2, 19.8 ⁇ 0.2, 21.9 ⁇ 0.2, 27.1 ⁇ 0.2, 28.8 ⁇ 0.2, and 29.5 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 32.
- the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid. Crystalline Form XXVII of AP1189 glutaric acid exhibits an XRPD diffractogram as shown in FIG. 38 .
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.1 ⁇ 0.2, 21.7 ⁇ 0.2, and 25.0 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXVII of AP1189 glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 16.9 ⁇ 0.2, 25.6 ⁇ 0.2, 27.1 ⁇ 0.2, 28.2 ⁇ 0.2, and 28.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 10.1 ⁇ 0.2, 14.3 ⁇ 0.2, 14.7 ⁇ 0.2, 15.1 ⁇ 0.2, 17.4 ⁇ 0.2, 21.1 ⁇ 0.2, 22.6 ⁇ 0.2, and 26.5 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 38 .
- One embodiment of the disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 10.1, 10.8, 12.6, 12.7, 13.5, 14.1, 14.3, 14.7, 15.1, 15.3, 15.7, 16.5, 16.7, 16.9, 17.4, 18.0, 18.3, 18.7, 18.9, 19.3, 19.6, 20.1, 20.2, 20.5, 20.9, 21.3, 21.7, 22.1, 22.6, 23.2, 24.0, 24.4, 25.0, 25.6, 26.0, 26.5, 26.8, 27.1, 27.6, 28.2, 28.7, 29.0, 29.4, 29.7, 30.5, 31.3, 32.0, 33.0, and 34.1.
- One embodiment of the disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 10.1 ⁇ 0.2, 10.8 ⁇ 0.2, 12.6 ⁇ 0.2, 12.7 ⁇ 0.2, 13.5 ⁇ 0.2, 14.1 ⁇ 0.2, 14.3 ⁇ 0.2, 14.7 ⁇ 0.2, 15.1 ⁇ 0.2, 15.3 ⁇ 0.2, 15.7 ⁇ 0.2, 16.5 ⁇ 0.2, 16.7 ⁇ 0.2, 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, 18.0 ⁇ 0.2, 18.3 ⁇ 0.2, 18.7 ⁇ 0.2, 18.9 ⁇ 0.2, 19.3 ⁇ 0.2, 19.6 ⁇ 0.2, 20.1 ⁇ 0.2, 20.2 ⁇ 0.2, 20.5 ⁇ 0.2, 20.9 ⁇ 0.2, 21.3 ⁇ 0.2, 21.7 ⁇ 0.2, 22.1 ⁇ 0.2, 22.6 ⁇ 0.2, 23.2 ⁇ 0.2, 24.0 ⁇ 0.2, 24.4 ⁇ 0.2, 25.0 ⁇ 0.2, 25.6 ⁇ 0.2, 26.0 ⁇ 0.2, 26.5 ⁇ 0.2, 26.
- one embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 10.1, 14.1, 14.3, 14.7, 15.1, 16.9, 17.4, 21.7, 22.1, 22.6, 25.0, 25.6, 26.5, 27.1, 28.2, and 28.7.
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 10.1 ⁇ 0.2, 14.1 ⁇ 0.2, 14.3 ⁇ 0.2, 14.7 ⁇ 0.2, 15.1 ⁇ 0.2, 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, 21.7 ⁇ 0.2, 22.1 ⁇ 0.2, 22.6 ⁇ 0.2, 25.0 ⁇ 0.2, 25.6 ⁇ 0.2, 26.5 ⁇ 0.2, 27.1 ⁇ 0.2, 28.2 ⁇ 0.2, and 28.7 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 33.
- the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid. Crystalline Form XXVIII of AP1189 glutaric acid exhibits an XRPD diffractogram as shown in FIG. 91 .
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 14.2 ⁇ 0.2, 16.9 ⁇ 0.2, and 24.5 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXVIII of AP1189 glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 15.2 ⁇ 0.2, 20.9 ⁇ 0.2, and 21.9 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 8.9 ⁇ 0.2, 10.1 ⁇ 0.2, 12.6 ⁇ 0.2, 17.4 ⁇ 0.2, 19.1 ⁇ 0.2, 20.6 ⁇ 0.2, and 28.4 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 91 .
- One embodiment of the disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 8.9, 10.1, 10.4, 10.7, 12.6, 13.4, 13.8, 14.2, 15.2, 15.6, 16.5, 16.9, 17.4, 18.2, 19.1, 19.8, 20.2, 20.6, 20.9, 21.7, 21.9, 22.5, 23.0, 23.6, 23.8, 24.5, 24.9, 25.3, 26.1, 27.2, 27.8, 28.4, 29.3, 29.6, 30.5, 31.0, 31.4, 32.4, 33.6, and 34.3.
- One embodiment of the disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 8.9 ⁇ 0.2, 10.1 ⁇ 0.2, 10.4 ⁇ 0.2, 10.7 ⁇ 0.2, 12.6 ⁇ 0.2, 13.4 ⁇ 0.2, 13.8 ⁇ 0.2, 14.2 ⁇ 0.2, 15.2 ⁇ 0.2, 15.6 ⁇ 0.2, 16.5 ⁇ 0.2, 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, 18.2 ⁇ 0.2, 19.1 ⁇ 0.2, 19.8 ⁇ 0.2, 20.2 ⁇ 0.2, 20.6 ⁇ 0.2, 20.9 ⁇ 0.2, 21.7 ⁇ 0.2, 21.9 ⁇ 0.2, 22.5 ⁇ 0.2, 23.0 ⁇ 0.2, 23.6 ⁇ 0.2, 23.8 ⁇ 0.2, 24.5 ⁇ 0.2, 24.9 ⁇ 0.2, 25.3 ⁇ 0.2, 26.1 ⁇ 0.2, 27.2 ⁇ 0.2, 27.8 ⁇ 0.2, 28.4 ⁇ 0.2, 29.3 ⁇ 0.2, 29.6 ⁇ 0.2, 30.5 ⁇ 0.2, 31.0
- one embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3, 8.9, 10.1, 12.6, 14.2, 15.2, 16.9, 17.4, 19.1, 20.6, 20.9, 21.9, 24.5, and 28.4.
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 6.3 ⁇ 0.2, 8.9 ⁇ 0.2, 10.1 ⁇ 0.2, 12.6 ⁇ 0.2, 14.2 ⁇ 0.2, 15.2 ⁇ 0.2, 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, 19.1 ⁇ 0.2, 20.6 ⁇ 0.2, 20.9 ⁇ 0.2, 21.9 ⁇ 0.2, 24.5 ⁇ 0.2, and 28.4 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 34.
- the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid. Crystalline Form XXIX of AP1189 adipic acid exhibits an XRPD diffractogram as shown in FIG. 39 .
- One embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation at 13.4 ⁇ 0.2, 14.5 ⁇ 0.2, and 25.5 ⁇ 0.2.
- One embodiment provides for a crystalline Form XXIX of AP1189 adipic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 17.6 ⁇ 0.2, 23.5 ⁇ 0.2, 25.4 ⁇ 0.2, and 27.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid further exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.2 ⁇ 0.2, 19.2 ⁇ 0.2, and 21.4 ⁇ 0.2.
- One embodiment of the disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K ⁇ radiation according to FIG. 39 .
- One embodiment of the disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.2, 10.5, 11.2, 12.7, 13.4, 14.5, 15.3, 15.8, 17.1, 17.6, 18.0, 18.8, 19.2, 20.5, 21.0, 21.4, 22.4, 22.8, 23.0, 23.5, 23.9, 24.4, 24.8, 25.4, 25.5, 26.1, 26.3, 27.1, 27.5, 28.1, 28.9, 29.5, 30.6, 32.2, 33.9, and 34.5.
- One embodiment of the disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.2 ⁇ 0.2, 10.5 ⁇ 0.2, 11.2 ⁇ 0.2, 12.7 ⁇ 0.2, 13.4 ⁇ 0.2, 14.5 ⁇ 0.2, 15.3 ⁇ 0.2, 15.8 ⁇ 0.2, 17.1 ⁇ 0.2, 17.6 ⁇ 0.2, 18.0 ⁇ 0.2, 18.8 ⁇ 0.2, 19.2 ⁇ 0.2, 20.5 ⁇ 0.2, 21.0 ⁇ 0.2, 21.4 ⁇ 0.2, 22.4 ⁇ 0.2, 22.8 ⁇ 0.2, 23.0 ⁇ 0.2, 23.5 ⁇ 0.2, 23.9 ⁇ 0.2, 24.4 ⁇ 0.2, 24.8, 25.4, 25.5, 26.1, 26.3, 27.1, 27.5, 28.1, 28.9, 29.5, 30.6, 32.2, 33.9, and 34.5 ⁇ 0.2.
- one embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.2, 13.4, 14.5, 17.6, 19.2, 21.4, 23.5, 25.4, 25.5, and 27.1.
- One embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of 5.2 ⁇ 0.2, 13.4 ⁇ 0.2, 14.5 ⁇ 0.2, 17.6 ⁇ 0.2, 19.2 ⁇ 0.2, 21.4 ⁇ 0.2, 23.5 ⁇ 0.2, 25.4 ⁇ 0.2, 25.5 ⁇ 0.2, and 27.1 ⁇ 0.2.
- One embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic exhibiting one or more X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K ⁇ radiation selected from the group consisting of the 2-theta values in listed in Table 35.
- the salts of AP1189 provided herein may be further characterised by the onset temperatures they exhibit as assessed by differential scanning calorimetry.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting in differential scanning calorimetry an onset temperature between 185 and 199° C.
- One specific embodiment of the present disclosure provides a crystalline Form A of AP1189 acetate exhibiting in differential scanning calorimetry an onset temperature of substantially 192° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form A of AP1189 acetate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 8 .
- One embodiment of the present disclosure provides a crystalline Form A of AP1189 acetate exhibiting a differential scanning calorimetry thermogram according to FIG. 8 .
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 192 ⁇ 7° C., such as 192 ⁇ 6° C., such as 192 ⁇ 5° C., such as 192 ⁇ 4° C., such as 192 ⁇ 3° C., such as 192 ⁇ 2° C., such as 192 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate exhibiting in differential scanning calorimetry an onset temperature between 187 and 201° C.
- One specific embodiment of the present disclosure provides a crystalline Form B of AP1189 succinate exhibiting in differential scanning calorimetry an onset temperature of substantially 194° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form B of AP1189 succinate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 13 .
- One embodiment of the present disclosure provides a crystalline Form B of AP1189 succinate exhibiting a differential scanning calorimetry thermogram according to FIG. 13 .
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 195 ⁇ 7° C., such as 195 ⁇ 6° C., such as 195 ⁇ 5° C., such as 1954° C., such as 1953° C., such as 195 ⁇ 2° C., such as 195 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting in differential scanning calorimetry an onset temperature between 227 and 241° C.
- One specific embodiment of the present disclosure provides a crystalline Form C of AP1189 tosylate exhibiting in differential scanning calorimetry an onset temperature of substantially 234° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 11 .
- One embodiment of the present disclosure provides a crystalline Form C of AP1189 tosylate exhibiting a differential scanning calorimetry thermogram according to FIG. 11 .
- One embodiment of the present disclosure provides for a crystalline Form C of AP1189 tosylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 234 ⁇ 7° C., such as 234 ⁇ 6° C., such as 234 ⁇ 5° C., such as 234 ⁇ 4° C., such as 234 ⁇ 3° C., such as 234 ⁇ 2° C., such as 234 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting in differential scanning calorimetry an onset temperature between 208 and 222° C.
- One specific embodiment of the present disclosure provides a crystalline Form D of AP1189 fumarate exhibiting in differential scanning calorimetry an onset temperature of substantially 215° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 12 .
- One embodiment of the present disclosure provides a crystalline Form D of AP1189 fumarate exhibiting a differential scanning calorimetry thermogram according to FIG. 12 .
- One embodiment of the present disclosure provides for a crystalline Form D of AP1189 fumarate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 215 ⁇ 7° C., such as 215 ⁇ 6° C., such as 215 ⁇ 5° C., such as 215 ⁇ 4° C., such as 215 ⁇ 3° C., such as 215 ⁇ 2° C., such as 215 ⁇ 1° C.
- Certain salts disclosed herein exhibit more than one onset temperature, e.g. two onset temperatures.
- the salts may be characterised by either of their onset temperatures in isolation, or as a combination of onset temperatures.
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature between 80 and 94° C.
- One specific embodiment of the present disclosure provides a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 87° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 40 .
- One embodiment of the present disclosure provides a crystalline Form III of AP1189 napadisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 40 .
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 87 ⁇ 7° C., such as 87 ⁇ 6° C., such as 87 ⁇ 5° C., such as 874° C., such as 873° C., such as 87 ⁇ 2° C., such as 87 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature between 180 and 194° C.
- One specific embodiment of the present disclosure provides a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 187° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 40 .
- One embodiment of the present disclosure provides a crystalline Form III of AP1189 napadisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 40 .
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 187 ⁇ 7° C., such as 187 ⁇ 6° C., such as 187 ⁇ 5° C., such as 187 ⁇ 4° C., such as 187 ⁇ 3° C., such as 187 ⁇ 2° C., such as 187 ⁇ 1° C.
- One embodiment of the disclosure provides for a crystalline Form IV of AP1189 napadisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 81 .
- One embodiment of the present disclosure provides a crystalline Form IV of AP1189 napadisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 81 .
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate exhibiting in differential scanning calorimetry an onset temperature between 200 and 214° C.
- One specific embodiment of the present disclosure provides a crystalline Form V of AP1189 esylate exhibiting in differential scanning calorimetry an onset temperature of substantially 207° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form V of AP1189 esylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 41 .
- One embodiment of the present disclosure provides a crystalline Form V of AP1189 esylate exhibiting a differential scanning calorimetry thermogram according to FIG. 41 .
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 207 ⁇ 7° C., such as 207 ⁇ 6° C., such as 207 ⁇ 5° C., such as 207 ⁇ 4° C., such as 207 ⁇ 3° C., such as 207 ⁇ 2° C., such as 207 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature between 71 and 85° C.
- One specific embodiment of the present disclosure provides a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 78° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 82 .
- One embodiment of the present disclosure provides a crystalline Form VI of AP1189 edisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 82 .
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 78 ⁇ 7° C., such as 78 ⁇ 6° C., such as 78 ⁇ 5° C., such as 78 ⁇ 4° C., such as 78 ⁇ 3° C., such as 78 ⁇ 2° C., such as 78 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature between 144 and 158° C.
- One specific embodiment of the present disclosure provides a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 151° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 82 .
- One embodiment of the present disclosure provides a crystalline Form VI of AP1189 edisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 82 .
- One embodiment of the present disclosure provides for a crystalline Form VI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 151 ⁇ 7° C., such as 151 ⁇ 6° C., such as 151 ⁇ 5° C., such as 151 ⁇ 4° C., such as 151 ⁇ 3° C., such as 151 ⁇ 2° C., such as 151 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature between 218 and 232° C.
- One specific embodiment of the present disclosure provides a crystalline Form VII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 225° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 42 .
- One embodiment of the present disclosure provides a crystalline Form VII of AP1189 edisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 42 .
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 225 ⁇ 7° C., such as 225 ⁇ 6° C., such as 225 ⁇ 5° C., such as 225 ⁇ 4° C., such as 225 ⁇ 3° C., such as 225 ⁇ 2° C., such as 225 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature between 201 and 215° C.
- One specific embodiment of the present disclosure provides a crystalline Form VIII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 208° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 43 .
- One embodiment of the present disclosure provides a crystalline Form VIII of AP1189 edisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 43 .
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 208 ⁇ 7° C., such as 208 ⁇ 6° C., such as 208 ⁇ 5° C., such as 208 ⁇ 4° C., such as 208 ⁇ 3° C., such as 208 ⁇ 2° C., such as 208 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature between 52 and 66° C.
- One specific embodiment of the present disclosure provides a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 59° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 44 .
- One embodiment of the present disclosure provides a crystalline Form IX of AP1189 edisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 44 .
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 59 ⁇ 7° C., such as 59 ⁇ 6° C., such as 59 ⁇ 5° C., such as 59 ⁇ 4° C., such as 59 ⁇ 3° C., such as 59 ⁇ 2° C., such as 59 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature between 144 and 158° C.
- One specific embodiment of the present disclosure provides a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature of substantially 151° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 44 .
- One embodiment of the present disclosure provides a crystalline Form IX of AP1189 edisylate exhibiting a differential scanning calorimetry thermogram according to FIG. 44 .
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 151 ⁇ 7° C., such as 151 ⁇ 6° C., such as 151 ⁇ 5° C., such as 151 ⁇ 4° C., such as 151 ⁇ 3° C., such as 151 ⁇ 2° C., such as 151 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting in differential scanning calorimetry an onset temperature between 172 and 186° C.
- One specific embodiment of the present disclosure provides a crystalline Form X of AP1189 nitrate exhibiting in differential scanning calorimetry an onset temperature of substantially 179° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 45 .
- One embodiment of the present disclosure provides a crystalline Form X of AP1189 nitrate exhibiting a differential scanning calorimetry thermogram according to FIG. 45 .
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 179 ⁇ 7° C., such as 179 ⁇ 6° C., such as 179 ⁇ 5° C., such as 179 ⁇ 4° C., such as 179 ⁇ 3° C., such as 179 ⁇ 2° C., such as 179 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature between 123 and 137° C.
- One specific embodiment of the present disclosure provides a crystalline Form XI of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature of substantially 130° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 46 .
- One embodiment of the present disclosure provides a crystalline Form XI of AP1189 cyclamate exhibiting a differential scanning calorimetry thermogram according to FIG. 46 .
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 130 ⁇ 7° C., such as 130 ⁇ 6° C., such as 130 ⁇ 5° C., such as 130 ⁇ 4° C., such as 130 ⁇ 3° C., such as 130 ⁇ 2° C., such as 130 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature between 131 and 145° C.
- One specific embodiment of the present disclosure provides a crystalline Form XII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature of substantially 138° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 47 .
- One embodiment of the present disclosure provides a crystalline Form XII of AP1189 cyclamate exhibiting a differential scanning calorimetry thermogram according to FIG. 47 .
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 138 ⁇ 7° C., such as 138 ⁇ 6° C., such as 138 ⁇ 5° C., such as 138 ⁇ 4° C., such as 138 ⁇ 3° C., such as 138 ⁇ 2° C., such as 138 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature between 134 and 148° C.
- One specific embodiment of the present disclosure provides a crystalline Form XIII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature of substantially 141° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 83 .
- One embodiment of the present disclosure provides a crystalline Form XIII of AP1189 cyclamate exhibiting a differential scanning calorimetry thermogram according to FIG. 83 .
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 141 ⁇ 7° C., such as 141 ⁇ 6° C., such as 141 ⁇ 5° C., such as 141 ⁇ 4° C., such as 141 ⁇ 3° C., such as 141 ⁇ 2° C., such as 141 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting in differential scanning calorimetry an onset temperature between 219 and 223° C.
- One specific embodiment of the present disclosure provides a crystalline Form XIV of AP1189 besylate exhibiting in differential scanning calorimetry an onset temperature of substantially 216° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 48 .
- One embodiment of the present disclosure provides a crystalline Form XIV of AP1189 besylate exhibiting a differential scanning calorimetry thermogram according to FIG. 48 .
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 216 ⁇ 7° C., such as 216 ⁇ 6° C., such as 216 ⁇ 5° C., such as 216 ⁇ 4° C., such as 216 ⁇ 3° C., such as 216 ⁇ 2° C., such as 216 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting in differential scanning calorimetry a peak temperature between 204 and 218° C.
- One specific embodiment of the present disclosure provides a crystalline Form XV of AP1189 oxalate exhibiting in differential scanning calorimetry a peal temperature of substantially 211° C.
- the peak temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting in differential scanning calorimetry a peak temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 49 .
- One embodiment of the present disclosure provides a crystalline Form XV of AP1189 oxalate exhibiting a differential scanning calorimetry thermogram according to FIG. 49 .
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate exhibiting in differential scanning calorimetry a peak temperature falling within the interval 211 ⁇ 7° C., such as 211 ⁇ 6° C., such as 211 ⁇ 5° C., such as 211 ⁇ 4° C., such as 211 ⁇ 3° C., such as 211 ⁇ 2° C., such as 211 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting in differential scanning calorimetry an onset temperature between 200 and 214° C.
- One specific embodiment of the present disclosure provides a crystalline Form XVI of AP1189 oxalate exhibiting in differential scanning calorimetry an onset temperature of substantially 207° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 50 .
- One embodiment of the present disclosure provides a crystalline Form XVI of AP1189 oxalate exhibiting a differential scanning calorimetry thermogram according to FIG. 50 .
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 207 ⁇ 7° C., such as 207 ⁇ 6° C., such as 207 ⁇ 5° C., such as 207 ⁇ 4° C., such as 207 ⁇ 3° C., such as 207 ⁇ 2° C., such as 207 ⁇ 1° C.
- One embodiment of the disclosure provides for a crystalline Form XVII of AP1189 oxalate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 51 .
- One embodiment of the present disclosure provides a crystalline Form XVII of AP1189 oxalate exhibiting a differential scanning calorimetry thermogram according to FIG. 51 .
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting in differential scanning calorimetry an onset temperature between 198 and 212° C.
- One specific embodiment of the present disclosure provides a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting in differential scanning calorimetry an onset temperature of substantially 205° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 52 .
- One embodiment of the present disclosure provides a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting a differential scanning calorimetry thermogram according to FIG. 52 .
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 205 ⁇ 7° C., such as 205 ⁇ 6° C., such as 205 ⁇ 5° C., such as 205 ⁇ 4° C., such as 205 ⁇ 3° C., such as 205 ⁇ 2° C., such as 205 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting in differential scanning calorimetry an onset temperature between 74 and 88° C.
- One specific embodiment of the present disclosure provides a crystalline Form XIX of AP1189 oxoglutarate exhibiting in differential scanning calorimetry an onset temperature of substantially 81° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 53 .
- One embodiment of the present disclosure provides a crystalline Form XIX of AP1189 oxoglutarate exhibiting a differential scanning calorimetry thermogram according to FIG. 53 .
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 81 ⁇ 7° C., such as 81 ⁇ 6° C., such as 81 ⁇ 5° C., such as 81 ⁇ 4° C., such as 81 ⁇ 3° C., such as 81 ⁇ 2° C., such as 81 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting in differential scanning calorimetry an onset temperature between 103 and 117° C.
- One specific embodiment of the present disclosure provides a crystalline Form XX of AP1189 DL-mandelic acid exhibiting in differential scanning calorimetry an onset temperature of substantially 110° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 54 .
- One embodiment of the present disclosure provides a crystalline Form XX of AP1189 DL-mandelic acid exhibiting a differential scanning calorimetry thermogram according to FIG. 54 .
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 110 ⁇ 7° C., such as 110 ⁇ 6° C., such as 110 ⁇ 5° C., such as 110 ⁇ 4° C., such as 1103° C., such as 1102° C., such as 110 ⁇ 1° C.
- One embodiment of the disclosure provides for a crystalline Form XXI of AP1189 mandelic acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 55 .
- One embodiment of the present disclosure provides a crystalline Form XXI of AP1189 mandelic acid exhibiting a differential scanning calorimetry thermogram according to FIG. 55 .
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting in differential scanning calorimetry an onset temperature between 132 and 146° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXII of AP1189 hippuric acid exhibiting in differential scanning calorimetry an onset temperature of substantially 139° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 56 .
- One embodiment of the present disclosure provides a crystalline Form XXII of AP1189 hippuric acid exhibiting a differential scanning calorimetry thermogram according to FIG. 56 .
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 139 ⁇ 7° C., such as 139 ⁇ 6° C., such as 139 ⁇ 5° C., such as 139 ⁇ 4° C., such as 1393° C., such as 1392° C., such as 139 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting in differential scanning calorimetry an onset temperature between 162 and 176° C.
- One specific embodiment of the present disclosure provides a crystalline Form XIII of AP1189 formate exhibiting in differential scanning calorimetry an onset temperature of substantially 169° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 84 .
- One embodiment of the present disclosure provides a crystalline Form XXIII of AP1189 formate exhibiting a differential scanning calorimetry thermogram according to FIG. 84 .
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate exhibiting in differential scanning calorimetry an onset temperature falling within the interval 169 ⁇ 7° C., such as 169 ⁇ 6° C., such as 169 ⁇ 5° C., such as 1694° C., such as 1693° C., such as 169 ⁇ 2° C., such as 169 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature between 182 and 196° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature of substantially 189° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 85 .
- One embodiment of the present disclosure provides a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting a differential scanning calorimetry thermogram according to FIG. 85 .
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 189 ⁇ 7° C., such as 189 ⁇ 6° C., such as 189 ⁇ 5° C., such as 189 ⁇ 4° C., such as 189 ⁇ 3° C., such as 189 ⁇ 2° C., such as 189 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature between 191 and 205° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature of substantially 198° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 86 .
- One embodiment of the present disclosure provides a crystalline Form XXV of AP1189 DL-lactic acid exhibiting a differential scanning calorimetry thermogram according to FIG. 86 .
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 198 ⁇ 7° C., such as 198 ⁇ 6° C., such as 198 ⁇ 5° C., such as 198 ⁇ 4° C., such as 198 ⁇ 3° C., such as 198 ⁇ 2° C., such as 198 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature between 102 and 116° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature of substantially 109° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 87 .
- One embodiment of the present disclosure provides a crystalline Form XXVI of AP1189 glutaric acid exhibiting a differential scanning calorimetry thermogram according to FIG. 87 .
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 109 ⁇ 7° C., such as 109 ⁇ 6° C., such as 109 ⁇ 5° C., such as 109 ⁇ 4° C., such as 109 ⁇ 3° C., such as 109 ⁇ 2° C., such as 109 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature between 153 and 167° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature of substantially 160° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 87 .
- One embodiment of the present disclosure provides a crystalline Form XXVI of AP1189 glutaric acid exhibiting a differential scanning calorimetry thermogram according to FIG. 87 .
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 160 ⁇ 7° C., such as 160 ⁇ 6° C., such as 160 ⁇ 5° C., such as 160 ⁇ 4° C., such as 160 ⁇ 3° C., such as 160 ⁇ 2° C., such as 160 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature between 156 and 170° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXVII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature of substantially 163° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 88 .
- One embodiment of the present disclosure provides a crystalline Form XXVII of AP1189 glutaric acid exhibiting a differential scanning calorimetry thermogram according to FIG. 88 .
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 163 ⁇ 7° C., such as 163 ⁇ 6° C., such as 163 ⁇ 5° C., such as 163 ⁇ 4° C., such as 163 ⁇ 3° C., such as 163 ⁇ 2° C., such as 163 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature between 138 and 152° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature of substantially 145° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 89 .
- One embodiment of the present disclosure provides a crystalline Form XXVIII of AP1189 glutaric acid exhibiting a differential scanning calorimetry thermogram according to FIG. 89 .
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 145 ⁇ 7° C., such as 145 ⁇ 6° C., such as 145 ⁇ 5° C., such as 145 ⁇ 4° C., such as 145 ⁇ 3° C., such as 145 ⁇ 2° C., such as 145 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature between 153 and 167° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature of substantially 160° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 89 .
- One embodiment of the present disclosure provides a crystalline Form XXVIII of AP1189 glutaric acid exhibiting a differential scanning calorimetry thermogram according to FIG. 89 .
- One embodiment of the present disclosure provides for a crystalline Form XXVIII of AP1189 glutaric acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 160 ⁇ 7° C., such as 160 ⁇ 6° C., such as 160 ⁇ 5° C., such as 160 ⁇ 4° C., such as 160 ⁇ 3° C., such as 160 ⁇ 2° C., such as 160 ⁇ 1° C.
- One embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting in differential scanning calorimetry an onset temperature between 176 and 190° C.
- One specific embodiment of the present disclosure provides a crystalline Form XXIX of AP1189 adipic acid exhibiting in differential scanning calorimetry an onset temperature of substantially 183° C.
- the onset temperature is assessed using a heating rate of 10° C./min.
- One embodiment of the disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting in differential scanning calorimetry an onset temperature as shown in the examples herein, specifically example 4, and/or in the figures herein, specifically FIG. 90 .
- One embodiment of the present disclosure provides a crystalline Form XXIX of AP1189 adipic acid exhibiting a differential scanning calorimetry thermogram according to FIG. 90 .
- One embodiment of the present disclosure provides for a crystalline Form XXIX of AP1189 adipic acid exhibiting in differential scanning calorimetry an onset temperature falling within the interval 183 ⁇ 7° C., such as 183 ⁇ 6° C., such as 183 ⁇ 5° C., such as 183 ⁇ 4° C., such as 183 ⁇ 3° C., such as 183 ⁇ 2° C., such as 183 ⁇ 1° C.
- FT-IR spectra may be obtained as outlined in Example 13. FT-IR are reported in peaks corresponding to specific wavenumbers given in cm ⁇ 1 . While the peaks are given herein with some degree of certainty, it is to be construed that the accuracy of an FT-IR measurement is typically ⁇ 1, ⁇ 2, or ⁇ 3 cm ⁇ 1 . Accordingly, any peak reported herein is to be interpreted as having an accuracy of ⁇ 1, 2, or ⁇ 3 cm ⁇ 1 .
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate having an FT-IR as shown in FIG. 57 .
- One embodiment of the present disclosure provides for a crystalline Form III of AP1189 napadisylate having in an FT-IR spectrum peaks as shown in Table 45.
- One embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate having an FT-IR as shown in FIG. 58 .
- One embodiment of the present disclosure provides for a crystalline Form IV of AP1189 napadisylate having in an FT-IR spectrum peaks as shown in Table 46.
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate having an FT-IR as shown in FIG. 59 .
- One embodiment of the present disclosure provides for a crystalline Form V of AP1189 esylate having in an FT-IR spectrum peaks as shown in Table 47.
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate having an FT-IR as shown in FIG. 60 .
- One embodiment of the present disclosure provides for a crystalline Form VII of AP1189 edisylate having in an FT-IR spectrum peaks as shown in Table 48.
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate having an FT-IR as shown in FIG. 61 .
- One embodiment of the present disclosure provides for a crystalline Form VIII of AP1189 edisylate having in an FT-IR spectrum peaks as shown in Table 49.
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate having an FT-IR as shown in FIG. 62 .
- One embodiment of the present disclosure provides for a crystalline Form IX of AP1189 edisylate having in an FT-IR spectrum peaks as shown in Table 50.
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate having an FT-IR as shown in FIG. 63 .
- One embodiment of the present disclosure provides for a crystalline Form X of AP1189 nitrate having in an FT-IR spectrum peaks as shown in Table 51.
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate having an FT-IR as shown in FIG. 64 .
- One embodiment of the present disclosure provides for a crystalline Form XI of AP1189 cyclamate having in an FT-IR spectrum peaks as shown in Table 52.
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate having an FT-IR as shown in FIG. 65 .
- One embodiment of the present disclosure provides for a crystalline Form XII of AP1189 cyclamate having in an FT-IR spectrum peaks as shown in Table 53.
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate having an FT-IR as shown in FIG. 66 .
- One embodiment of the present disclosure provides for a crystalline Form XIII of AP1189 cyclamate having in an FT-IR spectrum peaks as shown in Table 54.
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate having an FT-IR as shown in FIG. 67 .
- One embodiment of the present disclosure provides for a crystalline Form XIV of AP1189 besylate having in an FT-IR spectrum peaks as shown in Table 55.
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate having an FT-IR as shown in FIG. 68 .
- One embodiment of the present disclosure provides for a crystalline Form XV of AP1189 oxalate having in an FT-IR spectrum peaks as shown in Table 56.
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate having an FT-IR as shown in FIG. 69 .
- One embodiment of the present disclosure provides for a crystalline Form XVI of AP1189 oxalate having in an FT-IR spectrum peaks as shown in Table 57.
- One embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate having an FT-IR as shown in FIG. 70 .
- One embodiment of the present disclosure provides for a crystalline Form XVII of AP1189 oxalate having in an FT-IR spectrum peaks as shown in Table 58.
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid having an FT-IR as shown in FIG. 71 .
- One embodiment of the present disclosure provides for a crystalline Form XVIII of AP1189 (+)-camphor-10-sulfonic acid having in an FT-IR spectrum peaks as shown in Table 59.
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate having an FT-IR as shown in FIG. 72 .
- One embodiment of the present disclosure provides for a crystalline Form XIX of AP1189 oxoglutarate having in an FT-IR spectrum peaks as shown in Table 60.
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid having an FT-IR as shown in FIG. 73 .
- One embodiment of the present disclosure provides for a crystalline Form XX of AP1189 DL-mandelic acid having in an FT-IR spectrum peaks as shown in Table 61.
- One embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid having an FT-IR as shown in FIG. 74 .
- One embodiment of the present disclosure provides for a crystalline Form XXI of AP1189 DL-mandelic acid having in an FT-IR spectrum peaks as shown in Table 62.
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid having an FT-IR as shown in FIG. 75 .
- One embodiment of the present disclosure provides for a crystalline Form XXII of AP1189 hippuric acid having in an FT-IR spectrum peaks as shown in Table 63.
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate having an FT-IR as shown in FIG. 76 .
- One embodiment of the present disclosure provides for a crystalline Form XXIII of AP1189 formate having in an FT-IR spectrum peaks as shown in Table 64.
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid having an FT-IR as shown in FIG. 77 .
- One embodiment of the present disclosure provides for a crystalline Form XXIV of AP1189 DL-lactic acid having in an FT-IR spectrum peaks as shown in Table 65.
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid having an FT-IR as shown in FIG. 78 .
- One embodiment of the present disclosure provides for a crystalline Form XXV of AP1189 DL-lactic acid having in an FT-IR spectrum peaks as shown in Table 66.
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid having an FT-IR as shown in FIG. 79 .
- One embodiment of the present disclosure provides for a crystalline Form XXVI of AP1189 glutaric acid having in an FT-IR spectrum peaks as shown in Table 67.
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid having an FT-IR as shown in FIG. 80 .
- One embodiment of the present disclosure provides for a crystalline Form XXVII of AP1189 glutaric acid having in an FT-IR spectrum peaks as shown in Table 68.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetic acid having an IR spectrum as shown in FIG. 92 .
- solubility in aqueous solution is preferably meant.
- solubility is in aqueous medium.
- the crystalline Form A of AP1189 acetate was found to have a high solubility at pH 1.2.
- crystalline Form B of AP1189 succinate was found to have a higher solubility at pH 1.2-1.3. It is an object of the present disclosure to provide salts of AP1189 having a high solubility at low pH, as this improves in vivo uptake of AP1189 after administration to a subject, such as oral administration to a subject.
- One embodiment of the present disclosure provides for a salt of AP1189 having a solubility at pH 1.2 of at least 10 mM, such as least 15 mM, such as at least 20 mM, such as at least 25 mM, such as at least 30 mM, such as at least 35 mM.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate having a solubility at pH 1.2 of at least 100 mM, such as at least 110 mM, such as at least 120 mM.
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate having a solubility at pH 1.2 of at least 20 mM, such as at least 25 mM, such as at least 30 mM, such as at least 35 mM.
- the solubility of a compound may be assessed by adding a surplus of the compound to a volume of solvent such that some of the compound is not dissolved, then isolating the non-dissolved compound and measuring the amount.
- the solubility of a compound may alternatively be assessed by adding a surplus of the compound to a volume of solvent such that some of the compound is not dissolved, and then measure the amount of compound in solution. Measuring the amount of compound in solution may be done using any suitable method, such as HPLC, titration, or spectrometry.
- Salts of AP1189 may be prepared as disclosed herein.
- One embodiment of the present disclosure provides for a method of producing AP1189 acetate of crystalline Form A, said method comprising:
- mixture can mean a solution or a slurry of one or more solids in a solvent or mixture of solvents.
- the mixture is a solution, where the solute or solutes are substantially fully dissolved.
- the mixture is a slurry, wherein one or more solutes are only partly dissolved, and the remaining part or parts of the solute or solutes are not dissolved.
- One embodiment of the present disclosure provides for a method for producing AP1189 acetate of crystalline Form A, said method comprising:
- the acetate salt is ammonium acetate or a metal acetate salt such as sodium acetate, lithium acetate, magnesium acetate, potassium acetate, or calcium acetate.
- the method further comprises adding an acid in step i, such as an organic acid or a mineral acid.
- One embodiment of the disclosure provides for a method for producing AP1189 acetate of crystalline Form A, said method comprising:
- such method is effective in converting AP1189 acetate not of crystalline Form A to AP1189 acetate of crystalline Form A.
- composition can mean a solution or a slurry of one solid in a solvent or mixture of solvents.
- the composition is a solution, where the solute is substantially fully dissolved.
- the composition is a slurry, wherein the solute is only partly dissolved, and the remaining part of the solute is not dissolved.
- the composition may further comprise one or more other agents or reagents which may be dissolved or may be only partly dissolved.
- Such other agents includes, but are not limited to, surfactants, detergents, acids, bases, sugars, salts, biomolecules, bioactive agents, and other excipients such as pharmaceutical excipients.
- This present disclosure also relates to non-solid compositions, e.g. liquid compositions, gel compositions, pastes, creams, or ointments prepared from the crystalline forms disclosed herein.
- a liquid composition prepared from a crystalline form disclosed herein and a solvent In a specific embodiment, the solvent is aqueous.
- the present disclosure provides for a method of preparing a liquid composition, a gel composition, a paste, a cream, or an ointment, said method comprising mixing a crystalline form disclosed herein and one or more additional agents.
- a method of preparing a liquid composition said method comprising mixing a crystalline form disclosed herein and a solvent.
- the solvent is aqueous.
- One embodiment of the disclosure provides for a method for producing N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate of crystalline Form A, said method comprising:
- any one of the above agents of step i may be generated from a precursor in situ.
- One embodiment of the present disclosure provides for a method for producing N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium acetate of crystalline Form A, said method comprising:
- One embodiment of the present disclosure provides for a method of producing AP1189 succinate of crystalline Form B, said method comprising:
- One embodiment of the present disclosure provides for a method of producing AP1189 succinate of crystalline Form B, said method comprising:
- One embodiment of the present disclosure provides for a method for producing the N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate of crystalline Form B, said method comprising:
- any one of the above agents of step i may be generated from a precursor in situ.
- One embodiment of the present disclosure provides for a method for producing the N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium succinate of crystalline Form B, said method comprising:
- the solvent is a protic or a polar aprotic solvent.
- the solvent is selected from the group consisting of 1,4-dioxane, methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, anisole, isopropyl acetate, methylethyl ketone, water, and ethyl acetate.
- the mixture or the composition is heated at least once before the isolating step. In one embodiment, the mixture or the composition is heated and cooled in cycles before the isolation step. In one embodiment, the mixture or the composition is heated and cooled in cycles for up to 72 hours before the isolating step. In one embodiment the mixture or the composition is heated and cooled in cycles for 15 min to 72 hours before the isolating step. In one embodiment, one cycle comprises heating the mixture or the composition to at least a first threshold temperature, maintaining the temperature above said first threshold temperature for a first duration, then cooling the mixture or the composition to below a second threshold temperature and maintaining the temperature below said second threshold temperature for a second duration. In one embodiment of the present disclosure, the cycle is carried out 1 to 200 times.
- the first threshold temperature is 30° C., such as 35° C., such as 40° C., such as 45° C., such as 50° C., such as 55° C., such as 60° C., such as 65° C., such as 70° C., such as 75° C., such as 80° C.
- the second threshold temperature is 30° C., such as 25° C., such as 20° C., such as 15° C., such as 10° C., such as 7° C., such as 5° C.
- the first and/or the second duration is 1 to 2 min, such as 2 to 5 min, such as 5 to 10 min, such as 10 to 20 min, such as 20 to 30 min, such as 30 to 40 min, such as 40 to 50 min, such as 50 to 60 min, such as 1 hour to 1.5 hours, such as 1.5 to 2 hours, such as 2 to 3 hours, such as 3 to 4 hours, such as 4 to 5 hours, such as 5 to 6 hours, such as 6 to 7 hours, such as 7 to 8 hours.
- the first and the second durations are the same. In one embodiment, the first and the second durations are different. In one embodiment, the first duration is different or the same for each cycle. In one embodiment, the second duration is different or the same for each cycle.
- heating is to about 40° C.
- cooling is to about 20° C.
- the method further comprises a step of adding an anti-solvent to the mixture or the composition before the isolation step.
- the anti-solvent is a non-polar aprotic solvent.
- the anti-solvent is selected from the group consisting of tert-butyl methyl ether, THF, and acetone, and mixtures comprising tert-butyl methyl ether, THF, or acetone.
- the anti-solvent is water.
- Isolation of crystals may be carried out using an appropriate means.
- the isolation is carried out using filtration, centrifugation, and/or evaporation of the solvent or solvents.
- a slow evaporation method is utilised.
- a fast evaporation method is utilised.
- the evaporation is carried out using spray drying.
- the evaporation is carried out using fluid bed drying, freeze drying, vacuum drying, tumble drying, rotary evaporation, and/or thin-film evaporation.
- the drying is carried out using a conductive (contact) dryer, including tray dryers, rotary cone dryers, tumble dryers, and paddle dryers.
- the drying is carried out using a carrier gas.
- one or more pKa values, such as at least one pKa, of the corresponding acid to the counter ion of the AP1189 salt is about equal to or lower than the pKa value of succinic acid and/or acetic acid.
- the corresponding acid to the counter ion of the AP1189 fumarate is fumaric acid.
- the pKa value of acetic acid is 4.756.
- the pKa value corresponding to the first acid dissociation of succinic acid is 4.2.
- the pKa value corresponding to the second acid dissociation of succinic acid is 5.6.
- the pKa value of the corresponding acid to the counter ion of the AP1189 salt is about equal to or lower than 4.756. In another embodiment, the pKa value of the corresponding acid to the counter ion of the AP1189 salt is about equal to or lower than 4.2 and/or 5.6.
- One embodiment of the present disclosure provides for a crystalline Form A of AP1189 acetate produced by the method as disclosed herein.
- One embodiment of the present disclosure provides for a crystalline Form B of AP1189 succinate produced by the method as disclosed herein.
- One embodiment of the present disclosure provides for a method of producing crystalline Form A of AP1189 acetate as disclosed herein, wherein the method further comprises adding a seed crystal of crystalline Form A of AP1189 acetate before the isolation step.
- One embodiment of the present disclosure provides for a method of producing crystalline Form B of AP1189 succinate as disclosed herein, wherein the method further comprises adding a seed crystal of crystalline Form B of AP1189 succinate before the isolation step.
- One embodiment of the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising the crystalline Form A of AP1189 acetate as disclosed herein and a pharmaceutically acceptable excipient.
- One embodiment of the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising the crystalline Form B of AP1189 succinate as disclosed herein and a pharmaceutically acceptable excipient.
- an oral formulation, a pharmaceutical composition, or unit dosage form comprising the crystalline Form A of AP1189 acetate as disclosed herein or the crystalline Form B of AP1189 succinate as disclosed herein.
- compositions as disclosed herein, wherein the pharmaceutical composition is formulated for oral administration.
- Such composition may be in the form of a tablet or a capsule.
- One embodiment of the disclosure provides for a method of preparing a pharmaceutical composition comprising mixing the crystalline Form A of AP1189 acetate with a pharmaceutically acceptable excipient.
- One embodiment of the disclosure provides for a method of preparing a pharmaceutical composition comprising mixing the crystalline Form B of AP1189 succinate with a pharmaceutically acceptable excipient.
- One embodiment of the disclosure provides for the crystalline Form A of AP1189 acetate, the crystalline Form B of AP1189 succinate, or the pharmaceutical composition as disclosed herein for use in medicine.
- One embodiment of the present disclosure provides for the crystalline Form A of AP1189 acetate, the crystalline Form B of AP1189 succinate, or the pharmaceutical composition as disclosed herein, for use in the treatment of a kidney disease such as proteinuria, a cardiovascular disease, an arthritic disease, or a viral infection.
- One embodiment of the present disclosure provides for a method of treating a disease or disorder in a subject in need thereof, said method comprising administering crystalline Form A of AP1189 acetate, crystalline Form B of AP1189 succinate, or the pharmaceutical composition as disclosed herein, to a subject in need thereof.
- the disease or disorder is selected from the list consisting of a kidney disease such as proteinuria, a cardiovascular disease, an arthritic disease, or a viral infection.
- One embodiment of the present disclosure provides for a use of the crystalline Form A of AP1189 acetate or the crystalline Form B of AP1189 succinate, or the pharmaceutical composition as disclosed herein for the manufacture of a medicament for treatment of a disease or disorder.
- a pharmaceutical formulation such as an oral formulation, comprising the crystalline Form A of AP1189 acetate as disclosed herein or the crystalline Form B of AP1189 succinate as disclosed herein, for use in the treatment of a disease or disorder.
- the disease or disorder is selected from the group consisting of a kidney disease, an arthritic disease, a viral disease or disorder, and a cardiovascular disease and/or atherosclerosis.
- an oral formulation, pharmaceutical composition, or unit dosage form according to the present disclosure for use in the manufacture of a medicament for the treatment or prevention of a kidney disease.
- an oral formulation such as a solid oral formulation, comprising the crystalline form A of AP1189 acetate or the crystalline Form B of AP1189 succinate, and at least one pharmaceutically acceptable excipient, as disclosed herein, for use in treating or preventing a kidney disease.
- kidney disease present with proteinuria. In some embodiments said kidney disease is a proteinuric kidney disease.
- said kidney disease is nephrotic syndrome (glomerulonephrosis).
- said kidney disease is primary nephrotic syndrome (primary glomerulonephrosis).
- said primary nephrotic syndrome is membranous glomerulonephritis (MGN) (or membranous nephropathy (MN)).
- MGN membranous glomerulonephritis
- MN membranous nephropathy
- said primary nephrotic syndrome is focal segmental glomerulosclerosis (FSGS).
- FSGS focal segmental glomerulosclerosis
- said primary nephrotic syndrome is membranoproliferative glomerulonephritis (MPGN) (mesangiocapillary glomerulonephritis).
- MPGN membranoproliferative glomerulonephritis
- said membranoproliferative glomerulonephritis is selected from Type 1 MPGN and Type 2 MPGN.
- said primary nephrotic syndrome is rapidly progressive glomerulonephritis (RPGN) (crescentic GN).
- said primary nephrotic syndrome is minimal change disease (MCD).
- said kidney disease is secondary nephrotic syndrome (secondary glomerulonephrosis).
- said secondary nephrotic syndrome is caused by an underlying autoimmune disease, an underlying cancer disease, an underlying genetic disorder, or by an underlying disease selected from the group consisting of: Systemic lupus erythematosus (SLE), Diabetic nephropathy, Sarcoidosis, Sjögren's syndrome, Amyloidosis, Multiple myeloma, Vasculitis, Cancer and Genetic disorders (such as congenital nephrotic syndrome).
- SLE Systemic lupus erythematosus
- said secondary nephrotic syndrome is caused by Diabetic nephropathy, by an infection, such as a urinary tract infection, such as an infection selected from the group consisting of HIV, syphilis, hepatitis such as hepatitis A, B and C, post-streptococcal infection, urinary schistosomiasis and Ebola.
- an infection such as a urinary tract infection, such as an infection selected from the group consisting of HIV, syphilis, hepatitis such as hepatitis A, B and C, post-streptococcal infection, urinary schistosomiasis and Ebola.
- said secondary nephrotic syndrome is drug-induced.
- said kidney disease is an inflammatory kidney disease.
- said kidney disease is glomerulonephritis (GN).
- said glomerulonephritis is selected from the group consisting of IgA nephropathy (Berger's disease), IgM nephropathy, Post-infectious glomerulonephritis and Thin basement membrane disease.
- kidney disease is idiopathic membranous nephropathy (iMN).
- iMN idiopathic membranous nephropathy
- an oral formulation, a pharmaceutical composition, or unit dosage form according to the present disclosure for use in treating or preventing idiopathic membranous nephropathy (iMN).
- iMN idiopathic membranous nephropathy
- an oral formulation, pharmaceutical composition, or unit dosage form according to the present disclosure for use in the manufacture of a medicament for the treatment or prevention of an arthritic disease.
- an oral formulation such as a solid oral formulation, comprising the crystalline Form A of AP1189 acetate or crystalline Form B of AP1189 succinate, and at least one pharmaceutically acceptable excipient, as disclosed herein, for use in treating or preventing an arthritic disease.
- the arthritic disease is an auto-immune disease and/or an inflammatory disease that presents with joint inflammation.
- the arthritic disease is selected from the group consisting of inflammatory arthritis, degenerative arthritis, metabolic arthritis, reactive arthritis and infectious arthritis.
- the arthritic disease is inflammatory arthritis.
- the inflammatory arthritis is selected from the group consisting of Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Ankylosing Spondylitis.
- RA Rheumatoid Arthritis
- Psoriatic Arthritis Psoriatic Arthritis
- Ankylosing Spondylitis Rheumatoid Arthritis
- the inflammatory arthritis is Rheumatoid Arthritis (RA).
- RA Rheumatoid Arthritis
- the rheumatoid arthritis is severe active RA (CDAI>22). In one embodiment, the rheumatoid arthritis is RA with a CDAI>22.
- the rheumatoid arthritis is RA with a DAS28 score of above 5.1.
- the rheumatoid arthritis is juvenile rheumatoid arthritis (JRA).
- the degenerative arthritis is osteoarthritis.
- the metabolic arthritis is gouty arthritis.
- the reactive and/or infectious arthritis is arthritis associated with infection with one or more of Hepatitis C, Chlamydia , gonorrhoea, salmonella or shigella.
- the arthritic disease is arthritis as part of a systemic inflammatory disease.
- the arthritis as part of a systemic inflammatory disease, such as an inflammatory disease selected from the group consisting of systemic lupus erythematosus, mixed connective tissue disease, Still's disease, and Polymyalgia Rheumatica.
- a systemic inflammatory disease such as an inflammatory disease selected from the group consisting of systemic lupus erythematosus, mixed connective tissue disease, Still's disease, and Polymyalgia Rheumatica.
- an oral formulation, a pharmaceutical composition, or unit dosage form according to the present disclosure for use in treating or preventing rheumatoid arthritis.
- MTX metalhotrexate
- an oral formulation, a pharmaceutical composition, or unit dosage form according to the present disclosure for use in treating or preventing rheumatoid arthritis in patients with an inappropriate response to MTX (such as patients with a reduced response to MTX treatment, such as an MTX non-responder).
- MTX metalhotrexate
- an oral formulation, pharmaceutical composition, or unit dosage form according to the present disclosure for use in the manufacture of a medicament for the treatment or prevention of a viral disease or disorder.
- an oral formulation such as a solid oral formulation, comprising a pharmaceutically acceptable salt of AP1189, such as AP1189 acetate or AP1189 succinate, and at least one pharmaceutically acceptable excipient, as disclosed herein, for use in treating or preventing a viral disease or disorder.
- a pharmaceutically acceptable salt of AP1189 such as AP1189 acetate or AP1189 succinate
- at least one pharmaceutically acceptable excipient as disclosed herein
- said viral disease or disorder is a symptomatic viral disease or disorder.
- said viral disease or disorder is a symptomatic viral disease or disorder with inflammation, such as hyperinflammation.
- said viral disease or disorder is a symptomatic viral disease or disorder with inflammation, such as hyperinflammation, in one or more organs.
- Inflammation in one or more organs may also be referred to as local inflammation.
- said one or more organs are selected from the group consisting of lungs, the respiratory tract, kidney, liver, pancreas, spleen, exocrine glands, endocrine glands, lymph nodes, brain, heart, muscles, bone marrow, skin, skeleton, bladder, reproduction organs including the phallopian tubes, eye, ear, vascular system, the gastrointestinal tract including small intestines, colon, rectum, canalis analis and the prostate gland.
- said viral disease or disorder is inflammatory viral diseases or disorders.
- said viral disease or disorder is a viral respiratory infection, such as a viral lower respiratory infection.
- said viral disease or disorder is viral respiratory diseases or disorders.
- said viral disease or disorder is viral diseases or disorders of the lung.
- said viral disease or disorder is viral diseases or disorders with inflammation in the respiratory system, such as in the lungs and/or respiratory tract.
- said viral disease or disorder is viral diseases or disorders with one or more respiratory symptoms.
- said one or more respiratory symptoms are selected from the group consisting of cough, dry cough, dyspnea, impaired oxygenation, respiratory illness, respiratory dysfunction, respiratory failure, respiratory syndrome and acute respiratory disease (ARD).
- said viral disease or disorder is severe disease. Severe disease present with dyspnoea, increased respiratory frequency, reduced blood oxygen saturation and/or lung infiltrates.
- said viral disease or disorder is critical disease.
- Critical disease present with respiratory failure, septic shock, and/or multiple organ dysfunction (MOD) or multiple organ failure (MOF).
- said viral disease or disorder is viral pneumonia.
- said viral disease or disorder is viral bronchiolitis.
- said viral disease or disorder is viral diseases or disorders with respiratory failure.
- said viral disease or disorder is acute respiratory distress syndrome (ARDS).
- ARDS acute respiratory distress syndrome
- said viral disease or disorder is viral acute respiratory distress syndrome (ARDS).
- ARDS viral acute respiratory distress syndrome
- said viral disease or disorder is symptomatic COVID-19 with acute respiratory distress syndrome (ARDS).
- ARDS acute respiratory distress syndrome
- an oral formulation, a pharmaceutical composition, or unit dosage form according to the present disclosure for use in treating or preventing ARDS, such as viral ARDS.
- said viral disease or disorder is viral diseases and disorders with systemic inflammatory distress syndrome (SIDS) and/or sepsis.
- SIDS systemic inflammatory distress syndrome
- said viral disease or disorder is viral diseases and disorders with pulmonary insufficiency.
- said viral disease or disorder is viral diseases or disorders with cytokine release syndrome (CRS) and/or a cytokine storm (hypercytokinemia).
- CRS cytokine release syndrome
- hypercytokinemia hypercytokinemia
- said viral disease or disorder is caused by a viral infection selected from the group consisting of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), often referred to as the COVID-19 virus; SARS-CoV, MERS-CoV, the dengue virus and influenza virus (including Type A, Type B and Type C).
- SARS-CoV-2 Severe Acute Respiratory Syndrome CoronaVirus 2
- MERS-CoV the dengue virus and influenza virus
- Type A, Type B and Type C a viral infection selected from the group consisting of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), often referred to as the COVID-19 virus; SARS-CoV, MERS-CoV, the dengue virus and influenza virus (including Type A, Type B and Type C).
- an oral formulation, pharmaceutical composition, or unit dosage form according to the present disclosure for use in the manufacture of a medicament for the treatment or prevention of a cardiovascular disease and/or atherosclerosis.
- an oral formulation such as a solid oral formulation, comprising the crystalline Form A of AP1189 acetate as disclosed herein or the crystalline Form B of AP1189 succinate as disclosed herein, and at least one pharmaceutically acceptable excipient, as disclosed herein, for use in treating or preventing a cardiovascular disease and/or atherosclerosis.
- said cardiovascular disease is selected from the group consisting of coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack); stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, vascular disease, thromboembolic disease, and venous thrombosis.
- CAD coronary artery diseases
- said cardiovascular disease is atherosclerotic cardiovascular disease.
- said atherosclerotic cardiovascular disease is selected from the group consisting of coronary artery disease, stroke (cerebrovascular disease), and peripheral artery disease.
- said cardiovascular disease is vascular inflammation.
- an oral formulation, pharmaceutical composition, or unit dosage form according to the present disclosure for use in the manufacture of a medicament for the treatment or prevention of a systemic inflammatory disorder.
- an oral formulation such as a solid oral formulation, comprising the crystalline Form A of AP1189 acetate as disclosed herein or the crystalline Form B of AP1189 succinate, and at least one pharmaceutically acceptable excipient, as disclosed herein, for use in treating or preventing a systemic inflammatory disorder.
- Systemic disorders with possible involvement of the nervous system include a variety of diseases with presumed inflammatory and autoimmune pathomechanisms, among them Behçet disease, sarcoidosis, systemic lupus erythematosus, juvenile idiopathic arthritis, scleroderma, and Sjögren syndrome.
- This disease group encompasses systemic inflammatory disorders with a genetically defined dysregulation of the innate immune system as well as systemic autoimmune disorders characterized by alterations of the adaptive immunity such as autoantibodies and autoreactive T cells.
- said systemic inflammatory disorder is an autoimmune disorder.
- said systemic inflammatory disorder is selected from the group consisting of Behçet disease, sarcoidosis, systemic lupus erythematosus, juvenile idiopathic arthritis, scleroderma, Sjögren syndrome, myositis including dermamyositis and polymyositis, vasculitis, giant cell arteritis, ankylosing spondylitis, polymyalgia rheumatic and psoriatic arthritis.
- An acid is added as a slurry or solution in a protic or polar aprotic solvent to a heated slurry or solution of 3-[1-(2-nitrophenyl)-1-H-pyrrole-2-yl]-propanal and aminoguanidine or a salt thereof in a protic or polar aprotic solvent.
- the resulting mixture is heated and stirred, preferably until completion of the reaction, before cooled and optionally an anti-solvent, such as a non-polar aprotic solvent, is added.
- the resulting salt is isolated by conventional methods, such as filtration, centrifugation, evaporation of the solvents, including spray drying.
- An acid is added (such as an excess of said acid) as a slurry or solution in a protic or polar aprotic solvent to a slurry of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidine in a protic or polar aprotic solvent.
- the resulting mixture is heated and cooled in cycles between 15 min and 72 hours, before cooled and optionally an anti-solvent, such as a non-polar aprotic solvent, is added.
- the resulting salt is isolated by conventional methods, such as filtration, centrifugation, evaporation of the solvents, including spray drying.
- This method is feasible if the corresponding acid to the counterion is stronger in the salt formed.
- An excess of an acid is added as a slurry or solution in a protic or polar aprotic solvent to a slurry of N- ⁇ 3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene ⁇ -aminoguanidinium salt in a protic or polar aprotic solvent.
- the resulting mixture is heated and cooled in cycles between 15 min and 72 hours, before cooled and optionally an anti-solvent, such as a non-polar aprotic solvent, is added.
- the resulting salt is isolated by conventional methods, such as filtration, centrifugation, or evaporation of the solvents, including spray drying.
- 2-propanol:water 90:10 v/v was added to AP1189 acetate to prepare a slurry.
- 2-propanol:water 90:10 v/v was added to 1.1 equivalents of succinic acid.
- the counterion slurry was added to the acetate salt slurry.
- Temperature cycling was carried out between ambient and 40° C. for ca. 18 h with 4 hour hold periods at ambient temperature and 4 hour hold periods at 40° C. The entire slurry was then isolated by Buchner filtration and washed with deionised water. The solids were dried under vacuum at ambient.
- a polymorphism assessment was carried out in order to identify alternate polymorphs of AP1189 acetate: AP1189 acetate was dissolved in 1,4-dioxane-water and lyophilized to obtain an amorphous solid. Aliquots were suspended in the specific solvents and heated in temperature cycles between ambient and 40° C. for 3 days, before being isolated by filtration.
- Acetate Pattern 1 was obtained from 8 solvent systems.
- a mixture of Pattern 1 and 2 was obtained from 8 solvent systems.
- Pattern 3 was obtained from THF. Extended temperature cycling for a further 3 days for the acetate Pattern 1 and 2 mixture from ethyl acetate resulted in conversion to acetate Pattern 1.
- XRPD analysis was carried out on a PANalytical X'pert pro with PIXcel detector (128 channels), scanning the samples between 3 and 35° 2 ⁇ .
- the material was gently ground (where required) to release any agglomerates and loaded onto a multi-well plate with Kapton or Mylar polymer film to support the sample.
- the XRPD diffractogram for AP1189 acetate salt Pattern 1 crystallised from acetonitrile is shown in FIG. 1 .
- the corresponding XRPD diffractogram peak list for acetate Pattern 1 is shown in Table 3.
- Indexed unit cell data a [ ⁇ ] 7.8; b [ ⁇ ] 15.1; c [ ⁇ ] 20.7; alpha [°] 73.6; beta [°] 80.5; gamma [°] 86.5; volume [ ⁇ 3 ] 2311.8.
- the XRPD diffractogram for AP1189 acetate salt Pattern 1 and 2 crystallised from ethyl acetate is shown in FIG. 2 .
- the corresponding XRPD diffractogram peak list for acetate salt Pattern 1 and 2 is shown in Table 4.
- the XRPD diffractogram for AP1189 acetate salt Pattern 3 crystallised from THF is shown in FIG. 3 .
- the corresponding XRPD diffractogram peak list for acetate salt Pattern 3 is shown in Table 5.
- the XRPD diffractogram for AP1189 tosylate salt Pattern 1 crystallised from methanol is shown in FIG. 4 .
- the corresponding XRPD diffractogram peak list for tosylate salt Pattern 1 is shown in Table 6.
- the XRPD diffractogram for AP1189 fumarate salt Pattern 1 crystallised from isopropylalcohol:water 90:10 v/v is shown in FIG. 5 .
- the corresponding XRPD diffractogram peak list for fumarate salt Pattern 1 from isopropylalcohol:water 90:10 v/v is shown in Table 7.
- the XRPD diffractogram for AP1189 succinate salt Pattern 1 crystallised from isopropanol:water 90:10 v/v is shown in FIG. 6 .
- the corresponding XRPD diffractogram peak list for succinate salt Pattern 1 is shown in Table 8.
- the corresponding XRPD diffractogram peak list for napadisylate salt Pattern 1 is shown in Table 9.
- the XRPD diffractogram for AP1189 napadisylate salt Pattern 2 crystallised from THF is shown in FIG. 15 .
- the corresponding XRPD diffractogram peak list for napadisylate salt Pattern 2 is shown in Table 10.
- the XRPD diffractogram for AP1189 esylate salt Pattern 1 crystallised from methylethyl ketone is shown in FIG. 16 .
- the corresponding XRPD diffractogram peak list for esylate salt Pattern 1 is shown in Table 11.
- the corresponding XRPD diffractogram peak list for edisylate salt Pattern 1 is shown in Table 12.
- the XRPD diffractogram for AP1189 edisylate salt Pattern 2 crystallised from methylethyl ketone is shown in FIG. 18 .
- the corresponding XRPD diffractogram peak list for edisylate salt Pattern 2 is shown in Table 13.
- the XRPD diffractogram for AP1189 edisylate salt Pattern 4 crystallised from THF is shown in FIG. 19 .
- the corresponding XRPD diffractogram peak list for edisylate salt Pattern 4 is shown in Table 14.
- the corresponding XRPD diffractogram peak list for edisylate salt Pattern 5 is shown in Table 15.
- the XRPD diffractogram for AP1189 nitrate salt Pattern 1 crystallised from THF is shown in FIG. 21 .
- the corresponding XRPD diffractogram peak list for nitrate salt Pattern 1 is shown in Table 16.
- the XRPD diffractogram for AP1189 cyclamate salt Pattern 2 crystallised from THF is shown in FIG. 22 .
- the corresponding XRPD diffractogram peak list for cyclamate salt Pattern 2 is shown in Table 17.
- the XRPD diffractogram for AP1189 cyclamate salt Pattern 4 crystallised from acetone is shown in FIG. 23 .
- the corresponding XRPD diffractogram peak list for cyclamate salt Pattern 4 is shown in Table 18.
- the XRPD diffractogram for AP1189 cyclamate salt Pattern 5 crystallised from THF is shown in FIG. 24 .
- the corresponding XRPD diffractogram peak list for cyclamate salt Pattern 5 is shown in Table 19.
- the corresponding XRPD diffractogram peak list for besylate salt Pattern 1 is shown in Table 20.
- the corresponding XRPD diffractogram peak list for oxalate salt Pattern 1 is shown in Table 21.
- the XRPD diffractogram for AP189 oxalate salt Pattern 2 crystallised from acetone is shown in FIG. 27 .
- the corresponding XRPD diffractogram peak list for oxalate salt Pattern 2 is shown in Table 22.
- the XRPD diffractogram for AP1189 oxalate salt Pattern 4 crystallised from THF is shown in FIG. 28 .
- the corresponding XRPD diffractogram peak list for oxalate salt Pattern 4 is shown in Table 23.
- the corresponding XRPD diffractogram peak list for (+)-camphor-10-sulfonic acid salt Pattern 1 is shown in Table 24.
- the XRPD diffractogram for AP1189 oxoglutarate salt Pattern 1 crystallised from acetone is shown in FIG. 30 .
- the corresponding XRPD diffractogram peak list for oxoglutarate salt Pattern 1 is shown in Table 25.
- the XRPD diffractogram for AP1189 DL-mandelic acid salt Pattern 2 crystallised from methylethyl ketone is shown in FIG. 31 .
- the corresponding XRPD diffractogram peak list for DL-mandelic acid salt Pattern 2 is shown in Table 26.
- the XRPD diffractogram for AP1189 DL-mandelic acid salt Pattern 3 crystallised from acetone is shown in FIG. 32 .
- the corresponding XRPD diffractogram peak list for DL-mandelic acid salt Pattern 3 is shown in Table 27.
- the XRPD diffractogram for AP1189 hippuric acid salt Pattern 1 crystallised from methylethyl ketone is shown in FIG. 33 .
- the corresponding XRPD diffractogram peak list for hippuric acid salt Pattern 1 is shown in Table 28.
- the XRPD diffractogram for AP1189 formate salt Pattern 1 crystallised from acetone is shown in FIG. 34 .
- the corresponding XRPD diffractogram peak list for formate salt Pattern 1 is shown in Table 29.
- the XRPD diffractogram for AP1189 DL-lactic acid salt Pattern 1 crystallised from acetone is shown in FIG. 35 .
- the corresponding XRPD diffractogram peak list for L-lactic acid salt Pattern 1 is shown in Table 30.
- the XRPD diffractogram for AP1189 DL-lactic acid salt Pattern 1 crystallised from 2-propanol:water 80:20% v/v is shown in FIG. 36 .
- the corresponding XRPD diffractogram peak list for DL-lactic acid salt Pattern 1 is shown in Table 31.
- the XRPD diffractogram for AP1189 glutaric acid salt Pattern 1 crystallised from acetone is shown in FIG. 37 .
- the corresponding XRPD diffractogram peak list for glutaric acid salt Pattern 1 is shown in Table 32.
- the XRPD diffractogram for AP1189 glutaric acid salt Pattern 2 crystallised from methylethyl ketone is shown in FIG. 38 .
- the corresponding XRPD diffractogram peak list for glutaric acid salt Pattern 2 is shown in Table 33.
- the XRPD diffractogram for AP1189 glutaric acid salt Pattern 4 crystallised from acetone is shown in FIG. 91
- the corresponding XRPD diffractogram peak list for glutaric acid salt Pattern 4 is shown in Table 34.
- the XRPD diffractogram for AP1189 adipic acid salt Pattern 1 crystallised from 2-Propanol:water 80:20% v/v is shown in FIG. 39 .
- the corresponding XRPD diffractogram peak list for adipic acid salt Pattern 1 is shown in Table 35.
- AP1189 napadisylate pattern 2 0.7543 (11.0629); 2.557 (8.8634); 1 (8.1806); 2.6217 (7.941); 0.974 (7.9028); 1.0037 (7.7975); 0.8754 (7.739); 1.0347 (7.656); 3.5752 (7.4103); 0.8399 (7.096); 0.7845 (6.7841); 0.7859 (6.5499); 1.5389 (6.3551); 2.0976 (1.764).
- AP1189 edisylate pattern 2:1 (8.1754); 1.0457 (7.9043); 1.055 (7.7933); 1.0496 (7.7126); 1.0385 (7.6399); 3.6468 (7.2657); 1.0648 (7.074); 1.0135 (6.758); 1.0489 (6.5107); 2.0588 (6.3692); 1.8314 (2.6762); 0.4358 (1.8961).
- AP1189 oxalate pattern 2:1 (8.1689); 1.0959 (7.902); 1.0853 (7.7878); 1.2373 (7.7194); 1.4553 (7.6482); 2.6457 (7.5415); 0.988 (7.0686); 1.0003 (6.7689); 2.0665 (6.4477); 0.9929 (6.3465); 0.063 (2.0968).
- AP1189 oxalate pattern 4:1 (8.1515); 1.0445 (7.8892); 1.0462 (7.7742); 1.0282 (7.6758); 1.0219 (7.6301); 2.6642 (7.1097); 1.2483 (7.024); 1.0034 (6.7159); 2.0859 (6.3975); 0.997 (6.3192); 0.1217 (1.7624).
- AP1189 (+)-camphor-10-sulfonic acid pattern 1:0.8814 (11.1521); 1 (8.1744); 1.0627 (7.9089); 1.0996 (7.8055); 1.0638 (7.7356); 1.114 (7.6573); 3.3236 (7.4351); 1.012 (7.0913); 1.0191 (6.7741); 1.0391 (6.5267); 2.0264 (6.3743); 1.0414 (2.8818); 1.35 (2.661); 1.381 (2.3787); 1.0478 (2.2319); 1.0068 (1.9412); 0.0876 (1.9105); 0.9801 (1.8546); 1.1612 (1.7889); 2.1252 (1.276); 3.0996 (1.0314); 3.0831 (0.7379).
- AP1189 DL-mandelic acid pattern 2:1 (8.1765); 1.1357 (7.9075); 1.1573 (7.8014); 2.282 (7.658); 2.4615 (7.373); 2.4095 (7.2395); 1.2411 (7.1718); 1.0362 (7.0527); 0.9926 (6.7419); 2.2546 (6.4249); 0.9906 (6.3355); 1.1242 (4.6566); 1.9165 (2.4309); 2.6899 (2.0752); 2.7184 (0.9137).
- AP1189 adipic acid pattern 1:1 (8.1534); 1.0731 (7.889); 1.1078 (7.7765); 2.1422 (7.6374); 1.3346 (7.0193); 1.1785 (6.6987); 1.078 (6.4364); 2.1349 (6.3344); 0.3194 (3.7674); 6.2668 (2.1336); 1.1285 (1.8523); 6.2972 (1.4746); 1.5977 (1.0395).
- test compounds exhibited remarkably different solubilities, especially at low pH. Specifically, the acetate and succinate salts showed high solubility at pH 1.2, indicating the potential for using these compounds in applications where a high solubility at low pH is desirable.
- the solids were analysed by XRPD to check the polymorphic form. The remainder of the solids were druid under vacuum at ambient for ca. 3 days. The dried solids were characterised. The concentrations of the recovered mother liquors and was were determined by HPLC.
- AP1189 was added to 20 mL vials. The required volume of the appropriate solvent system was added to each vial, and the experiments were stirred at 65-69° C. The experiments were then cooled to 55° C., and seeded with AP1189 succinate. 2% seed load was used. The experiments were stirred at 55° C. for another 1 h to allow for equilibration. The experiments were then cooled to 5° C. at 0.1° C./min, and stirred at 5° C. After ca. 18 h of stirring at 5° C., 200 ⁇ L aliquot of each slurry was extracted and centrifuged using 0.2 ⁇ m nylon tubes.
- the isolated solids were dried under vacuum at ambient and analysed by HPLC (purity). The concentration and purity of the mother liquors were also determined by HPLC. To the remainder of the experiments, anti-solvent addition was carried out at 5° C., to reach the target final ratio. Afterwards, stirring continued at 5° C. for another ca. 4 h. The experiments (slurries) were vacuum filtered and the cakes each washed with 0.9 mL of the respective organic solvent (pre-cooled at 5° C.). The solids were dried under vacuum at ambient for ca. 48 h. The dried solids were characterised. The mother liquors were subsampled and analysed by HPLC for concentration and solution purity determination. The rest of the mother liquors were left open in an oven, to allow the solvents to evaporate under vacuum, at ambient. After 3 days, the residual solids were analysed by XRPD and HPLC (purity).
- AP1189 succinate exhibiting the crystal form of Pattern 1 was obtained using various crystallisation conditions. Isolated yield obtained was between 65 and 80%. Addition of water as anti-solvent improved the theoretical yield by 2 to 6% % w/w.
- AP1189 succinate was added to temperature controlled reactor in an EasyMax 102 (100 mL vessel). 55.6 mL (11.1 vol.) of 1-propanol/water (50:50 v/v %) was added to the reactor, and the experiment was stirred at 70° C. Target concentration was 90 mg/mL. Stirring speed was 200 rpm. When complete dissolution was observed, the experiment was cooled to 55° C., and seeded with AP1189 succinate. 2% seed load was used, and it persisted with evidence of slurry formation. Post-seeding, stirring continued at 55° C. for 2 hours to allow experiment to equilibrate. The experiment was cooled to 5° C.
- the diluted samples preparations were analysed by HPLC within 5 hours from preparation and the content of AP1189 was determined from the area under the curve by comparing to standard solutions of AP1189 acetate and AP1189 succinate respectively.
- the solubilities of the test compounds at pH 1.2 are shown in Table 43.
- the solubilities of the test compounds at pH 4.5 and pH 6.8 are shown in Table 44, where all purities were found to be within 92% and 95%.
- the tosylate salt of AP1189 having XRPD pattern 1 was prepared by crystallisation from methanol.
- the fumarate salt of AP1189 having XRPD pattern 1 was prepared by crystallisation from isopropylalcohol:water 90:10 v/v.
- Naphthalene-1,5-Disulfonic Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L 2-Propanol:water 90:10% v/v. A further 500 ⁇ L 2-Propanol:water 90:10% v/v was added to Naphthalene-1,5-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Naphthalene-1,5-Disulfonic Acid having XRPD Pattern 2 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L THF. A further 500 ⁇ L of THF was added to Naphthalene-1,5-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Ethanesulfonic Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 1 mL of methylethyl ketone. Ethanesulfonic acid (1.1 molar equivalents) was transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Ethane-1,2-disulfonic Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L 2-Propanol:water (80:20% v/v). A further 500 ⁇ L of 2-Propanol:water (80:20% v/v) was added to Ethane-1,2-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.).
- Ethane-1,2-disulfonic having XRPD Acid Pattern 2 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L methylethyl ketone. A further 500 ⁇ L of methylethyl ketone was added to Ethane-1,2-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Ethane-1,2-disulfonic Acid having XRPD Pattern 4 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L THF. A further 500 ⁇ L of THF was added to Ethane-1,2-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Ethane-1,2-disulfonic Acid having XRPD Pattern 5 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L 2-Propanol:water (80:20% v/v). A further 500 ⁇ L of 2-Propanol:water (80:20% v/v) was added to Ethane-1,2-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Nitric Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 1 mL of THF. Nitric acid (1.1 molar equivalents) was transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Cyclamic Acid having XRPD Pattern 2 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L THF. A further 500 ⁇ L of THF was added to Cyclamic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Cyclamic Acid having XRPD Pattern 4 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L Acetone. A further 500 ⁇ L of Acetone was added to Cyclamic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Cyclamic Acid having XRPD Pattern 5 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L THF. A further 500 ⁇ L of THF was added to Ethane-1,2-disulfonic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD. After storage at 40° C./75% RH for 24 hours the diffractogram was consistent with pattern 5 by XRPD.
- Benzenesulfonic Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 1 mL of 2-Propanol:water 80:20% v/v. Benzenesulfonic acid (1.1 molar equivalents) was transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Oxalic Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L 2-Propanol:water 80:20% v/v. A further 500 ⁇ L of 2-Propanol:water 80:20% v/v was added to Oxalic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Oxalic Acid having XRPD Pattern 2 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L Acetone. A further 500 ⁇ L of Acetone was added to Oxalic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Oxalic Acid having XRPD Pattern 4 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L THF. A further 500 ⁇ L of THF was added to Oxalic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- (+)-Camphor-10-Sulfonic Acid having XRPD Pattern 1 was prepared as follows:
- Ketoglutaric Acid having XRPD Pattern 1 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 1 mL of Acetone. Ketoglutaric acid (1.1 molar equivalents) was transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L methylethyl ketone. A further 500 ⁇ L of methylethyl ketone was added to DL-Mandelic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L Acetone. A further 500 ⁇ L of Acetone was added to DL-Mandelic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L methylethyl ketone. A further 500 ⁇ L of methylethyl ketone was added to Hippuric acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Formic Acid having XRPD Pattern 1 was prepared as follows: 50 mg of AP1189 Acetate was weighed into a 1.5 mL HPLC vial and dissolved in 1 mL of Acetone. Formic acid (1.1 molar equivalents) was transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- L-Lactic Acid having XRPD Pattern 1 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L Acetone. A further 500 ⁇ L of Acetone was added to L-Lactic acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Glutaric Acid having XRPD Pattern 1 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L Acetone. A further 500 ⁇ L of Acetone was added to Glutaric acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Glutaric Acid having XRPD Pattern 2 was prepared as follows:
- AP1189 Acetate 50 mg was weighed into a 1.5 mL HPLC vial and dissolved in 500 ⁇ L methylethyl ketone. A further 500 ⁇ L of methylethyl ketone was added to Glutaric acid (1.1 molar equivalents), which was then transferred by pipette into the API. The resulting mixture was thermally cycled for 3 days between 40° C. and 5° C. (Ramp rate: 0.1° C./min with isothermal holds of 1 hour at 40° C. and 5° C.). Solids were isolated by centrifuge filtration and analysed wet by XRPD. Sample was dried at 40° C. under vacuum for 24 hours then reanalysed by XRPD.
- Adipic Acid having XRPD Pattern 1 was prepared as follows:
- Infrared spectroscopy was carried out on a Bruker ALPHA P spectrometer. Sufficient material was placed onto the centre of the plate of the spectrometer and the spectra were obtained using the following parameters: Resolution: 4 cm ⁇ 1 ; Background Scan Time: 16 scans; Sample Scan Time: 16 scans; Data Collection: 4000 to 400 cm ⁇ 1 , Result Spectrum: Transmittance; Software: OPUS version 6.
- Tables 45-68 show the FT-IR peak lists for various AP1189 salt polymorphs.
- FIG. 92 shows the IR spectrum of AP1189 acetate Pattern 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21180702 | 2021-06-21 | ||
EP21180708 | 2021-06-21 | ||
EP2118-0708.6 | 2021-06-21 | ||
EP21180702.9 | 2021-06-21 | ||
EP21180708.6 | 2021-06-21 | ||
EP21209855.2 | 2021-11-23 | ||
EP21209855 | 2021-11-23 | ||
PCT/EP2022/066884 WO2022268814A1 (en) | 2021-06-21 | 2022-06-21 | Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salts |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/066884 Continuation WO2022268814A1 (en) | 2021-06-21 | 2022-06-21 | Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salts |
Publications (2)
Publication Number | Publication Date |
---|---|
US20230002319A1 US20230002319A1 (en) | 2023-01-05 |
US20230271922A9 true US20230271922A9 (en) | 2023-08-31 |
Family
ID=84544160
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/821,500 Pending US20230271922A9 (en) | 2021-06-21 | 2022-08-23 | Polymorphs of phenyl pyrrole aminoguandium salts |
US18/065,702 Pending US20230114865A1 (en) | 2021-06-21 | 2022-12-14 | Phenyl pyrrole aminoguanidine salts and formulations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/065,702 Pending US20230114865A1 (en) | 2021-06-21 | 2022-12-14 | Phenyl pyrrole aminoguanidine salts and formulations |
Country Status (9)
Country | Link |
---|---|
US (2) | US20230271922A9 (he) |
EP (2) | EP4359076A1 (he) |
JP (1) | JP2024522817A (he) |
KR (2) | KR20240024177A (he) |
AU (2) | AU2022300305A1 (he) |
BR (1) | BR112023026909A2 (he) |
CA (2) | CA3220753A1 (he) |
IL (2) | IL309104A (he) |
WO (2) | WO2022268814A1 (he) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023218048A1 (en) * | 2022-05-12 | 2023-11-16 | Synact Pharma Aps | Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2348016T3 (en) * | 2006-06-09 | 2016-05-30 | Synact Pharma Aps | Phenylpyrrolaminoguanidine derivatives |
KR102494613B1 (ko) * | 2018-06-22 | 2023-02-06 | 신액트 파마 에이피에스 | 단백뇨의 치료 |
PT3773558T (pt) * | 2019-05-10 | 2022-09-13 | Synact Pharma Aps | Tratamento combinado de doença artrítica |
KR20220161315A (ko) * | 2020-03-31 | 2022-12-06 | 신액트 파마 에이피에스 | 증후성 바이러스 질환의 치료 |
-
2022
- 2022-06-21 EP EP22737436.0A patent/EP4359076A1/en active Pending
- 2022-06-21 CA CA3220753A patent/CA3220753A1/en active Pending
- 2022-06-21 JP JP2023578136A patent/JP2024522817A/ja active Pending
- 2022-06-21 BR BR112023026909A patent/BR112023026909A2/pt unknown
- 2022-06-21 AU AU2022300305A patent/AU2022300305A1/en active Pending
- 2022-06-21 IL IL309104A patent/IL309104A/he unknown
- 2022-06-21 WO PCT/EP2022/066884 patent/WO2022268814A1/en active Application Filing
- 2022-06-21 IL IL309102A patent/IL309102A/he unknown
- 2022-06-21 WO PCT/EP2022/066906 patent/WO2022268825A1/en active Application Filing
- 2022-06-21 KR KR1020247000873A patent/KR20240024177A/ko unknown
- 2022-06-21 KR KR1020237043107A patent/KR20240024818A/ko unknown
- 2022-06-21 CA CA3220756A patent/CA3220756A1/en active Pending
- 2022-06-21 EP EP22735858.7A patent/EP4359383A1/en active Pending
- 2022-06-21 AU AU2022296767A patent/AU2022296767A1/en active Pending
- 2022-08-23 US US17/821,500 patent/US20230271922A9/en active Pending
- 2022-12-14 US US18/065,702 patent/US20230114865A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3220756A1 (en) | 2022-12-29 |
AU2022300305A1 (en) | 2024-01-25 |
CA3220753A1 (en) | 2022-12-29 |
KR20240024818A (ko) | 2024-02-26 |
JP2024522817A (ja) | 2024-06-21 |
EP4359383A1 (en) | 2024-05-01 |
BR112023026909A2 (pt) | 2024-03-05 |
EP4359076A1 (en) | 2024-05-01 |
AU2022296767A1 (en) | 2024-02-01 |
IL309104A (he) | 2024-02-01 |
WO2022268825A1 (en) | 2022-12-29 |
KR20240024177A (ko) | 2024-02-23 |
IL309102A (he) | 2024-02-01 |
WO2022268814A1 (en) | 2022-12-29 |
US20230114865A1 (en) | 2023-04-13 |
US20230002319A1 (en) | 2023-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10301287B2 (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
US20120029083A1 (en) | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof | |
US8865915B2 (en) | Process for the preparation of the L-arginine salt of perindopril | |
US20230271922A9 (en) | Polymorphs of phenyl pyrrole aminoguandium salts | |
US8329740B2 (en) | Polymorphs of sunitinib malate | |
US20130296575A1 (en) | Sunitinib and salts thereof and their polymorphs | |
US6806373B2 (en) | Process for preparing leflunomide form I | |
KR102111248B1 (ko) | 새로운 엠파글리플로진의 공결정 | |
EP3820881B1 (en) | Novel polymorphic forms of cyclo (-his-pro) | |
US20180273499A1 (en) | Salts and solid state forms of vortioxetine | |
US20050222240A1 (en) | Crystalline pyrazoles | |
JP2008174551A (ja) | ラベプラゾールナトリウムの結晶形態 | |
JP2024523459A (ja) | フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体 | |
CN117836271A (zh) | 苯基吡咯氨基胍的盐和苯基吡咯氨基胍鎓盐的多晶型物 | |
WO2024133643A1 (en) | Polymorph of phenyl pyrrole hydrazine carboximidamide compound | |
US7655800B2 (en) | Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses | |
US9464086B2 (en) | Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
RU2345994C2 (ru) | МЕЗИЛАТ 4-(4-ТРАНС-ГИДРОКСИЦИКЛОГЕКСИЛ) АМИНО-2-ФЕНИЛ-7Н-ПИРРОЛО[2,3d] ПИРИМИДИНА И ЕГО ПОЛИМОРФНЫЕ ФОРМЫ (ВАРИАНТЫ) | |
US7232904B2 (en) | Crystal of arylethenesulfonamide derivative and preparation process thereof | |
RU2573384C2 (ru) | Новые полиморфы и соли | |
TWI335335B (en) | A novel crystal of a triterpene derivative | |
KR102150825B1 (ko) | 새로운 sglt-2 억제제의 신규한 공결정 | |
US20040180953A1 (en) | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | |
US20220089550A1 (en) | Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)-n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide | |
JP2018515477A (ja) | 免疫調節薬の新規な結晶形 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SYNACT PHARMA APS, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOESEN, THOMAS;JONASSEN, THOMAS ENGELBRECHT NORDKILD;REECE, HAYLEY ANN;AND OTHERS;SIGNING DATES FROM 20220706 TO 20220714;REEL/FRAME:060866/0132 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |